-- phpMyAdmin SQL Dump
-- version 5.1.1
-- https://www.phpmyadmin.net/
--
-- Host: 127.0.0.1
-- Generation Time: Mar 02, 2022 at 11:14 AM
-- Server version: 10.4.21-MariaDB
-- PHP Version: 7.3.30

SET SQL_MODE = "NO_AUTO_VALUE_ON_ZERO";
START TRANSACTION;
SET time_zone = "+00:00";


/*!40101 SET @OLD_CHARACTER_SET_CLIENT=@@CHARACTER_SET_CLIENT */;
/*!40101 SET @OLD_CHARACTER_SET_RESULTS=@@CHARACTER_SET_RESULTS */;
/*!40101 SET @OLD_COLLATION_CONNECTION=@@COLLATION_CONNECTION */;
/*!40101 SET NAMES utf8mb4 */;

--
-- Database: `dbstruct_ci`
--

-- --------------------------------------------------------

--
-- Table structure for table `dsflag`
--

CREATE TABLE `dsflag` (
  `FlagNum` int(11) DEFAULT NULL,
  `FlagCom` text DEFAULT NULL,
  `FlagNotes` text DEFAULT NULL,
  `SpecType` varchar(30) DEFAULT NULL,
  `required` int(11) NOT NULL
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

--
-- Dumping data for table `dsflag`
--

INSERT INTO `dsflag` (`FlagNum`, `FlagCom`, `FlagNotes`, `SpecType`, `required`) VALUES
(1, 'No dosing records; no unflagged (1-5) pk samples; missing sample date and time or concentration (but not LLQ or BLQ); concentration = NR or NSR or NRR; negative AFRELTM when study day >0', 'this can be due to dosing/sampling date issue.\r\nflag=1 also used to flag dose records for subjects having only pk samples with flag=1 through 5 (no analyzable pk records)', 'PPK-ISOP-NIVO', 1),
(2, 'Post first dose LLOQ or BLQ or concentration = BD', NULL, 'PPK-ISOP-NIVO', 1),
(3, 'Day 1 pre-dose samples', NULL, 'PPK-ISOP-NIVO', 1),
(4, 'Duplicate sample with same concentration at same AFRELTM (eToolbox/PAMS set up for NCA analysis)', NULL, 'PPK-ISOP-NIVO', 1),
(5, 'If concentration>2000 ug/mL', NULL, 'PPK-ISOP-NIVO', 1),
(6, 'Duplicate samples with different concentrations', NULL, 'PPK-ISOP-NIVO', 1),
(7, 'Crossover subjects with nivo treatment in Arm B of CA209026', 'Flag both PK and Dosing records at subject level', 'PPK-ISOP-NIVO', 1),
(8, 'Error in dose amount', 'Defined as a +/- 50% deviation between nominal dose*WTB and AMT for weight-based dosing and nominal dose and AMT for flat-dosing. Subsequent pk samples are flagged as well', 'PPK-ISOP-NIVO', 1),
(9, 'Crossover PK samples for combination study in study CA209032', 'Flag pk and dose records, CA209032 only', 'PPK-ISOP-NIVO', 1),
(13, 'Imputed dose time', 'For a non-missed dose, if dose date is available but time is missing, then dosing time needs to be imputed by using the following (apply rules in the order presented):\r\n1. If infusion stop time is available but infusion start time is missing, the protocol defined duration (e.g. 1 hour or 30 min) is used to determine the start of infusion and vice versa if stop time is not available.\r\n2. If both infusion stop and start times are missing on any day other than day 1\r\na. If a trough sample was taken on the same day, use the trough sample time as the dosing time (start of infusion).\r\nb. If there is no trough but an EOI sample is taken on the same day then use EOI sample time minus duration of infusion to impute start time of the dose (start of infusion).\r\n3. If both infusion stop and start times are missing on day 1 then use pre-dose sample time or end of infusion sample time on the same day along with nominal infusion duration to determine the start of infusion time .\r\n4. If there are no concentrations associated with the missing dose time, then the dose time on the previous (or next if it is the first dose) occasion\'s dose will be used as the current dosing time.  This rule will be applied recursively if the dose time is missing for multiple dosing occasions.', 'PPK-ISOP-NIVO', 1),
(14, 'Imputed infusion duration', 'If infusion duration >=+/-100% of protocol defined duration, then impute the duration to protocol defined duration (e.g., 1 hour or 30 min) and flag the dose records and following PK samples', 'PPK-ISOP-NIVO', 1),
(15, 'Impute missing dose amount with nominal/actual dose', 'If dose information is missing for one or a few occasions of a subject, however treatment information (e.g., NIVO 3 mg/kg) is available flag the dose and following PK samples:\r\na. If the nominal dosing does not deviate +/- 50% to actual dosing (geo mean) for occasions with dosing information within that subjects (nominal 3 mg/kg, then actual should be 1.5-4.5 mg/kg), then impute missing dosing by using nominal dosing (e.g., 3 mg/kg * baseline body weight).\r\nb. If the nominal dosing deviation is greater than +/- 50% to actual dosing (geo mean) for occasions within that subjects, then impute missing dosing by using last observation carried forward approach. \r\nThe following scenarios use FLAG = 1: If dose information is missing for all occasions of a subject, and treatment information (e.g., NIVO 3 mg/kg) is unavailable, then add FLAG for exclusion.', 'PPK-ISOP-NIVO', 1),
(16, 'NPRELTM is inaccurate due to source data; AFRELTM, NPRELTM, and APRELTM are accurate', NULL, 'PPK-ISOP-NIVO', 0),
(20, 'Cross over or placebo subject', NULL, 'PPK-ISOP-NIVO', 0),
(21, 'Error in nominal dose - imputed with correct value', 'For dose record that have non-missing nominal dose and treatment, if nominal dose did not match TREATMENT specified dose amount in protocol, correct nominal dose and flag the dose record. Correct nominal dose before check dose amt error of flag 8', 'PPK-ISOP-NIVO', 0),
(22, 'APRELTM > 5 for EOI samples', NULL, 'PPK-ISOP-NIVO', 0),
(23, 'PK sample collected using incorrect kit in Study CA209142', 'Flag the record if (not applied to follow-up visit): \r\n1). subject in the Nivo monotherapy arm and week is not equal to cycle*2 -1\r\n2). subject in the Nivo + Ipi arm and cycle < 5 and week is not equal to cycle*3 -2;\r\n3). subject in the Nivo + Ipi arm and cycle >=5 and week is not equal to cycle*2 + 3;', 'PPK-ISOP-NIVO', 0),
(24, 'Error in cycle and week - corrected with query response', 'For error in cycle and week in pk samples, correct cycle and week based on query result in study CA209142', 'PPK-ISOP-NIVO', 0),
(1, 'No dosing records; no unflagged (1-5) pk samples; missing sample date and time or concentration (but not LLQ or BLQ); concentration = NR or NSR or NRR; negative AFRELTM when study day >0', 'this can be due to dosing/sampling date issue.\r\nflag=1 also used to flag dose records for subjects having only pk samples with flag=1 through 5 (no analyzable pk records)', 'PPK-ISOP-IPI', 1),
(2, 'Post first dose LLOQ or BLQ or concentration = BD', NULL, 'PPK-ISOP-IPI', 1),
(3, 'Day 1 pre-dose samples', NULL, 'PPK-ISOP-IPI', 1),
(4, 'Duplicate sample with same concentration at same AFRELTM (eToolbox/PAMS set up for NCA analysis)', NULL, 'PPK-ISOP-IPI', 1),
(5, 'If concentration>2000 ug/mL', NULL, 'PPK-ISOP-IPI', 0),
(6, 'Duplicate samples with different concentrations', NULL, 'PPK-ISOP-IPI', 1),
(7, 'Crossover subjects with nivo treatment in Arm B of CA209026', 'Flag both PK and Dosing records at subject level', 'PPK-ISOP-IPI', 0),
(8, 'Error in dose amount', 'Defined as a +/- 50% deviation between nominal dose*WTB and AMT for weight-based dosing and nominal dose and AMT for flat-dosing. Subsequent pk samples are flagged as well', 'PPK-ISOP-IPI', 1),
(9, 'Crossover PK samples for combination study in study CA209032', 'Flag pk and dose records, CA209032 only', 'PPK-ISOP-IPI', 0),
(13, 'Imputed dose time', 'For a non-missed dose, if dose date is available but time is missing, then dosing time needs to be imputed by using the following (apply rules in the order presented):\r\n1. If infusion stop time is available but infusion start time is missing, the protocol defined duration (e.g. 1 hour or 30 min) is used to determine the start of infusion and vice versa if stop time is not available.\r\n2. If both infusion stop and start times are missing on any day other than day 1\r\na. If a trough sample was taken on the same day, use the trough sample time as the dosing time (start of infusion).\r\nb. If there is no trough but an EOI sample is taken on the same day then use EOI sample time minus duration of infusion to impute start time of the dose (start of infusion).\r\n3. If both infusion stop and start times are missing on day 1 then use pre-dose sample time or end of infusion sample time on the same day along with nominal infusion duration to determine the start of infusion time .\r\n4. If there are no concentrations associated with the missing dose time, then the dose time on the previous (or next if it is the first dose) occasion\'s dose will be used as the current dosing time.  This rule will be applied recursively if the dose time is missing for multiple dosing occasions.', 'PPK-ISOP-IPI', 1),
(14, 'Imputed infusion duration', 'If infusion duration >=+/-100% of protocol defined duration, then impute the duration to protocol defined duration (e.g., 1 hour or 30 min) and flag the dose records and following PK samples', 'PPK-ISOP-IPI', 1),
(15, 'Impute missing dose amount with nominal/actual dose', 'If dose information is missing for one or a few occasions of a subject, however treatment information (e.g., NIVO 3 mg/kg) is available flag the dose and following PK samples:\r\na. If the nominal dosing does not deviate +/- 50% to actual dosing (geo mean) for occasions with dosing information within that subjects (nominal 3 mg/kg, then actual should be 1.5-4.5 mg/kg), then impute missing dosing by using nominal dosing (e.g., 3 mg/kg * baseline body weight).\r\nb. If the nominal dosing deviation is greater than +/- 50% to actual dosing (geo mean) for occasions within that subjects, then impute missing dosing by using last observation carried forward approach. \r\nThe following scenarios use FLAG = 1: If dose information is missing for all occasions of a subject, and treatment information (e.g., NIVO 3 mg/kg) is unavailable, then add FLAG for exclusion.', 'PPK-ISOP-IPI', 1),
(21, 'Error in nominal dose - imputed with correct value', 'For dose record that have non-missing nominal dose and treatment, if nominal dose did not match TREATMENT specified dose amount in protocol, correct nominal dose and flag the dose record. Correct nominal dose before check dose amt error of flag 8', 'PPK-ISOP-IPI', 0),
(22, 'APRELTM > 5 for EOI samples', NULL, 'PPK-ISOP-IPI', 0),
(23, 'PK sample collected using incorrect kit in Study CA209142', 'Flag the record if (not applied to follow-up visit): \r\n1). subject in the Nivo monotherapy arm and week is not equal to cycle*2 -1\r\n2). subject in the Nivo + Ipi arm and cycle < 5 and week is not equal to cycle*3 -2;\r\n3). subject in the Nivo + Ipi arm and cycle >=5 and week is not equal to cycle*2 + 3;', 'PPK-ISOP-IPI', 0),
(24, 'Error in cycle and week - corrected with query response', 'For error in cycle and week in pk samples, correct cycle and week based on query result in study CA209142', 'PPK-ISOP-IPI', 0),
(1, 'No Dosing Records, all PK samples flagged; missing sample date and time or concentration; error in dosing date/time', 'this can be due to dosing/sampling date issue; for error in dose date/time, flag related PK samples with same flag number; negative AFRELTM when study day >0;', 'PPK-standard', 1),
(2, 'Post first dose LLOQ or BLQ or concentration = BD', NULL, 'PPK-standard', 1),
(3, 'Day 1 pre-dose samples', NULL, 'PPK-standard', 1),
(4, 'Duplicate sample with same concentration at same AFRELTM (eToolbox/PAMS set up for NCA analysis)', NULL, 'PPK-standard', 1),
(6, 'Duplicate samples with different concentrations', NULL, 'PPK-standard', 1),
(8, 'Error in dose amount', 'Defined as a +/- 50% deviation between nominal dose*WTB and AMT for weight-based dosing and nominal dose and AMT for flat-dosing. Subsequent pk samples are flagged as well', 'PPK-standard', 1),
(13, 'Imputed dose time', 'For a non-missed dose, if dose date is available but time is missing, then dosing time needs to be imputed by using the following (apply rules in the order presented):\r\n1. If infusion stop time is available but infusion start time is missing, the protocol defined duration (e.g. 1 hour or 30 min) is used to determine the start of infusion and vice versa if stop time is not available.\r\n2. If both infusion stop and start times are missing on any day other than day 1\r\na. If a trough sample was taken on the same day, use the trough sample time as the dosing time (start of infusion).\r\nb. If there is no trough but an EOI sample is taken on the same day then use EOI sample time minus duration of infusion to impute start time of the dose (start of infusion).\r\n3. If both infusion stop and start times are missing on day 1 then use pre-dose sample time or end of infusion sample time on the same day along with nominal infusion duration to determine the start of infusion time .\r\n4. If there are no concentrations associated with the missing dose time, then the dose time on the previous (or next if it is the first dose) occasion\'s dose will be used as the current dosing time.  This rule will be applied recursively if the dose time is missing for multiple dosing occasions.', 'PPK-standard', 1),
(15, 'Impute missing dose amount with nominal/actual dose', 'If dose information is missing for one or a few occasions of a subject, however treatment information (e.g., NIVO 3 mg/kg) is available flag the dose and following PK samples:\r\na. If the nominal dosing does not deviate +/- 50% to actual dosing (geo mean) for occasions with dosing information within that subjects (nominal 3 mg/kg, then actual should be 1.5-4.5 mg/kg), then impute missing dosing by using nominal dosing (e.g., 3 mg/kg * baseline body weight).\r\nb. If the nominal dosing deviation is greater than +/- 50% to actual dosing (geo mean) for occasions within that subjects, then impute missing dosing by using last observation carried forward approach. \r\nThe following scenarios use FLAG = 1: If dose information is missing for all occasions of a subject, and treatment information (e.g., NIVO 3 mg/kg) is unavailable, then add FLAG for exclusion.', 'PPK-standard', 0),
(100, 'Dose excluded due to lloq samples', 'Flag=100 is used to flag dose records for subjects having only pk samples with flag=1 through 5 (no analyzable pk records); while flag=1 is used to flag dose records for subjects having only pk samples with flag=1, 3, 4, 5', 'PPK-ISOP-IPI', 0),
(1, 'No Dosing Records, all PK samples flagged; missing sample date and time or concentration; error in dosing date/time', 'this can be due to dosing/sampling date issue; for error in dose date/time, flag related PK samples with same flag number; negative AFRELTM when study day >0;', 'PPK-ISOP-RELA', 1),
(2, 'Post first dose LLOQ or BLQ or concentration = BD', NULL, 'PPK-ISOP-RELA', 1),
(3, 'Day 1 pre-dose samples', NULL, 'PPK-ISOP-RELA', 1),
(4, 'Duplicate sample with same concentration at same AFRELTM (eToolbox/PAMS set up for NCA analysis)', NULL, 'PPK-ISOP-RELA', 1),
(6, 'Duplicate samples with different concentrations', NULL, 'PPK-ISOP-RELA', 1),
(8, 'Error in dose amount', 'Defined as a +/- 50% deviation between nominal dose*WTB and AMT for weight-based dosing and nominal dose and AMT for flat-dosing. Subsequent pk samples are flagged as well', 'PPK-ISOP-RELA', 1),
(13, 'Imputed dose time', 'For a non-missed dose, if dose date is available but time is missing, then dosing time needs to be imputed by using the following (apply rules in the order presented):\r\n1. If infusion stop time is available but infusion start time is missing, the protocol defined duration (e.g. 1 hour or 30 min) is used to determine the start of infusion and vice versa if stop time is not available.\r\n2. If both infusion stop and start times are missing on any day other than day 1\r\na. If a trough sample was taken on the same day, use the trough sample time as the dosing time (start of infusion).\r\nb. If there is no trough but an EOI sample is taken on the same day then use EOI sample time minus duration of infusion to impute start time of the dose (start of infusion).\r\n3. If both infusion stop and start times are missing on day 1 then use pre-dose sample time or end of infusion sample time on the same day along with nominal infusion duration to determine the start of infusion time .\r\n4. If there are no concentrations associated with the missing dose time, then the dose time on the previous (or next if it is the first dose) occasion\'s dose will be used as the current dosing time.  This rule will be applied recursively if the dose time is missing for multiple dosing occasions.', 'PPK-ISOP-RELA', 1),
(14, 'Imputed infusion duration', 'If infusion duration >=+/-100% of protocol defined duration, then impute the duration to protocol defined duration (e.g., 1 hour or 30 min) and flag the dose records and following PK samples', 'PPK-ISOP-RELA', 1),
(15, 'Impute missing dose amount with nominal/actual dose', 'If dose information is missing for one or a few occasions of a subject, however treatment information (e.g., NIVO 3 mg/kg) is available flag the dose and following PK samples:\r\na. If the nominal dosing does not deviate +/- 50% to actual dosing (geo mean) for occasions with dosing information within that subjects (nominal 3 mg/kg, then actual should be 1.5-4.5 mg/kg), then impute missing dosing by using nominal dosing (e.g., 3 mg/kg * baseline body weight).\r\nb. If the nominal dosing deviation is greater than +/- 50% to actual dosing (geo mean) for occasions within that subjects, then impute missing dosing by using last observation carried forward approach. \r\nThe following scenarios use FLAG = 1: If dose information is missing for all occasions of a subject, and treatment information (e.g., NIVO 3 mg/kg) is unavailable, then add FLAG for exclusion.', 'PPK-ISOP-RELA', 0);

-- --------------------------------------------------------

--
-- Table structure for table `dsstruct`
--

CREATE TABLE `dsstruct` (
  `varorder` int(11) NOT NULL,
  `var_name` char(10) NOT NULL,
  `var_label` char(50) NOT NULL,
  `units` varchar(20) NOT NULL,
  `type` varchar(10) NOT NULL,
  `round` varchar(20) DEFAULT NULL,
  `missVal` varchar(20) DEFAULT NULL,
  `note` text DEFAULT NULL,
  `source` text DEFAULT NULL,
  `requiredFlag` int(11) DEFAULT NULL,
  `SpecType` varchar(30) DEFAULT NULL,
  `nameChange` int(11) DEFAULT NULL,
  `labelChange` int(11) DEFAULT NULL,
  `unitChange` int(11) DEFAULT NULL,
  `typeChange` int(11) DEFAULT NULL,
  `roundChange` int(11) DEFAULT NULL,
  `missValChange` int(11) DEFAULT NULL,
  `noteChange` int(11) DEFAULT NULL,
  `sourceChange` int(11) DEFAULT NULL,
  `erflag` varchar(10) DEFAULT NULL
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

--
-- Dumping data for table `dsstruct`
--

INSERT INTO `dsstruct` (`varorder`, `var_name`, `var_label`, `units`, `type`, `round`, `missVal`, `note`, `source`, `requiredFlag`, `SpecType`, `nameChange`, `labelChange`, `unitChange`, `typeChange`, `roundChange`, `missValChange`, `noteChange`, `sourceChange`, `erflag`) VALUES
(1, 'PROTOCOL', 'Original Protocol Number', 'NA', 'Char', 'NA', 'NA', 'e.g. CA209010, MDX1106-01, ONO-4538-01\r\n', 'Derived according to notes', 1, 'PPK-NIVO', 0, 1, 0, 0, 0, 1, 1, 1, ''),
(2, 'BSTUDY', 'BMS Protocol number', 'NA', 'Char', 'NA', 'NA', 'Same as PROTOCOL, except: CA209001=MDX1106-01, CA209003=MDX1106-03, CA209005=ONO-4538-01, CA209051=ONO-4538-02\r', 'Derived according to notes', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(3, 'BSTUDYN', 'BMS Study Identifier (numeric)', 'NA', 'Num', 'NA', '.', '', 'Last 3 digits of BSTUDY', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(4, 'USUBJID', 'Unique patient identifier', 'NA', 'Char', 'NA', 'NA', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(5, 'EPID', 'BMS unique patient identifier', 'NA', 'Char', 'NA', 'NA', '', 'Derived form \"BMS study-site-pat\" from each of the raw datasets used', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(6, 'NMID', 'NONMEM ID', 'NA', 'Num', 'NA', '.', 'NONMEM ID will be generated from EPID', 'Derived based on EPID (Exclude \"CA209\", and concatenate numeric values)', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(7, 'VISIT', 'Visit label', 'NA', 'Char', 'NA', 'NA', 'Populate for all records', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(8, 'ATAFD', 'Actual time after first dose', 'hr', 'Num', '0.01', '.', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(9, 'NTAFD', 'Nominal time after first dose', 'hr', 'Num', '0.1', '.', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(10, 'NTAPD', 'Nominal time after previous dose', 'hr', 'Num', '0.1', '.', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(11, 'ATAPD', 'Actual time after previous dose', 'hr', 'Num', '0.01', '.', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(12, 'EVID', 'Event ID', 'NA', 'Num', 'NA', '.', '0=PK Event, 1=Dose Event', 'Derived according to notes', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(13, 'MDV', 'Missing DV', 'NA', 'Num', 'NA', '.', '0=observed value, 1=missing DV or suspicious data or dosing event', 'Derived according to notes', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(14, 'AMT', 'Dose amount of nivolumab', 'mg', 'Num', 'NA', '.', 'Only populated on dosing records. Use \".\" for non-dosing record (i.e., observations)', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(15, 'RATE', 'Rate of infusion', 'mg/hr', 'Num', '0.01', '.', '', 'AMT/DUR', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(16, 'DUR', 'Infusion duration', 'hr', 'Num', '0.01', '.', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(17, 'CONC', 'Serum concentration of nivolumab', 'ug/mL', 'Num', '0.01', '.', 'Use \".\" if it\'s a missing values or below LLOQ ', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(18, 'CONCSTAT', 'Concentration Status', 'NA', 'Num', 'NA', '0', '0=Evaluable Concentration, 1=BLOQ, 2=OUTLIER or Not Reportable, 3=Missing value, 4=Duplicate record for NCA setup. If concstatus in PAMS/eToolbox = missing then always code concstat = 0. Otherwise concstat = concstatus. Only populated for pk records.', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(19, 'LOGC', 'log(CONC)', 'NA', 'Num', '4 significant digits', '.', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(20, 'TX', 'Treatment description', 'NA', 'Char', 'NA', 'NA', 'Eg. nivo 3 mg/kg Q2W', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(21, 'NDOSE', 'Nominal dose of nivolumab', 'mg/kg', 'Num', 'NA', '.', '3=3 mg/kg, etc', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(22, 'DOSENUM', 'Dose Number', 'NA', 'Num', 'NA', '.', 'Sequential number: 1 = first dose, 2 = second dose, etc. For PK records retain from dose records', 'Derived according to notes', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(23, 'OCC', 'Occasion Identifier', 'NA', 'Num', 'NA', '.', '1=the first PK-related dose, 2=second PK-related dose, 3=third PK-related dose. Dose refers to BMS-936558. After assigning OCC, change pre first PK-related records (pk and dose) from . to 0', 'Derived according to notes', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(24, 'AGE', 'Age', 'years', 'Num', 'NA', '.', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(25, 'SEX', 'Sex', 'NA', 'Char', 'NA', 'NA', 'Male or Female', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(26, 'SEXN', 'Sex (numeric)', 'NA', 'Num', 'NA', '.', '1=Male, 2=Female', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(27, 'BBWT', 'Baseline body weight', 'kg', 'Num', 'NA', '.', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(28, 'BALB', 'Baseline serum albumin', 'g/dL', 'Num', 'NA', '.', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(29, 'BLDH', 'Baseline lactate dehydrogenase', 'U/L', 'Num', 'NA', '.', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(30, 'LDHULN', 'LDH Upper limit of normal', 'U/L', 'Num', 'NA', '.', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(31, 'BALP', 'Baseline serum alkaline phosphatase', 'U/L', 'Num', 'NA', '.', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(32, 'BHT', 'Baseline Height', 'cm', 'Num', 'NA', '.', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(33, 'BBMI', 'Baseline body mass index', 'kg/m2', 'Num', '0.01', '.', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(34, 'BBSA', 'Baseline body surface area', 'm2', 'Num', '0.01', '.', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(35, 'BALT', 'Baseline alanine aminotransferase', 'U/L', 'Num', 'NA', '.', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(36, 'BAST', 'Baseline aspartate aminotransferase', 'U/L', 'Num', 'NA', '.', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(37, 'BCRCL', 'Baseline creatinine clearance', 'mL/min', 'Num', '0.01', '.', '', 'Derived according to equation in Section 4.1', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(38, 'BSCR', 'Baseline serum creatinine', 'mg/dL', 'Num', 'NA', '.', '*0.011312 convert from umol/L to mg/dL', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(39, 'BGFR', 'Baseline GFR', 'ml/min/1.73m2', 'Num', '0.01', '.', '', 'Derived according to equation in Section 4.1', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(40, 'BALC', 'Baseline abs lymphocyte count', 'x10^3c/uL', 'Num', 'NA', '.', 'x10^9c/L is the same as x10^3c/uL', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(41, 'BTBILI', 'Baseline total bilirubin', 'mg/dL', 'Num', 'NA', '.', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(42, 'BDBILI', 'Baseline direct bilirubin', 'mg/dL', 'Num', 'NA', '.', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(43, 'HEPA', 'Liver dysfunction groups (char)', 'NA', 'Char', 'NA', 'NA', 'GROUP A: Normal (total bilirubin<=ULN and AST<=ULN), GROUP B: Mild (total bilirubin > 1.0x-1.5xULN or AST > ULN), GROUP C: Moderate (total bilirubin > 1.5x-3xULN), GROUP D: Severe (total bilirubin > 3xULN). Assign in reverse order to assign most severe group.', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(44, 'HEPAN', 'Liver dysfunction groups (num)', 'NA', 'Num', 'NA', '.', '1=GROUP A: Normal\r, 2=GROUP B: Mild\r, 3=GROUP C: Moderate\r, 4=GROUP D: Severe\r\n', 'Derived from HEPA', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(45, 'RACE', 'Race', 'NA', 'Char', 'NA', 'NA', 'White, Black/African American, Asian, American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander, Others, Unknown', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(46, 'RACEN', 'Race (numeric)', 'NA', 'Num', 'NA', '.', '1=White, 2=Black/African American, 3=Asian, 4=Others, 5=Unknown. American Indian/Alaska Native and Native Hawaiian/Other Pacific Islander are coded as 4.\n', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(47, 'CNTCODE', 'Country Code label', 'NA', 'Char', 'NA', 'NA', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(48, 'TTYPEF', 'Tumor Type label', 'NA', 'Char', 'NA', 'NA', 'Melanoma, SQ Non-small cell lung Cancer, NSQ Non-small cell lung Cancer, Unknown Histology Non-small cell lung cancer, Renal cell carcinoma, Colorectal cancer, Prostate cancer, Classical Hodgkin lymphoma, Squamous cell carcinoma of the head and neck, Bladder Cancer, Triple Negative Breast Cancer, Gastric Cancer, Pancreatic Cancer, Small Cell Lung Cancer, Ovarian Cancer, Hepatocellular Carcinoma, Glioblastoma, Adjuvant Melanoma, Cervical Cancer, Multiple Myeloma, Hodgkins Lymphoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Indolent Non-Hodgkins Lymphoma, Other Non-Hodgkins Lymphoma, Breast Cancer, Endometrial Cancer, Thyroid Cancer, Mesothelioma, Other', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(49, 'TTYPEN', 'Tumor Type', 'NA', 'Num', 'NA', '.', '1=Melanoma, 2=SQ Non-small cell lung cancer, 3=NSQ Non-small cell lung cancer, 4=Unknown Histology Non-small cell lung cancer, 5=Renal cell carcinoma, 6=Colorectal cancer, 7=Prostate cancer, 8=Classical Hodgkin lymphoma, 9=Squamous cell carcinoma of the head and neck, 10=Bladder, 11=Triple Negative Breast Cancer, 12=Gastric Cancer, 13=Pancreatic Cancer, 14=Small Cell Lung Cancer, 15=Ovarian Cancer, 16=Hepatocellular Carcinoma, 17=Glioblastoma, 18=Adjuvant Melanoma, 19=Cervical Cancer, 20=Multiple Myeloma, 21=Hodgkins Lymphoma, 22=Diffuse Large B-Cell Lymphoma, 23=Chronic Lymphocytic Leukemia, 24=Indolent Non-Hodgkins Lymphoma, 25=Other Non-Hodgkins Lymphoma, 26=Breast Cancer, 27=Endometrial Cancer, 28=Thyroid Cancer, 29=Mesothelioma, -99=Missing, 100=Other\r\n', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(50, 'BTSIZE', 'Baseline tumor burden', 'cm', 'Num', 'NA', '.', 'Sum of longest diameters of all target lesions,  convert tumor burden from mm to cm by dividing by 10', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(51, 'BTSIZE2', 'Baseline tumor burden', 'cm2', 'Num', 'NA', '.', 'Sum of products of diameters for all target lesions per IRRC', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(52, 'PS', 'Baseline performance status', 'NA', 'Num', 'NA', '.', '0 (Normal), 1, 2, 3, 4; If convert from KPS, 0=KPS 100, 1=KPS 90/80, 2=KPS 70/60, 3=KPS 50/40, 4=KPS 30/20/10    ', 'ECOG or Derived from KPS', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(53, 'ADA', 'Immunogenicity by visit level', 'NA', 'Num', 'NA', '.', '0=negative, 1=positive (any type), -99 =NSR, NRR, NA or missing', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(54, 'ADALIST', 'Immunogenicity by subject level', 'NA', 'Char', 'NA', 'NA', 'Immunogenicity Council Definition - Persistent Positive, Only the Last Sample Positive, Other Positive, Negative, NA', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(55, 'PDL11', 'PDL1 expression (1% cutoff)', 'NA', 'Char', 'NA', 'NA', 'positive, negative status - tumor only (>= 1% cutoff)', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(56, 'PDL15', 'PDL1 expression (5% cutoff)', 'NA', 'Char', 'NA', 'NA', 'positive, negative status - tumor only (>= 5% cutoff)', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(57, 'PDL110', 'PDL1 expression (10% cutoff)', 'NA', 'Char', 'NA', 'NA', 'positive, negative status - tumor only (>= 10% cutoff)', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(58, 'FLAG', 'Exclusion flag', 'NA', 'Num', 'NA', '0', '', 'See flag table in section 4', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(59, 'FLAGCOM', 'Exclusion flag comment', 'NA', 'Char', 'NA', 'NA', '', 'Description for FLAG per flag table in section 4', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(60, 'DTC', 'Date and time of event', 'NA', 'Char', 'NA', 'NA', 'Date and time of dose for EVID=1, Date and time of sample for EVID=0. Use ISO 8601 format which is a text representation of date and time e.g., 2013-05-09T08:58 where T is a time designator indicating time follows.', 'Derived according to notes', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(61, 'SAMPLEID', 'PK Sample ID', 'NA', 'Char', 'NA', 'NA', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(62, 'BUILD_DT', 'Dataset Creation Date', 'NA', 'Char', 'NA', 'NA', '', 'Created at run time', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(63, 'RECNUM', 'Record Number', 'NA', 'Num', 'NA', '.', 'Sequential numbering of records in a data set', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(64, 'LINE', 'Line of therapy', 'NA', 'Num', 'NA', '.', '', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(65, 'NDOSEF', 'Flat dose of nivolumab', 'mg', 'Num', 'NA', '.', '240=240 mg, etc', '', 1, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(66, 'BRAF', 'BRAF Mutation', 'NA', 'Num', 'NA', '.', 'BRAF mutation and wild type\r: 0 = negative (wild type), 1 = positive (Mutant)', '', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(67, 'MSTATUS', 'Metastatic status', 'NA', 'Char', 'NA', '.', 'M0, M1a, M1b, M1c (M1c includes with and without brain metastasis)', '', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(68, 'CHEW_SNU', 'Chewing tobacco/snuff', 'NA', 'Char', 'NA', 'NA', 'Never, Current, Former, Unknown', '', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(69, 'PIPE', 'Pipe smoking status', 'NA', 'Char', 'NA', 'NA', 'Never, Current, Former, Unknown', '', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(70, 'CIGAR', 'Cigar smoking status', 'NA', 'Char', 'NA', 'NA', 'Never, Current, Former, Unknown', '', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(71, 'CIGARETT', 'Cigarette smoking status', 'NA', 'Char', 'NA', 'NA', 'Never, Current, Former, Unknown', '', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(72, 'PDL1V', 'PDL1 expression value', 'NA', 'Num', 'NA', '.', '', '', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(73, 'PDL1A', 'PDL1 assay', 'NA', 'Char', 'NA', 'NA', 'e.g., JH, DAKO-Validated (preferred), DAKO-verified', '', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(74, 'COMBO', 'Combination treatment', 'NA', 'Num', 'NA', '.', '0=BMS-936558 was administered alone, 1=BMS-936558 and ipilimumab were administered concurrently, 2=BMS-936558 and chemotherapy', 'Derived as per notes', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(75, 'AIMG', 'Immunogenicity assay', 'NA', 'Num', 'NA', '.', '', '', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(76, 'LINEC', 'Line of therapy (Categorization)', 'NA', 'Char', 'NA', 'NA', '1, >1', 'LINEC=\'1\' where LINE=1, LINEC=\'>1\' where LINE>1. If LINE is missing then impute LINEC based on protocol', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(77, 'LINEN', 'Line of Therapy (Numerical)', 'NA', 'Num', 'NA', '.', '1, 2', 'LINEN=1 where LINEC=\'1\', LINEN=2 where LINEC=\'>1\'', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(78, 'IPICO', 'Ipi co-administered with nivo', 'NA', 'Num', 'NA', '.', '1=Yes, 0=No. Time-varying covariate. Get IPI dosing data from ex/adex filtered by EXTRT to ppk dataset by USUBJID and date.  For dose records, if an ipi dose (dose amt > 0) was given on the same date as a nivo dose (dose amt > 0) then IPICO would be 1.  For pk records please use LOCF from dose records.  Day-1, predose records will have IPICO as missing.', '', 0, 'PPK-NIVO', 1, 1, 0, 0, 0, 1, 1, 1, ''),
(79, 'NDOSEIPI', 'Nominal first dose for ipilimumab', 'mg/kg', 'Num', 'NA', '0', '0=No ipi', '', 0, 'PPK-NIVO', 1, 1, 1, 0, 0, 1, 1, 1, ''),
(80, 'NIPIFRQ', 'Nominal frequency for ipilimumab', 'week', 'Num', 'NA', '.', '3=Q3W, 6=Q6W, 12=Q12W', '', 0, 'PPK-NIVO', 1, 1, 1, 0, 0, 1, 1, 1, ''),
(81, 'CROSSOVR', 'Crossover NIVO to NIVO+IPI combo', 'NA', 'Num', 'NA', '.', '0=Not a crossover subject, 1=Cross over subject', '', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(82, 'TMB', 'Tumor Mutation Burden', 'mutations/Mb', 'Num', 'NA', '.', '', '', 0, 'PPK-NIVO', 0, 0, 1, 0, 0, 1, 1, 1, ''),
(83, 'TMBC', 'TMB Category', 'NA', 'Char', 'NA', 'Not Evaluable', 'High TMB, Low TBM, Not Evaluable. Nivo mono cutoff mutation >=12.61. Nivo + Ipi cutoff mutation >=10.09', 'Derived from TMB and Notes', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(84, 'BOR', 'Best overall response', 'NA', 'Char', 'NA', 'NA', 'Use BOR per CSR. CR = Complete response, PR = Partial response, SD = Stable disease, PD = Progressive disease, NE = Unevaluable, NA = Missing or not reported, NN = NON-CR/NON-PD, ND = No Disease ', '', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(85, 'BORN', 'Best overall response (numerical)', 'NA', 'Num', 'NA', '.', '1=CR, 2=PR, 3=SD, 4=PD, 5=NE, 6=NA, 7=NN, 8=ND', 'Derived from BOR', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(86, 'BORPER', 'BOR assessed by', 'NA', 'Char', 'NA', 'NA', '', '', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(87, 'BORCRT', 'BOR Criteria', 'NA', 'Char', 'NA', 'NA', 'mWHO, RECIST v1.0, RECIST v1.1\n', '', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(88, 'ETH', 'Ethnicity', 'NA', 'Char', 'NA', 'NA', 'Japanese, Others', 'Derived based on RACE and CNTCODE. ETH = Japanese where RACE = Asian and CNTCODE = Japan', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(89, 'ETHN', 'Ethnicity (numerical)', 'NA', 'Num', 'NA', '.', '1=Japanese, 100=Others', 'Derived based on ETH', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(90, 'NDUR', 'Nominal Nivolumab Infusion Duration', 'hr', 'Num', 'NA', '.', '', '', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(91, 'RGMN1', 'Dosing regimen in the first stage', 'week', 'Num', 'NA', '.', '2=Q2W, 3=Q3W', '', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(92, 'RGMNSS', 'Dose regimen in maintenance stage', 'week', 'Num', 'NA', '.', 'If no maintenance stage, the value of RGMNSS should be equal to the RGMN1 (do not leave blank)', '', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(93, 'NDOSE1', 'Nominal Dose at the first stage', 'NA', 'Num', 'NA', '.', '', 'Derived based on TX', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(94, 'NDOSESS', 'Nominal Dose at maintenance stage', 'NA', 'Num', 'NA', '.', 'If no maintenance stage, the value of NDOSESS should be equal to the NDOSE1 (do not leave blank)', 'Derived based on TX', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(95, 'DU1', 'Dose unit for NDOSE1', 'NA', 'Char', 'NA', 'NA', 'either mg or mg/kg', 'Derived based on TX', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(96, 'DUSS', 'Dose unit for NDOSESS', 'NA', 'Char', 'NA', 'NA', 'either mg or mg/kg; If no maintenance stage, the value of DUSS should be equal to the DU1 (do not leave blank)', 'Derived based on TX', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(97, 'ETIOLOGY', 'Etiology', 'NA', 'Char', 'NA', 'Not Reported', 'HBV, HCV, Uninfected, and Not Reported', '', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(98, 'ETIOLOGN', 'Etiology [N]', 'NA', 'Num', 'NA', '.', 'For ETIOLOGY = \'UNINFECTED\', ETIOLOGN = 1; For ETIOLOGY = \'HCV-INFECTED\', ETIOLOGN = 2; For ETIOLOGY = \'HBV - INFECTED\', ETIOLOGN = 3; For ETIOLOGY = \'HCV AND HBV COINFECTION\', ETIOLOGN = 4', 'Derived from ETIOLOGY', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(99, 'MSITX', 'MSI status and treatment in CA209142', 'NA', 'Char', 'NA', 'NA', 'NIVO; NIVO 1 + IPI 1; NIVO 3 + IPI 1; NIVO 1 + IPI 3; NIVO + IPI (MSI-H)', 'For 142 only\n142: lvl1142.dm$TRTGRP', 0, 'PPK-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(100, 'PROTOCOL', 'Original Protocol Number', 'NA', 'Char', 'NA', 'NA', 'e.g. CA209010, MDX1106-01, ONO-4538-01\n', 'Derived according to notes', 1, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(101, 'BSTUDY', 'BMS Protocol number', 'NA', 'Char', 'NA', 'NA', 'Same as PROTOCOL, except: CA209001=MDX1106-01, CA209003=MDX1106-03, CA209005=ONO-4538-01, CA209051=ONO-4538-02\r', 'Derived according to notes', 1, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(102, 'BSTUDYN', 'BMS Study Identifier (numeric)', 'NA', 'Num', 'NA', '.', '', 'Last 3 digits of BSTUDY', 1, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(103, 'USUBJID', 'Unique patient identifier', 'NA', 'Char', 'NA', 'NA', '', '', 1, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(104, 'EPID', 'BMS unique patient identifier', 'NA', 'Char', 'NA', 'NA', '', 'Derived form \"BMS study-site-pat\" from each of the raw datasets used', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(105, 'NMID', 'NONMEM ID', 'NA', 'Num', 'NA', '.', 'NONMEM ID will be generated from EPID', 'Derived based on EPID (Exclude \"CA209\", and concatenate numeric values)', 1, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(106, 'VISIT', 'Visit label', 'NA', 'Char', 'NA', 'NA', 'Populate for all records', '', 1, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(107, 'ATAFD', 'Actual time after first dose', 'hr', 'Num', '0.01', '.', '', '', 1, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 1, 1, 1, 1, ''),
(108, 'NTAFD', 'Nominal time after first dose', 'hr', 'Num', '0.1', '.', '', '', 1, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 1, 1, 1, 1, ''),
(109, 'NTAPD', 'Nominal time after previous dose', 'hr', 'Num', '0.1', '.', '', '', 1, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 1, 1, 1, 1, ''),
(110, 'ATAPD', 'Actual time after previous dose', 'hr', 'Num', '0.01', '.', '', '', 1, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 1, 1, 1, 1, ''),
(111, 'EVID', 'Event ID', 'NA', 'Num', 'NA', '.', '0=PK Event, 1=Dose Event', 'Derived according to notes', 1, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(112, 'MDV', 'Missing DV', 'NA', 'Num', 'NA', '.', '0=observed value, 1=missing DV or suspicious data or dosing event', 'Derived according to notes', 1, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(113, 'AMT', 'Dose amount', 'mg', 'Num', 'NA', '.', 'Only populated on dosing records. Use \".\" for non-dosing record (i.e., observations)', '', 1, 'PPK-NIVO-MODEL', 0, 1, 1, 0, 0, 1, 1, 1, ''),
(114, 'RATE', 'Rate of infusion', 'mg/hr', 'Num', '0.01', '.', '', 'AMT/DUR', 0, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 1, 1, 1, 1, ''),
(115, 'DUR', 'Infusion duration', 'hr', 'Num', '0.01', '.', '', '', 0, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 1, 1, 1, 1, ''),
(116, 'CONC', 'Serum concentration', 'ug/mL', 'Num', '0.01', '.', 'Use \".\" if it\'s a missing values or below LLOQ ', '', 1, 'PPK-NIVO-MODEL', 0, 1, 1, 0, 1, 1, 1, 1, ''),
(117, 'CONCSTAT', 'Concentration Status', 'NA', 'Num', 'NA', '0', '0=Evaluable Concentration, 1=BLOQ, 2=OUTLIER or Not Reportable, 3=Missing value, 4=Duplicate record for NCA setup. If concstatus in PAMS/eToolbox = missing then always code concstat = 0. Otherwise concstat = concstatus. Only populated for pk records.', '', 1, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(118, 'LOGC', 'log(CONC)', 'NA', 'Num', '4 significant digits', '.', '', '', 1, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(119, 'TX', 'Treatment description', 'NA', 'Char', 'NA', 'NA', 'Eg. nivo 3 mg/kg Q2W', '', 1, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(120, 'NDOSE', 'Nominal dose', 'mg/kg', 'Num', 'NA', '.', '3=3 mg/kg, etc', '', 0, 'PPK-NIVO-MODEL', 0, 1, 1, 0, 0, 1, 1, 1, ''),
(121, 'DOSENUM', 'Dose Number', 'NA', 'Num', 'NA', '.', 'Sequential number: 1 = first dose, 2 = second dose, etc. For PK records retain from dose records', 'Derived according to notes', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(122, 'OCC', 'Occasion Identifier', 'NA', 'Num', 'NA', '.', '1=the first PK-related dose, 2=second PK-related dose, 3=third PK-related dose. After assigning OCC, change pre first PK-related records (pk and dose) from . to 0', 'Derived according to notes', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(123, 'AGE', 'Age', 'years', 'Num', 'NA', '.', '', '', 1, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 0, 1, 1, 1, ''),
(124, 'SEX', 'Sex', 'NA', 'Char', 'NA', 'NA', 'Male or Female', '', 1, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(125, 'SEXN', 'Sex (numeric)', 'NA', 'Num', 'NA', '.', '1=Male, 2=Female', '', 1, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(126, 'BBWT', 'Baseline body weight', 'kg', 'Num', 'NA', '.', '', '', 0, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 0, 1, 1, 1, ''),
(127, 'BALB', 'Baseline serum albumin', 'g/dL', 'Num', 'NA', '.', '', '', 0, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 0, 1, 1, 1, ''),
(128, 'BLDH', 'Baseline lactate dehydrogenase', 'U/L', 'Num', 'NA', '.', '', '', 0, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 0, 1, 1, 1, ''),
(129, 'LDHULN', 'LDH Upper limit of normal', 'U/L', 'Num', 'NA', '.', '', '', 0, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 0, 1, 1, 1, ''),
(130, 'BALP', 'Baseline serum alkaline phosphatase', 'U/L', 'Num', 'NA', '.', '', '', 0, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 0, 1, 1, 1, ''),
(131, 'BHT', 'Baseline Height', 'cm', 'Num', 'NA', '.', '', '', 0, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 0, 1, 1, 1, ''),
(132, 'BBMI', 'Baseline body mass index', 'kg/m2', 'Num', '0.01', '.', '', '', 0, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 0, 1, 1, 1, ''),
(133, 'BBSA', 'Baseline body surface area', 'm2', 'Num', '0.01', '.', '', '', 0, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 0, 1, 1, 1, ''),
(134, 'BALT', 'Baseline alanine aminotransferase', 'U/L', 'Num', 'NA', '.', '', '', 0, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 0, 1, 1, 1, ''),
(135, 'BAST', 'Baseline aspartate aminotransferase', 'U/L', 'Num', 'NA', '.', '', '', 0, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 0, 1, 1, 1, ''),
(136, 'BCRCL', 'Baseline creatinine clearance', 'mL/min', 'Num', '0.01', '.', '', 'Derived according to equation in Section 4.1', 0, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 0, 1, 1, 1, ''),
(137, 'BSCR', 'Baseline serum creatinine', 'mg/dL', 'Num', 'NA', '.', '*0.011312 convert from umol/L to mg/dL', '', 0, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 0, 1, 1, 1, ''),
(138, 'BGFR', 'Baseline GFR', 'ml/min/1.73m2', 'Num', '0.01', '.', '', 'Derived according to equation in Section 4.1', 0, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 0, 1, 1, 1, ''),
(139, 'BALC', 'Baseline abs lymphocyte count', 'x10^3c/uL', 'Num', 'NA', '.', 'x10^9c/L is the same as x10^3c/uL', '', 0, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 0, 1, 1, 1, ''),
(140, 'BTBILI', 'Baseline total bilirubin', 'mg/dL', 'Num', 'NA', '.', '', '', 0, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 0, 1, 1, 1, ''),
(141, 'BDBILI', 'Baseline direct bilirubin', 'mg/dL', 'Num', 'NA', '.', '', '', 0, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 0, 1, 1, 1, ''),
(142, 'HEPA', 'Liver dysfunction groups (char)', 'NA', 'Char', 'NA', 'NA', 'GROUP A: Normal (total bilirubin<=ULN and AST<=ULN), GROUP B: Mild (total bilirubin > 1.0x-1.5xULN or AST > ULN), GROUP C: Moderate (total bilirubin > 1.5x-3xULN), GROUP D: Severe (total bilirubin > 3xULN). Assign in reverse order to assign most severe group.', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(143, 'HEPAN', 'Liver dysfunction groups (num)', 'NA', 'Num', 'NA', '.', '1=GROUP A: Normal\r, 2=GROUP B: Mild\r, 3=GROUP C: Moderate\r, 4=GROUP D: Severe\r\n', 'Derived from HEPA', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(144, 'RACE', 'Race', 'NA', 'Char', 'NA', 'NA', 'White, Black/African American, Asian, American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander, Others, Unknown', '', 1, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(145, 'RACEN', 'Race (numeric)', 'NA', 'Num', 'NA', '.', '1=White, 2=Black/African American, 3=Asian, 4=Others, 5=Unknown. American Indian/Alaska Native and Native Hawaiian/Other Pacific Islander are coded as 4.\n', '', 1, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(146, 'CNTCODE', 'Country Code label', 'NA', 'Char', 'NA', 'NA', '', '', 1, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(147, 'TTYPEF', 'Tumor Type label', 'NA', 'Char', 'NA', 'NA', 'Melanoma, SQ Non-small cell lung Cancer, NSQ Non-small cell lung Cancer, Unknown Histology Non-small cell lung cancer, Renal cell carcinoma, Colorectal cancer, Prostate cancer, Classical Hodgkin lymphoma, Squamous cell carcinoma of the head and neck, Bladder Cancer, Triple Negative Breast Cancer, Gastric Cancer, Pancreatic Cancer, Small Cell Lung Cancer, Ovarian Cancer, Hepatocellular Carcinoma, Glioblastoma, Adjuvant Melanoma, Cervical Cancer, Multiple Myeloma, Hodgkins Lymphoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Indolent Non-Hodgkins Lymphoma, Other Non-Hodgkins Lymphoma, Breast Cancer, Endometrial Cancer, Thyroid Cancer, Mesothelioma, Other', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(148, 'TTYPEN', 'Tumor Type', 'NA', 'Num', 'NA', '.', '1=Melanoma, 2=SQ Non-small cell lung cancer, 3=NSQ Non-small cell lung cancer, 4=Unknown Histology Non-small cell lung cancer, 5=Renal cell carcinoma, 6=Colorectal cancer, 7=Prostate cancer, 8=Classical Hodgkin lymphoma, 9=Squamous cell carcinoma of the head and neck, 10=Bladder, 11=Triple Negative Breast Cancer, 12=Gastric Cancer, 13=Pancreatic Cancer, 14=Small Cell Lung Cancer, 15=Ovarian Cancer, 16=Hepatocellular Carcinoma, 17=Glioblastoma, 18=Adjuvant Melanoma, 19=Cervical Cancer, 20=Multiple Myeloma, 21=Hodgkins Lymphoma, 22=Diffuse Large B-Cell Lymphoma, 23=Chronic Lymphocytic Leukemia, 24=Indolent Non-Hodgkins Lymphoma, 25=Other Non-Hodgkins Lymphoma, 26=Breast Cancer, 27=Endometrial Cancer, 28=Thyroid Cancer, 29=Mesothelioma, -99=Missing, 100=Other', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(149, 'BTSIZE', 'Baseline tumor burden', 'cm', 'Num', 'NA', '.', 'Sum of longest diameters of all target lesions,  convert tumor burden from mm to cm by dividing by 10', '', 0, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 0, 1, 1, 1, ''),
(150, 'BTSIZE2', 'Baseline tumor burden', 'cm2', 'Num', 'NA', '.', 'Sum of products of diameters for all target lesions per IRRC', '', 0, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 0, 1, 1, 1, ''),
(151, 'PS', 'Baseline performance status', 'NA', 'Num', 'NA', '.', '0 (Normal), 1, 2, 3, 4; If convert from KPS, 0=KPS 100, 1=KPS 90/80, 2=KPS 70/60, 3=KPS 50/40, 4=KPS 30/20/10', 'ECOG or Derived from KPS', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(152, 'ADA', 'Immunogenicity by visit level', 'NA', 'Num', 'NA', '.', '0=negative, 1=positive (any type), -99 =NSR, NRR, NA or missing', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(153, 'ADALIST', 'Immunogenicity by subject level', 'NA', 'Char', 'NA', 'NA', 'Immunogenicity Council Definition - Persistent Positive, Only the Last Sample Positive, Other Positive, Negative, NA', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(154, 'PDL11', 'PDL1 expression (1% cutoff)', 'NA', 'Char', 'NA', 'NA', 'positive, negative status - tumor only (>= 1% cutoff)', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(155, 'PDL15', 'PDL1 expression (5% cutoff)', 'NA', 'Char', 'NA', 'NA', 'positive, negative status - tumor only (>= 5% cutoff)', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(156, 'PDL110', 'PDL1 expression (10% cutoff)', 'NA', 'Char', 'NA', 'NA', 'positive, negative status - tumor only (>= 10% cutoff)', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(157, 'FLAG', 'Exclusion flag', 'NA', 'Num', 'NA', '0', '', 'See flag table in section 4', 1, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(158, 'FLAGCOM', 'Exclusion flag comment', 'NA', 'Char', 'NA', 'NA', '', 'Description for FLAG per flag table in section 4', 1, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(159, 'DTC', 'Date and time of event', 'NA', 'Char', 'NA', 'NA', 'Date and time of dose for EVID=1, Date and time of sample for EVID=0. Use ISO 8601 format which is a text representation of date and time e.g., 2013-05-09T08:58 where T is a time designator indicating time follows.', 'Derived according to notes', 1, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(160, 'SAMPLEID', 'PK Sample ID', 'NA', 'Char', 'NA', 'NA', '', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(161, 'BUILD_DT', 'Dataset Creation Date', 'NA', 'Char', 'NA', 'NA', '', 'Created at run time', 1, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(162, 'RECNUM', 'Record Number', 'NA', 'Num', 'NA', '.', 'Sequential numbering of records in a data set', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(163, 'LINE', 'Line of therapy', 'NA', 'Num', 'NA', '.', '', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(164, 'NDOSEF', 'Flat dose', 'mg', 'Num', 'NA', '.', '240=240 mg, etc', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(165, 'BRAF', 'BRAF Mutation', 'NA', 'Num', 'NA', '.', 'BRAF mutation and wild type\r: 0 = negative (wild type), 1 = positive (Mutant)', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(166, 'MSTATUS', 'Metastatic status', 'NA', 'Char', 'NA', '.', 'M0, M1a, M1b, M1c (M1c includes with and without brain metastasis)', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(167, 'CHEW_SNU', 'Chewing tobacco/snuff', 'NA', 'Char', 'NA', 'NA', 'Never, Current, Former, Unknown', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(168, 'PIPE', 'Pipe smoking status', 'NA', 'Char', 'NA', 'NA', 'Never, Current, Former, Unknown', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(169, 'CIGAR', 'Cigar smoking status', 'NA', 'Char', 'NA', 'NA', 'Never, Current, Former, Unknown', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(170, 'CIGARETT', 'Cigarette smoking status', 'NA', 'Char', 'NA', 'NA', 'Never, Current, Former, Unknown', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(171, 'PDL1V', 'PDL1 expression value', 'NA', 'Num', 'NA', '.', '', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(172, 'PDL1A', 'PDL1 assay', 'NA', 'Char', 'NA', 'NA', 'e.g., JH, DAKO-Validated (preferred), DAKO-verified', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(173, 'COMBO', 'Combination treatment', 'NA', 'Num', 'NA', '.', '0=ipilimumab was administered alone, 1=ipilimumab and nivolumab were administered concurrently', 'Derived as per notes', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(174, 'AIMG', 'Immunogenicity assay', 'NA', 'Num', 'NA', '.', '', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(175, 'LINEC', 'Line of therapy (Categorization)', 'NA', 'Char', 'NA', 'NA', '1, >1', 'LINEC=\'1\' where LINE=1, LINEC=\'>1\' where LINE>1. If LINE is missing then impute LINEC based on protocol', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(176, 'LINEN', 'Line of Therapy (Numerical)', 'NA', 'Num', 'NA', '.', '1, 2', 'LINEN=1 where LINEC=\'1\', LINEN=2 where LINEC=\'>1\'', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(177, 'IPICO', 'Ipi co-administered with nivo', 'NA', 'Num', 'NA', '.', '1=Yes, 0=No. Time-varying covariate. Get IPI dosing data from ex/adex filtered by EXTRT to ppk dataset by USUBJID and date.  For dose records, if an ipi dose (dose amt > 0) was given on the same date as a nivo dose (dose amt > 0) then IPICO would be 1.  For pk records please use LOCF from dose records.  Day-1, predose records will have IPICO as missing.', '', 0, 'PPK-NIVO-MODEL', 1, 1, 0, 0, 0, 1, 1, 1, ''),
(178, 'NDOSEIPI', 'Nominal first dose for ipilimumab', 'mg/kg', 'Num', 'NA', '0', '0=No ipi', '', 0, 'PPK-NIVO-MODEL', 1, 1, 1, 0, 0, 1, 1, 1, ''),
(179, 'NIPIFRQ', 'Nominal frequency for ipilimumab', 'week', 'Num', 'NA', '.', '3=Q3W, 6=Q6W, 12=Q12W', '', 0, 'PPK-NIVO-MODEL', 1, 1, 1, 0, 0, 1, 1, 1, ''),
(180, 'CROSSOVR', 'Crossover NIVO to NIVO+IPI combo', 'NA', 'Num', 'NA', '.', '0=Not a crossover subject, 1=Cross over subject', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(181, 'TMB', 'Tumor Mutation Burden', 'mutations/Mb', 'Num', 'NA', '.', '', '', 0, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 0, 1, 1, 1, ''),
(182, 'BOR', 'Best overall response', 'NA', 'Char', 'NA', 'NA', 'Use BOR per CSR. CR = Complete response, PR = Partial response, SD = Stable disease, PD = Progressive disease, NE = Unevaluable, NA = Missing or not reported, NN = NON-CR/NON-PD, ND = No Disease ', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(183, 'BORN', 'Best overall response (numerical)', 'NA', 'Num', 'NA', '.', '1=CR, 2=PR, 3=SD, 4=PD, 5=NE, 6=NA, 7=NN, 8=ND', 'Derived from BOR', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(184, 'BORPER', 'BOR assessed by', 'NA', 'Char', 'NA', 'NA', '', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(185, 'BORCRT', 'BOR Criteria', 'NA', 'Char', 'NA', 'NA', 'mWHO, RECIST v1.0, RECIST v1.1\n', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(186, 'ETH', 'Ethnicity', 'NA', 'Char', 'NA', 'NA', 'Japanese, Others', 'Derived based on RACE and CNTCODE. ETH = Japanese where RACE = Asian and CNTCODE = Japan', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(187, 'ETHN', 'Ethnicity (numerical)', 'NA', 'Num', 'NA', '.', '1=Japanese, 100=Others', 'Derived based on ETH', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(188, 'NDUR', 'Nominal Infusion Duration', 'hr', 'Num', 'NA', '.', '', '', 0, 'PPK-NIVO-MODEL', 0, 0, 1, 0, 0, 1, 1, 1, ''),
(189, 'RGMN1', 'Dosing regimen in the first stage', 'week', 'Num', 'NA', '.', '2=Q2W, 3=Q3W', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(190, 'RGMNSS', 'Dose regimen in maintenance stage', 'week', 'Num', 'NA', '.', 'If no maintenance stage, the value of RGMNSS should be equal to the RGMN1 (do not leave blank)', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(191, 'NDOSE1', 'Nominal Dose at the first stage', 'NA', 'Num', 'NA', '.', '', 'Derived based on TX', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(192, 'NDOSESS', 'Nominal Dose at maintenance stage', 'NA', 'Num', 'NA', '.', 'If no maintenance stage, the value of NDOSESS should be equal to the NDOSE1 (do not leave blank)', 'Derived based on TX', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(193, 'DU1', 'Dose unit for NDOSE1', 'NA', 'Char', 'NA', 'NA', 'either mg or mg/kg', 'Derived based on TX', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(194, 'DUSS', 'Dose unit for NDOSESS', 'NA', 'Char', 'NA', 'NA', 'either mg or mg/kg; If no maintenance stage, the value of DUSS should be equal to the DU1 (do not leave blank)', 'Derived based on TX', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(195, 'ETIOLOGY', 'Etiology', 'NA', 'Char', 'NA', 'Not Reported', 'HBV, HCV, Uninfected, and Not Reported', '', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(196, 'ETIOLOGN', 'Etiology [N]', 'NA', 'Num', 'NA', '.', 'For ETIOLOGY = \'UNINFECTED\', ETIOLOGN = 1; For ETIOLOGY = \'HCV-INFECTED\', ETIOLOGN = 2; For ETIOLOGY = \'HBV - INFECTED\', ETIOLOGN = 3; For ETIOLOGY = \'HCV AND HBV COINFECTION\', ETIOLOGN = 4', 'Derived from ETIOLOGY', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(197, 'MSITX', 'MSI status and treatment in CA209142', 'NA', 'Char', 'NA', 'NA', 'NIVO; NIVO 1 + IPI 1; NIVO 3 + IPI 1; NIVO 1 + IPI 3; NIVO + IPI (MSI-H)', 'For 142 only\n142: lvl1142.dm$TRTGRP', 0, 'PPK-NIVO-MODEL', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(273, 'STUDYID', 'Study ID', 'NA', 'Char', 'NA', 'NA', 'Eg. CA209003 ', '', 1, 'ER-safety', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(274, 'USUBJID', 'Unique patient identifier', 'NA', 'Char', 'NA', 'NA', '', '', 1, 'ER-safety', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(275, 'ID', 'ID', 'NA', 'Num', 'NA', '.', 'Sequential numbering, (1, 2, 3, ...). One ID per subject.', 'Derived according to notes', 1, 'ER-safety', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(276, 'GR3COD', 'AE Term of Gr3+ AE', 'NA', 'Char', 'NA', 'NA', 'Missing if GR3F=0', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'gr3'),
(277, 'GR3M', 'Time to Gr3+ AE', 'month', 'Num', 'NA', '.', 'GR3D/365.25*12', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'gr3'),
(278, 'GR3D', 'Time to Gr3+ AE', 'day', 'Num', 'NA', '.', 'Time from 1st treatment to the 1st event/censoring. For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.  ', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset\nDerived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'gr3'),
(279, 'GR3F', 'Flag of Gr3+ AE', 'NA', 'Num', 'NA', '.', 'Gr. 3+ AE: AETOXGRN>=3, TEAE100=\'Y\', ADSL$SAFFL=\'Y\'. 1-Event, 0-No event (Censored)', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'gr3'),
(280, 'AEDECOD', 'AE Term of AE-DC/D', 'NA', 'Char', 'NA', 'NA', 'Missing if AEDCF=0', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'aedcd'),
(281, 'AEDCM', 'Time to AE-DC/D', 'month', 'Num', 'NA', '.', 'AEDCD/365.25*12', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'aedcd'),
(282, 'AEDCD', 'Time to AE-DC/D', 'day', 'Num', 'NA', '.', 'Time from 1st treatment to the 1st event/censoring; For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.  ', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset. Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'aedcd'),
(283, 'AEDCF', 'Flag of AE-DC/D', 'NA', 'Num', 'NA', '.', 'AE-DC/D: AEDISCFL^=\"\" or AESDTH=\"Y\"  (also need to review the AEDECOD of the list to exclude disease related terms), TEAE100=\'Y\', ADSL$SAFFL=\'Y\'. 1-Event, 0-No event (Censored)', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'aedcd'),
(284, 'IMAECOD', 'AE Term of immune-related AE', 'NA', 'Char', 'NA', 'NA', 'Missing if IMAEF=0', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'imae'),
(285, 'IMAEM', 'Time to immune-related AE', 'month', 'Num', 'NA', '.', 'IMAED/362.25*12', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'imae'),
(286, 'IMAED', 'Time to immune-related AE', 'day', 'Num', 'NA', '.', 'Time from 1st treatment to the 1st event/censoring. For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.  ', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset. Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'imae'),
(287, 'IMAEF', 'Flag of immune-related AE', 'NA', 'Num', 'NA', '.', 'IMAE: 8<=CLASSE2N<=20, TEAE100=\'Y\', ADSL$SAFFL=\'Y\'. 1-Event, 0-No event (Censored)', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'imae'),
(288, 'IMAEGR2C', 'AE Term of Gr2+ IMAE', 'NA', 'Char', 'NA', 'NA', 'Missing if IMAEGR2F=0', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'imaegr2'),
(289, 'IMAEGR2M', 'Time to Gr2+ IMAE', 'month', 'Num', 'NA', '.', 'IMAEGR2D/365.25*12', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'imaegr2'),
(290, 'IMAEGR2D', 'Time to Gr2+ IMAE', 'day', 'Num', 'NA', '.', 'Time from 1st treatment to the 1st event/censoring. For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.  ', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset\nDerived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'imaegr2'),
(291, 'IMAEGR2F', 'Flag of Gr2+ IMAE', 'NA', 'Num', 'NA', '.', 'Gr. 2+ IMAE: AETOXGRN>=2,  8<=CLASSE2N<=20, TEAE100=\'Y\', ADSL$SAFFL=\'Y\'. 1-Event, 0-No event (Censored)', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'imaegr2'),
(292, 'DRAEDCM', 'Time to drug-related AE-DC/D', 'month', 'Num', 'NA', '.', 'DRAEDCD/365.25*12', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'draedcd'),
(293, 'DRAEDCD', 'Time to drug-related AE-DC/D', 'day', 'Num', 'NA', '.', 'Time from 1st treatment to the 1st drug-related event/censoring (in month). For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.  ', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset. Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'draedcd'),
(294, 'DRAEDCDC', 'AE Term of drug-related AE-DC/D', 'NA', 'Char', 'NA', 'NA', 'Missing if DRAEDCF=0', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'draedcd'),
(295, 'DRAEDCF', 'Flag of drug-related AE-DC/D', 'NA', 'Num', 'NA', '.', 'Drug-related: AREL=\'RELATED\', AE-DC/D : AEDISCFL^=\"\" or AESDTH=\"Y\" (also need to review the AEDECOD of the list to exclude disease related terms), TEAE100=\'Y\', ADSL$SAFFL=\'Y\'. 1-Event, 0-No event (Censored).', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'draedcd'),
(296, 'DRGR2M', 'Time to drug-related Gr2+ AE', 'month', 'Num', 'NA', '.', 'DRGR2D/365.25*12', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'drgr2'),
(297, 'DRGR2D', 'Time to drug-related Gr2+ AE', 'day', 'Num', 'NA', '.', 'Time from 1st treatment to the 1st drug-related Grade 2+ event/censoring. For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.  ', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset. Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'drgr2'),
(298, 'DRGR2F', 'Flag of drug-related Gr2+ AE', 'NA', 'Num', 'NA', '.', 'Drug-related: AREL=\'RELATED\', Gr. 2+ AE: AETOXGRN>=2,  TEAE100=\'Y\', ADSL$SAFFL=\'Y\'. 1-Event, 0-No event (Censored)', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'drgr2'),
(299, 'DRGR2COD', 'AE Term of drug-related Gr2+ AE', 'NA', 'Char', 'NA', 'NA', 'Missing if DRGR2F=0', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'drgr2'),
(300, 'DRGR3M', 'Time to drug-related Gr3+ AE', 'month', 'Num', 'NA', '.', 'DRGR3D/365.25*12', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'drgr3'),
(301, 'DRGR3D', 'Time to drug-related Gr3+ AE', 'day', 'Num', 'NA', '.', 'Time from 1st treatment to the 1st drug-related Grade 3+ event/censoring. For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.  ', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset. Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'drgr3'),
(302, 'DRGR3F', 'Flag of drug-related Gr3+ AE', 'NA', 'Num', 'NA', '.', 'Drug-related: AREL=\'RELATED\', Gr. 3+ AE: AETOXGRN>=3,  TEAE100=\'Y\', ADSL$SAFFL=\'Y\'. 1-Event, 0-No event (Censored)', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'drgr3'),
(303, 'DRGR3COD', 'AE Term of drug-related Gr3+ AE', 'NA', 'Char', 'NA', 'NA', 'Missing if DRGR3F=0', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'drgr3'),
(304, 'DRAEM', 'Time to drug-related AE', 'month', 'Num', 'NA', '.', 'DRAED/365.25*12', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'drae'),
(305, 'DRAED', 'Time to drug-related AE', 'day', 'Num', 'NA', '.', 'Time from 1st treatment to the 1st drug-related adverse event/censoring. For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.  ', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset. Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'drae'),
(306, 'DRAEF', 'Flag of drug-related AE', 'NA', 'Num', 'NA', '.', 'Drug-related: AREL=\'RELATED\', TEAE100=\'Y\', ADSL$SAFFL=\'Y\'. 1-Event, 0-No event (Censored)', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'drae'),
(307, 'DRAECOD', 'AE Term of drug-related AE', 'NA', 'Char', 'NA', 'NA', 'Missing if DRAEF=0', 'Derived according to notes', 0, 'ER-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'drae'),
(308, 'STUDYID', 'Study ID', 'NA', 'Char', 'NA', 'NA', 'Eg. CA209003 ', '', 1, 'ER-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(309, 'USUBJID', 'Unique patient identifier', 'NA', 'Char', 'NA', 'NA', '', '', 1, 'ER-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(310, 'ID', 'ID', 'NA', 'Num', 'NA', '.', 'Sequential numbering, (1, 2, 3, ...). One ID per subject.', 'Derived according to notes', 1, 'ER-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, ''),
(311, 'BOR', 'Best overall response', 'NA', 'Char', 'NA', 'NA', 'Use BOR per CSR. CR = Complete response, PR = Partial response, SD = Stable disease, PD = Progressive disease, NE = Unevaluable, NA = Missing or not reported, NN = NON-CR/NON-PD, ND = No Disease ', '', 0, 'ER-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'bor'),
(312, 'BORN', 'Best overall response (numerical)', 'NA', 'Num', 'NA', '.', '1=CR, 2=PR, 3=SD, 4=PD, 5=NE, 6=NA, 7=NN, 8=ND', 'Derived from BOR', 0, 'ER-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'bor'),
(313, 'CNSRPFS', 'Censoring PFS', 'NA', 'Num', 'NA', '.', '0=Censored, 1=Death/Event', '', 0, 'ER-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'pfs'),
(314, 'PFS', 'Time to PFS in days', 'day', 'Num', 'NA', '.', '', '', 0, 'ER-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'pfs'),
(315, 'PFSM', 'Time to PFS in months', 'month', 'Num', 'NA', '.', '', '', 0, 'ER-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'pfs'),
(316, 'CNSROS', 'Censoring OS', 'NA', 'Num', 'NA', '.', '0=Censored, 1=Death/Event', '', 0, 'ER-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'os'),
(317, 'OSD', 'Time to OS in days', 'day', 'Num', 'NA', '.', '', '', 0, 'ER-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'os'),
(318, 'OSM', 'Time to OS in months', 'month', 'Num', 'NA', '.', '', '', 0, 'ER-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'os'),
(426, 'DNCP', 'Dose normalized conc', 'ug/mL/mg', 'Num', 'NA', 'NA', ' CONC/AMT when AMT is retained from the previous dose record', ' ', 0, 'PPK-NIVO-MODEL', 0, 1, 0, 0, 0, 1, 1, 1, ''),
(1173, 'PROJID', 'Project Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1174, 'STUDYID', 'Study Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1175, 'STUDYIDN', 'Study Identifier (N)', 'NA', 'Num', 'NA', '.', 'Convert alphanumeric studies to numeric using alphabetic letter position, e.g. A=01, U=21. Study 76U would be STUDYIDN=7621.', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1176, 'USUBJID', 'Unique Subject Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1177, 'USUBJIDN', 'Unique Subject Identifier (N)', 'NA', 'Num', 'NA', '.', 'Unique numerical representation of USUBJID.', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1178, 'ID', 'NONMEM ID', 'NA', 'Num', 'NA', '.', 'Sequential numbering, (1, 2, 3, ...). One ID per subject.', 'Derived based on USUBJID (Exclude \"CA209\", and concatenate numeric values)', 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL);
INSERT INTO `dsstruct` (`varorder`, `var_name`, `var_label`, `units`, `type`, `round`, `missVal`, `note`, `source`, `requiredFlag`, `SpecType`, `nameChange`, `labelChange`, `unitChange`, `typeChange`, `roundChange`, `missValChange`, `noteChange`, `sourceChange`, `erflag`) VALUES
(1179, 'RECSEQ', 'Record Sequence', 'NA', 'Num', 'NA', '.', 'Sequential values should start with 1 on the first non-header row of the data file and incrementing by 1 for each subsequent row.', 'Derived according to notes', 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1180, 'VISIT', 'Visit', 'NA', 'Char', 'NA', 'blank', 'Clinic visit captured in STDM domains EX or PC and variable VISIT', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1181, 'AFRELTM', 'Actual Rel Time From First Dose', 'hr', 'Num', '0.01', '.', 'Rel: Relative. Derived from (Analysis date/time of the current event/record of the subject) - (Analysis date/time of the first dosing event/record of the subject)', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1182, 'NFRELTM', 'Nominal Rel Time From First Dose', 'hr', 'Num', '0.1', '.', 'Rel: Relative. Planned elapsed time (for sample point or start of sampling interval) from first exposure to study treatment.', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1183, 'NPRELTM', 'Nominal Rel Time From Previous Dose', 'hr', 'Num', '0.1', '.', 'Rel: Relative. For PK it can be derived from NTIME in PC domain.', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1184, 'APRELTM', 'Actual Rel Time From Previous Dose', 'hr', 'Num', '0.01', '.', 'Rel: Relative. Derived from (Analysis date/time of the current event/record of the subject) - (Analysis date/time of the previous dosing event/record of the subject).', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1185, 'EVID', 'Event ID', 'NA', 'Num', 'NA', '.', '0=PK event, 1=dose event.', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1186, 'MDV', 'Missing DV', 'NA', 'Num', 'NA', '.', '0=observed value, 1=missing DV or suspicious data or dosing event', 'Derived according to notes', 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1187, 'DOSEA', 'Actual Dose of Nivolumab', 'mg', 'Num', 'NA', '.', 'Populated on all individual records as carry-forward.', NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1188, 'AMT', 'Actual Amount of Nivolumab', 'mg', 'Num', 'NA', '.', 'Only populated on dosing records. Use \".\" for non-dosing record (i.e., observations)', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1189, 'RATE', 'Infusion Rate', 'mg/hr', 'Num', '0.01', '.', 'AMT/DOSEDUR', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1190, 'DOSEDUR', 'Duration of Treatment Dose', 'hr', 'Num', '0.01', '.', 'Derived from (End dose date/time) - (Start dose date/time) - (infusion interruption if available).', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1191, 'DV', 'Serum Concentration of Nivolumab', 'ug/mL', 'Num', 'NA', '.', 'Use \".\" if it\'s a missing values or below LLOQ', NULL, 1, 'PPK-ISOP-NIVO', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1192, 'DVL', 'Log Analysis Value', 'NA', 'Num', '4 significant digits', '.', NULL, NULL, 1, 'PPK-ISOP-NIVO', 0, 1, 0, 0, 1, 1, 1, 1, NULL),
(1193, 'CONCSTAT', 'Concentration Status', 'NA', 'Num', 'NA', '.', '0=Evaluable Concentration, 1=BLOQ, 2=OUTLIER or Not Reportable, 3=Missing value, 4=Duplicate record for NCA setup. If concstatus in PAMS/eToolbox=missing then always code CONCSTAT=0. Otherwise CONCSTAT=CONCSTATUS. Only populated for pk records.', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1194, 'BLQFN', 'Blq Flag', 'NA', 'Num', 'NA', '.', 'BLQ: Below the Limit of Quantification. 0=No, 1=Yes.', NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1195, 'DOSEP', 'Planned Dose of Nivolumab', 'mg/kg', 'Num', 'NA', '.', 'DOSEP represents the planned treatment dosage associated with the record. This is the numeric amount of the dose used for the popPK analysis and may differ from the EX.EXDOSE. Populated on all individual records as carry-forward.', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1196, 'DOSEPF', 'Planned Flat Dose of Nivolumab', 'mg', 'Num', 'NA', '.', '240=240 mg, etc', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1197, 'DOSENUM', 'Dose Number', 'NA', 'Num', 'NA', '.', 'Sequential number: 1=first dose, 2=second dose, etc. For PK records retain from dose records', 'Derived according to notes', 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1198, 'OCC', 'Occasion', 'NA', 'Num', 'NA', '.', '1=the first PK-related dose, 2=second PK-related dose, 3=third PK-related dose. Dose refers to BMS-936558. After assigning OCC, change pre first PK-related records (pk and dose) from . to 0', 'Derived according to notes', 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1199, 'TRTA', 'Actual Treatment', 'NA', 'Char', 'NA', 'blank', 'Eg. nivo 3 mg/kg Q2W', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1200, 'EXCLF', 'Record Exclusion', 'NA', 'Num', 'NA', '0', NULL, NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1201, 'EXCLFC', 'Comment for the Record Exclusion', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1202, 'FLAG', 'Flagged Records', 'NA', 'Num', 'NA', '0', NULL, 'FLAG number per Flag table in Programming Algorithms and Imputations section.', 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1203, 'FLAGC', 'Comment for the Flagged Records', 'NA', 'Char', 'NA', 'blank', NULL, 'Description for FLAG per Flag table in Programming Algorithms and Imputations section.', 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1204, 'DTC', 'Date and Time of Event', 'NA', 'Char', 'NA', 'blank', 'Date/time of event. Use ISO 8601 format which is a text representation of date and time e.g., 2013-05-09T08:58 where T is a time designator indicating time follows.', 'Derived according to notes', 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1205, 'SAMPLEID', 'PK Sample ID', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1206, 'AGE', 'Age', 'year', 'Num', 'NA', '.', NULL, NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1207, 'SEX', 'Sex', 'NA', 'Char', 'NA', 'blank', 'Male or Female', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1208, 'SEXN', 'Sex (N)', 'NA', 'Num', 'NA', '.', '1=Male, 2=Female', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1209, 'WTB', 'Baseline Body Weight', 'kg', 'Num', 'NA', '.', NULL, NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1210, 'HTB', 'Baseline Height', 'cm', 'Num', 'NA', '.', NULL, NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1211, 'BMIB', 'Baseline Body Mass Index', 'kg/m2', 'Num', '0.01', '.', NULL, NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1212, 'BSAB', 'Baseline Body Surface Area', 'm2', 'Num', '0.01', '.', NULL, NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1213, 'ALBB', 'Baseline Serum Albumin', 'g/dL', 'Num', 'NA', '.', NULL, NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1214, 'LDHB', 'Baseline Lactate Dehydrogenase', 'U/L', 'Num', 'NA', '.', NULL, NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1215, 'LDHULN', 'LDH Upper Limit of Normal', 'U/L', 'Num', 'NA', '.', 'LDH: Lactate Dehydrogenase.', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1216, 'ALPB', 'Baseline Serum Alkaline Phosphatase', 'U/L', 'Num', 'NA', '.', NULL, NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1217, 'ALTB', 'Baseline Alanine Transaminase', 'U/L', 'Num', 'NA', '.', NULL, NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1218, 'ASTB', 'Baseline Aspartate Transaminase', 'U/L', 'Num', 'NA', '.', NULL, NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1219, 'CRCLB', 'Baseline Creatinine Clearance', 'mL/min', 'Num', '0.01', '.', NULL, 'Derived according to equation in Derivation table.', 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1220, 'CREATB', 'Baseline Creatinine Serum', 'mg/dL', 'Num', 'NA', '.', '*0.011312 convert from umol/L to mg/dL', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1221, 'EGFRB', 'Baseline eGFR', 'mL/min/1.73m2', 'Num', '0.01', '.', 'eGFR: Estimated Glomerular Filtration Rate.', 'Derived according to equation in Derivation table.', 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1222, 'ALCB', 'Baseline Abs Lymphocyte Count', 'x10^3c/uL', 'Num', 'NA', '.', 'Abs: Absolute. x10^9c/L is the same as x10^3c/uL.', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1223, 'TBILB', 'Baseline Total Bilirubin', 'mg/dL', 'Num', 'NA', '.', NULL, NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1224, 'DBILB', 'Baseline Direct Bilirubin', 'mg/dL', 'Num', 'NA', '.', NULL, NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1225, 'HEPA', 'Liver Dysfunction Groups', 'NA', 'Char', 'NA', 'blank', 'GROUP A: Normal (total bilirubin<=ULN and AST<=ULN), GROUP B: Mild (total bilirubin > 1.0x-1.5xULN or AST > ULN), GROUP C: Moderate (total bilirubin > 1.5x-3xULN), GROUP D: Severe (total bilirubin > 3xULN). Assign in reverse order to assign most severe group.', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1226, 'HEPAN', 'Liver Dysfunction Groups (N)', 'NA', 'Num', 'NA', '.', '1=GROUP A: Normal, 2=GROUP B: Mild, 3=GROUP C: Moderate, 4=GROUP D: Severe', 'Derived from HEPA', 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1227, 'RACE', 'Race', 'NA', 'Char', 'NA', 'blank', 'White, Black/African American, Asian, American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander, Others, Unknown', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1228, 'RACEN', 'Race (N)', 'NA', 'Num', 'NA', '.', '1=White, 2=Black/African American, 3=Asian, 4=Others, 5=Unknown. American Indian/Alaska Native and Native Hawaiian/Other Pacific Islander are coded as 4.', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1229, 'COUNTRY', 'Country', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1230, 'TTYPEF', 'Tumor Type', 'NA', 'Char', 'NA', 'blank', 'Melanoma, SQ Non-Small Cell Lung Cancer, NSQ Non-Small Cell Lung Cancer, Unknown Histology Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Colorectal Cancer, Prostate Cancer, Classical Hodgkin Lymphoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Triple Negative Breast Cancer, Gastric Cancer, Pancreatic Cancer, Small Cell Lung Cancer, Ovarian Cancer, Hepatocellular Carcinoma, Glioblastoma, Adjuvant Melanoma, Cervical Cancer, Multiple Myeloma, Hodgkins Lymphoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Indolent Non-Hodgkins Lymphoma, Other Non-Hodgkins Lymphoma, Breast Cancer, Endometrial Cancer, Thyroid Cancer, Mesothelioma, Nasopharyngeal Carcinoma, Esophageal Cancer, Adjuvant Gastroesophageal Junction Cancer, Juvenile Myelomonocytic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Other', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1231, 'TTYPEN', 'Tumor Type (N)', 'NA', 'Num', 'NA', '.', '1=Melanoma, 2=SQ Non-Small Cell Lung Cancer, 3=NSQ Non-Small Cell Lung Cancer, 4=Unknown Histology Non-Small Cell Lung Cancer, 5=Renal Cell Carcinoma, 6=Colorectal Cancer, 7=Prostate Cancer, 8=Classical Hodgkin Lymphoma, 9=Squamous Cell Carcinoma of the Head and Neck, 10=Bladder Cancer, 11=Triple Negative Breast Cancer, 12=Gastric Cancer, 13=Pancreatic Cancer, 14=Small Cell Lung Cancer, 15=Ovarian Cancer, 16=Hepatocellular Carcinoma, 17=Glioblastoma, 18=Adjuvant Melanoma, 19=Cervical Cancer, 20=Multiple Myeloma, 21=Hodgkins Lymphoma, 22=Diffuse Large B-Cell Lymphoma, 23=Chronic Lymphocytic Leukemia, 24=Indolent Non-Hodgkins Lymphoma, 25=Other Non-Hodgkins Lymphoma, 26=Breast Cancer, 27=Endometrial Cancer, 28=Thyroid Cancer, 29=Mesothelioma, 30=Nasopharyngeal Carcinoma, 31=Esophageal Cancer, 32=Adjuvant Gastroesophageal Junction Cancer, 33=Juvenile Myelomonocytic Leukemia, 34=Acute Myeloid Leukemia, 35=Myelodysplastic Syndromes, 100=Other', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1232, 'TSIZEB', 'Baseline Tumor Burden', 'cm', 'Num', 'NA', '.', 'Sum of longest diameters of all target lesions,  convert tumor burden from mm to cm by dividing by 10', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1233, 'TSIZE2B', 'Baseline Tumor Burden', 'cm2', 'Num', 'NA', '.', 'Sum of products of diameters for all target lesions.', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1234, 'PS', 'Baseline Performance Status', 'NA', 'Num', 'NA', '.', '0 (Normal), 1, 2, 3, 4; If convert from KPS, 0=KPS 100, 1=KPS 90/80, 2=KPS 70/60, 3=KPS 50/40, 4=KPS 30/20/10', 'ECOG or Derived from KPS', 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1235, 'ADA', 'Immunogenicity by Visit Level', 'NA', 'Num', 'NA', '.', '0=negative, 1=positive (any type)', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1236, 'ADALIST', 'Immunogenicity by Subject Level', 'NA', 'Char', 'NA', 'blank', 'Immunogenicity Council Definition - Persistent Positive, Only the Last Sample Positive, Other Positive, Negative, NA', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1237, 'PDL11', 'PDL1 Expression (1% cutoff)', 'NA', 'Char', 'NA', 'blank', 'positive, negative status - tumor only (>= 1% cutoff). positive,negative, unknown, missing.', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1238, 'PDL15', 'PDL1 Expression (5% cutoff)', 'NA', 'Char', 'NA', 'blank', 'positive, negative status - tumor only (>= 5% cutoff). positive,negative, unknown, missing.', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1239, 'PDL110', 'PDL1 Expression (10% cutoff)', 'NA', 'Char', 'NA', 'blank', 'positive, negative status - tumor only (>= 10% cutoff). positive,negative, unknown, missing.', NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1240, 'BUILDDT', 'Dataset Creation Date', 'NA', 'Char', 'NA', 'blank', NULL, 'Created at run time', 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1241, 'LINE', 'Line of Therapy', 'NA', 'Num', 'NA', '.', NULL, NULL, 1, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1242, 'LINEC', 'Line of Therapy (Categorization)', 'NA', 'Char', 'NA', 'blank', '1, >1', 'LINEC=\'1\' where LINE=1, LINEC=\'>1\' where LINE>1. If LINE is missing then impute LINEC based on protocol', 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1243, 'LINEN', 'Line of Therapy (Categorization, N)', 'NA', 'Num', 'NA', '.', '1, 2', 'LINEN=1 where LINEC=\'1\', LINEN=2 where LINEC=\'>1\'', 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1244, 'BRAF', 'BRAF Mutation', 'NA', 'Num', 'NA', '.', 'BRAF mutation or wild type: 0=negative (wild type), 1=positive (Mutant)', NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1245, 'MSTATUS', 'Metastatic Status', 'NA', 'Char', 'NA', 'blank', 'M0, M1a, M1b, M1c (M1c includes with and without brain metastasis)', NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1246, 'CHEWSNU', 'Chewing Tobacco/Snuff', 'NA', 'Char', 'NA', 'blank', 'Never, Current, Former, Unknown', NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1247, 'PIPE', 'Pipe Smoking Status', 'NA', 'Char', 'NA', 'blank', 'Never, Current, Former, Unknown', NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1248, 'CIGAR', 'Cigar Smoking Status', 'NA', 'Char', 'NA', 'blank', 'Never, Current, Former, Unknown', NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1249, 'CIGARETT', 'Cigarette Smoking Status', 'NA', 'Char', 'NA', 'blank', 'Never, Current, Former, Unknown', NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1250, 'PDL1A', 'PDL1 Assay', 'NA', 'Char', 'NA', 'blank', 'e.g., JH, DAKO-Validated (preferred), DAKO-verified', NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1251, 'COMBO', 'Combination Treatment', 'NA', 'Num', 'NA', '.', '0=BMS-936558 was administered alone, 1=BMS-936558 and ipilimumab were administered concurrently, 2=BMS-936558 and chemotherapy, 3=BMS-936558, ipilimumab and chemotherapy', 'Derived according to notes', 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1252, 'AIMG', 'Immunogenicity Assay', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1253, 'IPICO', 'Ipi Co-Administered With Nivo', 'NA', 'Num', 'NA', '.', 'Ipi: ipilimumab. Nivo: nivolumab. 1=Yes, 0=No. Time-varying covariate. Get IPI dosing data from ex/adex filtered by EXTRT to ppk dataset by USUBJID and date.  For dose records, if an ipi dose (dose amt > 0) was given on the same date as a nivo dose (dose amt > 0) then IPICO would be 1.  For pk records please use LOCF from dose records.  Day-1, predose records will have IPICO as missing.', NULL, 0, 'PPK-ISOP-NIVO', 1, 1, 0, 0, 0, 1, 1, 1, NULL),
(1254, 'CROSSOVR', 'Crossover Nivo to Nivo+Ipi Combo', 'NA', 'Num', 'NA', '.', 'Ipi: ipilimumab. Nivo: nivolumab. 0=Not a crossover subject, 1=Cross over subject', NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1255, 'TMB', 'Tumor Mutation Burden', 'mutations/Mb', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 0, 1, 1, 1, NULL),
(1256, 'TMBC', 'Tumor Mutation Burden Category', 'NA', 'Char', 'NA', 'blank', 'High TMB, Low TMB, Not Evaluable. Nivo mono cutoff mutation >=12.61. Nivo + Ipi cutoff mutation >=10.09', 'Derived from TMB and Notes', 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1257, 'BOR', 'Best Overall Response', 'NA', 'Char', 'NA', 'blank', 'CR=Complete response, PR=Partial response, SD=Stable disease, PD=Progressive disease, NE=Unevaluable, NA=Missing or not reported, NN=NON-CR/NON-PD, ND=No Disease.', NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1258, 'BORN', 'Best Overall Response (N)', 'NA', 'Num', 'NA', '.', '1=CR, 2=PR, 3=SD, 4=PD, 5=NE, 6=NA, 7=NN, 8=ND', 'Derived from BOR', 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1259, 'BORPER', 'BOR Assessed by', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1260, 'BORCRT', 'BOR Criteria', 'NA', 'Char', 'NA', 'blank', 'mWHO, RECIST v1.0, RECIST v1.1', NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1261, 'ETH', 'Ethnicity', 'NA', 'Char', 'NA', 'blank', 'Japanese, Others', 'Derived based on RACE and CNTCODE. ETH=Japanese where RACE=Asian and CNTCODE=Japan', 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1262, 'ETHN', 'Ethnicity (N)', 'NA', 'Num', 'NA', '.', '1=Japanese, 100=Others', 'Derived based on ETH', 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1263, 'ETHJ', 'Japanese Ethnicity', 'NA', 'Char', 'NA', 'blank', 'Japanese, Non-Japanese Asian, Non-Asian', NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1264, 'ETHJN', 'Japanese Ethnicity (N)', 'NA', 'Num', 'NA', '.', '1=Japanese, 2=Non-Japanese Asian, 3=Non-Asian', NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1265, 'ETHC', 'Chinese Ethnicity', 'NA', 'Char', 'NA', 'blank', 'Chinese, Non-Chinese Asian, Non-Asian', NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1266, 'ETHCN', 'Chinese Ethnicity (N)', 'NA', 'Num', 'NA', '.', '1=Chinese, 2=Non-Chinese Asian, 3=Non-Asian', NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1267, 'NDOSEDUR', 'Nominal Duration of Treatment Dose', 'hr', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1268, 'DOSEP1', 'Planned Nivo Dose at the First Stage', 'NA', 'Num', 'NA', '.', 'Nivo: nivolumab.', 'Derived based on TX', 0, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1269, 'DU1', 'Dose Unit for DOSEP1', 'NA', 'Char', 'NA', 'blank', 'either mg or mg/kg', 'Derived based on TX', 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1270, 'FREQ1', 'Dose Frequency at the First Stage', 'week', 'Num', 'NA', '.', '2=Q2W, 3=Q3W', NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1271, 'DOSEPSS', 'Planned Nivo Dose at Maintenance Stage', 'NA', 'Num', 'NA', '.', 'Nivo: nivolumab. If no maintenance stage, the value of DOSEPSS should be equal to the DOSEP1 (do not leave blank)', 'Derived based on TX', 0, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1272, 'DUSS', 'Dose Unit for DOSEPSS', 'NA', 'Char', 'NA', 'blank', 'either mg or mg/kg; If no maintenance stage, the value of DUSS should be equal to the DU1 (do not leave blank)', 'Derived based on TX', 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1273, 'FREQSS', 'Dose Frequency at Maintenance Stage', 'week', 'Num', 'NA', '.', 'If no maintenance stage, the value of FREQSS should be equal to the FREQ1 (do not leave blank)', NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1274, 'NDOSEIPI', 'Nominal First Dose for Ipilimumab', 'mg/kg', 'Num', 'NA', '0', '0=No ipi', NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1275, 'IPIFRQ', 'Nominal Frequency for Ipilimumab', 'week', 'Num', 'NA', '.', '3=Q3W, 6=Q6W, 12=Q12W', NULL, 0, 'PPK-ISOP-NIVO', 1, 1, 1, 0, 0, 1, 1, 1, NULL),
(1276, 'ETIOLOGY', 'Etiology', 'NA', 'Char', 'NA', 'blank', 'HBV, HCV, Uninfected, and Not Reported', NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1277, 'ETIOLOGN', 'Etiology (N)', 'NA', 'Num', 'NA', '.', 'For ETIOLOGY=\'UNINFECTED\', ETIOLOGN=1; For ETIOLOGY=\'HCV-INFECTED\', ETIOLOGN=2; For ETIOLOGY=\'HBV - INFECTED\', ETIOLOGN=3; For ETIOLOGY=\'HCV AND HBV COINFECTION\', ETIOLOGN=4', 'Derived from ETIOLOGY', 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1278, 'MSITX', 'MSI Status and Treatment in CA209142', 'NA', 'Char', 'NA', 'blank', 'MSI: Microsatellite Instability. NIVO; NIVO 1 + IPI 1; NIVO 3 + IPI 1; NIVO 1 + IPI 3; NIVO + IPI (MSI-H)', NULL, 0, 'PPK-ISOP-NIVO', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1279, 'PROJID', 'Project Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1280, 'STUDYID', 'Study Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1281, 'STUDYIDN', 'Study Identifier (N)', 'NA', 'Num', 'NA', '.', NULL, NULL, 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1282, 'USUBJID', 'Unique Subject Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1283, 'USUBJIDN', 'Unique Subject Identifier (N)', 'NA', 'Num', 'NA', '.', 'Unique numerical representation of USUBJID.', NULL, 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1284, 'ID', 'NONMEM ID', 'NA', 'Num', 'NA', '.', 'Sequential numbering, (1, 2, 3, ...). One ID per subject.', 'Derived based on USUBJID (Exclude \"CA209\", and concatenate numeric values)', 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1285, 'RECSEQ', 'Record Sequence', 'NA', 'Num', 'NA', '.', 'Sequential values should start with 1 on the first non-header row of the data file and incrementing by 1 for each subsequent row.', 'Derived according to notes', 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1286, 'VISIT', 'Visit', 'NA', 'Char', 'NA', 'blank', 'Clinic visit captured in STDM domains EX or PC and variable VISIT', NULL, 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1287, 'AFRELTM', 'Actual Rel Time From First Dose', 'hr', 'Num', '0.01', '.', 'Rel: Relative. Derived from (Analysis date/time of the current event/record of the subject) - (Analysis date/time of the first dosing event/record of the subject)', NULL, 1, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1288, 'NFRELTM', 'Nominal Rel Time From First Dose', 'hr', 'Num', '0.1', '.', 'Rel: Relative. Planned elapsed time (for sample point or start of sampling interval) from first exposure to study treatment.', NULL, 1, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1289, 'NPRELTM', 'Nominal Rel Time From Previous Dose', 'hr', 'Num', '0.1', '.', 'Rel: Relative. For PK it can be derived from NTIME in PC domain.', NULL, 1, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1290, 'APRELTM', 'Actual Rel Time From Previous Dose', 'hr', 'Num', '0.01', '.', 'Rel: Relative. Derived from (Analysis date/time of the current event/record of the subject) - (Analysis date/time of the previous dosing event/record of the subject).', NULL, 1, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1291, 'EVID', 'Event ID', 'NA', 'Num', 'NA', '.', '0=PK event, 1=dose event.', 'Derived according to notes', 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1292, 'MDV', 'Missing DV', 'NA', 'Num', 'NA', '.', '0=observed value, 1=missing DV or suspicious data or dosing event', 'Derived according to notes', 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1293, 'DOSEA', 'Actual Dose of Ipilimumab', 'mg', 'Num', 'NA', '.', 'Populated on all individual records as carry-forward.', NULL, 1, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1294, 'AMT', 'Actual Amount of Ipilimumab', 'mg', 'Num', 'NA', '.', 'Only populated on dosing records. Use \".\" for non-dosing record (i.e., observations)', NULL, 1, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1295, 'RATE', 'Infusion Rate', 'mg/hr', 'Num', '0.01', '.', 'AMT/DOSEDUR', NULL, 1, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1296, 'DOSEDUR', 'Duration of Treatment Dose', 'hr', 'Num', '0.01', '.', 'Derived from (End dose date/time) - (Start dose date/time) - (infusion interruption if available).', NULL, 1, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1297, 'DV', 'Serum Concentration of Ipilimumab', 'ug/mL', 'Num', 'NA', '.', 'Use \".\" if it\'s a missing values or below LLOQ', NULL, 1, 'PPK-ISOP-IPI', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1298, 'DVL', 'Log Analysis Value', 'NA', 'Num', '4 significant digits', '.', NULL, NULL, 1, 'PPK-ISOP-IPI', 0, 1, 0, 0, 1, 1, 1, 1, NULL),
(1299, 'CONCSTAT', 'Concentration Status', 'NA', 'Num', 'NA', '.', '0=Evaluable Concentration, 1=BLOQ, 2=OUTLIER or Not Reportable, 3=Missing value, 4=Duplicate record for NCA setup. If concstatus in PAMS/eToolbox=missing then always code CONCSTAT=0. Otherwise CONCSTAT=CONCSTATUS. Only populated for pk records.', NULL, 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1300, 'BLQFN', 'Blq Flag', 'NA', 'Num', 'NA', '.', 'BLQ: Below the Limit of Quantification. 0=No, 1=Yes.', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1301, 'DOSEP', 'Planned Dose of Ipilimumab', 'mg/kg', 'Num', 'NA', '.', 'DOSEP represents the planned treatment dosage associated with the record. This is the numeric amount of the dose used for the popPK analysis and may differ from the EX.EXDOSE. Populated on all individual records as carry-forward.', NULL, 1, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1302, 'DOSENUM', 'Dose Number', 'NA', 'Num', 'NA', '.', 'Sequential number: 1=first dose, 2=second dose, etc. For PK records retain from dose records', 'Derived according to notes', 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1303, 'OCC', 'Occasion', 'NA', 'Num', 'NA', '.', '1=the first PK-related dose, 2=second PK-related dose, 3=third PK-related dose. After assigning OCC, change pre first PK-related records (pk and dose) from . to 0', 'Derived according to notes', 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1304, 'TRTA', 'Actual Treatment', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1305, 'EXCLF', 'Record Exclusion', 'NA', 'Num', 'NA', '0', NULL, NULL, 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1306, 'EXCLFC', 'Comment for the Record Exclusion', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1307, 'FLAG', 'Flagged Records', 'NA', 'Num', 'NA', '0', NULL, 'FLAG number per Flag table in Programming Algorithms and Imputations section.', 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1308, 'FLAGC', 'Comment for the Flagged Records', 'NA', 'Char', 'NA', 'blank', NULL, 'Description for FLAG per Flag table in Programming Algorithms and Imputations section.', 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1309, 'DTC', 'Date and Time of Event', 'NA', 'Char', 'NA', 'blank', 'Date/time of event. Use ISO 8601 format which is a text representation of date and time e.g., 2013-05-09T08:58 where T is a time designator indicating time follows.', 'Derived according to notes', 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1310, 'SAMPLEID', 'PK Sample ID', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1311, 'NIVOCO', 'Nivo Co-Administered With Ipi', 'NA', 'Num', 'NA', '.', 'Ipi: ipilimumab. Nivo: nivolumab. 1=Yes, 0=No. Time-varying covariate. Get nivo dosing data from ex/adex filtered by EXTRT to ppk dataset by USUBJID and date.  For dose records, if a nivo dose (dose amt > 0) was given on the same date as an ipi dose (dose amt > 0) then NIVOCO would be 1.  For pk records please use LOCF from dose records.  Day-1, predose records will have NIVOCO as missing.', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1312, 'NDOSENIV', 'Nominal First Dose for Nivolumab', 'mg/kg or mg', 'Num', 'NA', '.', 'No nivo = 0', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1313, 'NIVFRQ', 'Nominal Frequency for Nivolumab', 'week', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1314, 'COMBO', 'Combination Treatment', 'NA', 'Num', 'NA', '.', '0=ipilimumab was administered alone, 1=ipilimumab and nivolumab were administered concurrently, 2=ipilimumab and chemo therapy combination', 'Derived according to notes', 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1315, 'AGE', 'Age', 'year', 'Num', 'NA', '.', NULL, NULL, 1, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1316, 'SEX', 'Sex', 'NA', 'Char', 'NA', 'blank', 'Male or Female', NULL, 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1317, 'SEXN', 'Sex (N)', 'NA', 'Num', 'NA', '.', '1=Male, 2=Female', NULL, 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1318, 'WTB', 'Baseline Body Weight', 'kg', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1319, 'HTB', 'Baseline Height', 'cm', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1320, 'BMIB', 'Baseline Body Mass Index', 'kg/m2', 'Num', '0.01', '.', NULL, NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1321, 'BSAB', 'Baseline Body Surface Area', 'm2', 'Num', '0.01', '.', NULL, NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1322, 'ALBB', 'Baseline Serum Albumin', 'g/dL', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1323, 'LDHB', 'Baseline Lactate Dehydrogenase', 'U/L', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1324, 'LDHULN', 'LDH Upper Limit of Normal', 'U/L', 'Num', 'NA', '.', 'LDH: Lactate Dehydrogenase.', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1325, 'LDHULNB', 'Normalized LDHB Upper Limit of Normal', 'NA', 'Num', '0.001', '.', 'LDHB/LDHULN', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1326, 'ALPB', 'Baseline Serum Alkaline Phosphatase', 'U/L', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1327, 'ALTB', 'Baseline Alanine Transaminase', 'U/L', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1328, 'ASTB', 'Baseline Aspartate Transaminase', 'U/L', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1329, 'CRCLB', 'Baseline Creatinine Clearance', 'mL/min', 'Num', '0.01', '.', NULL, 'Derived according to equation in Derivation table.', 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1330, 'CREATB', 'Baseline Creatinine Serum', 'mg/dL', 'Num', 'NA', '.', '*0.011312 convert from umol/L to mg/dL', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1331, 'EGFRB', 'Baseline eGFR', 'mL/min/1.73m2', 'Num', '0.01', '.', 'eGFR: Estimated Glomerular Filtration Rate.', 'Derived according to equation in Derivation table.', 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1332, 'ALCB', 'Baseline Abs Lymphocyte Count', 'x10^3c/uL', 'Num', 'NA', '.', 'Abs: Absolute. x10^9c/L is the same as x10^3c/uL.', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1333, 'TBILB', 'Baseline Total Bilirubin', 'mg/dL', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1334, 'DBILB', 'Baseline Direct Bilirubin', 'mg/dL', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1335, 'HEPA', 'Liver Dysfunction Groups', 'NA', 'Char', 'NA', 'blank', 'GROUP A: Normal (total bilirubin<=ULN and AST<=ULN), GROUP B: Mild (total bilirubin > 1.0x-1.5xULN or AST > ULN), GROUP C: Moderate (total bilirubin > 1.5x-3xULN), GROUP D: Severe (total bilirubin > 3xULN). Assign in reverse order to assign most severe group.', NULL, 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1336, 'HEPAN', 'Liver Dysfunction Groups (N)', 'NA', 'Num', 'NA', '.', '1=GROUP A: Normal, 2=GROUP B: Mild, 3=GROUP C: Moderate, 4=GROUP D: Severe', 'Derived from HEPA', 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1337, 'RACE', 'Race', 'NA', 'Char', 'NA', 'blank', 'White, Black/African American, Asian, American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander, Others, Unknown', NULL, 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1338, 'RACEN', 'Race (N)', 'NA', 'Num', 'NA', '.', '1=White, 2=Black/African American, 3=Asian, 4=Others, 5=Unknown. American Indian/Alaska Native and Native Hawaiian/Other Pacific Islander are coded as 4.', NULL, 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1339, 'COUNTRY', 'Country', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1340, 'TTYPEF', 'Tumor Type', 'NA', 'Char', 'NA', 'blank', 'Melanoma, SQ Non-Small Cell Lung Cancer, NSQ Non-Small Cell Lung Cancer, Unknown Histology Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Colorectal Cancer, Prostate Cancer, Classical Hodgkin Lymphoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Triple Negative Breast Cancer, Gastric Cancer, Pancreatic Cancer, Small Cell Lung Cancer, Ovarian Cancer, Hepatocellular Carcinoma, Glioblastoma, Adjuvant Melanoma, Cervical Cancer, Multiple Myeloma, Hodgkins Lymphoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Indolent Non-Hodgkins Lymphoma, Other Non-Hodgkins Lymphoma, Breast Cancer, Endometrial Cancer, Thyroid Cancer, Mesothelioma, Nasopharyngeal Carcinoma, Esophageal Cancer, Adjuvant Gastroesophageal Junction Cancer, Juvenile Myelomonocytic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Other', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1341, 'TTYPEN', 'Tumor Type (N)', 'NA', 'Num', 'NA', '.', '1=Melanoma, 2=SQ Non-Small Cell Lung Cancer, 3=NSQ Non-Small Cell Lung Cancer, 4=Unknown Histology Non-Small Cell Lung Cancer, 5=Renal Cell Carcinoma, 6=Colorectal Cancer, 7=Prostate Cancer, 8=Classical Hodgkin Lymphoma, 9=Squamous Cell Carcinoma of the Head and Neck, 10=Bladder Cancer, 11=Triple Negative Breast Cancer, 12=Gastric Cancer, 13=Pancreatic Cancer, 14=Small Cell Lung Cancer, 15=Ovarian Cancer, 16=Hepatocellular Carcinoma, 17=Glioblastoma, 18=Adjuvant Melanoma, 19=Cervical Cancer, 20=Multiple Myeloma, 21=Hodgkins Lymphoma, 22=Diffuse Large B-Cell Lymphoma, 23=Chronic Lymphocytic Leukemia, 24=Indolent Non-Hodgkins Lymphoma, 25=Other Non-Hodgkins Lymphoma, 26=Breast Cancer, 27=Endometrial Cancer, 28=Thyroid Cancer, 29=Mesothelioma, 30=Nasopharyngeal Carcinoma, 31=Esophageal Cancer, 32=Adjuvant Gastroesophageal Junction Cancer, 33=Juvenile Myelomonocytic Leukemia, 34=Acute Myeloid Leukemia, 35=Myelodysplastic Syndromes, 100=Other', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1342, 'TSIZEB', 'Baseline Tumor Burden', 'cm', 'Num', 'NA', '.', 'Sum of longest diameters of all target lesions,  convert tumor burden from mm to cm by dividing by 10', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1343, 'TSIZE2B', 'Baseline Tumor Burden', 'cm2', 'Num', 'NA', '.', 'Sum of products of diameters for all target lesions.', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1344, 'PS', 'Baseline Performance Status', 'NA', 'Num', 'NA', '.', '0 (Normal), 1, 2, 3, 4; If convert from KPS, 0=KPS 100, 1=KPS 90/80, 2=KPS 70/60, 3=KPS 50/40, 4=KPS 30/20/10', 'ECOG or Derived from KPS', 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1345, 'ADA', 'Immunogenicity by Visit Level', 'NA', 'Num', 'NA', '.', '0=negative, 1=positive (any type)', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1346, 'ADALIST', 'Immunogenicity by Subject Level', 'NA', 'Char', 'NA', 'blank', 'Immunogenicity Council Definition - Persistent Positive, Only the Last Sample Positive, Other Positive, Negative, NA', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1347, 'AIMG', 'Immunogenicity Assay', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1348, 'PDL11', 'PDL1 Expression (1% cutoff)', 'NA', 'Char', 'NA', 'blank', 'positive, negative status - tumor only (>= 1% cutoff). positive,negative, unknown, missing.', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1349, 'PDL15', 'PDL1 Expression (5% cutoff)', 'NA', 'Char', 'NA', 'blank', 'positive, negative status - tumor only (>= 5% cutoff). positive,negative, unknown, missing.', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1350, 'PDL110', 'PDL1 Expression (10% cutoff)', 'NA', 'Char', 'NA', 'blank', 'positive, negative status - tumor only (>= 10% cutoff). positive,negative, unknown, missing.', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1351, 'PDL1A', 'PDL1 Assay', 'NA', 'Char', 'NA', 'blank', 'e.g., JH, DAKO-Validated (preferred), DAKO-verified', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1352, 'LINE', 'Line of Therapy', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1353, 'LINEC', 'Line of Therapy (Categorization)', 'NA', 'Char', 'NA', 'blank', '1, >1', 'LINEC=\'1\' where LINE=1, LINEC=\'>1\' where LINE>1. If LINE is missing then impute LINEC based on protocol', 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1354, 'LINEN', 'Line of Therapy (Categorization, N)', 'NA', 'Num', 'NA', '.', '1, 2', 'LINEN=1 where LINEC=\'1\', LINEN=2 where LINEC=\'>1\'', 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1355, 'BRAF', 'BRAF Mutation', 'NA', 'Num', 'NA', '.', 'BRAF mutation or wild type: 0=negative (wild type), 1=positive (Mutant)', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1356, 'MSTATUS', 'Metastatic Status', 'NA', 'Char', 'NA', 'blank', 'M0, M1a, M1b, M1c (M1c includes with and without brain metastasis)', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1357, 'CHEWSNU', 'Chewing Tobacco/Snuff', 'NA', 'Char', 'NA', 'blank', 'Never, Current, Former, Unknown', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1358, 'PIPE', 'Pipe Smoking Status', 'NA', 'Char', 'NA', 'blank', 'Never, Current, Former, Unknown', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1359, 'CIGAR', 'Cigar Smoking Status', 'NA', 'Char', 'NA', 'blank', 'Never, Current, Former, Unknown', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1360, 'CIGARETT', 'Cigarette Smoking Status', 'NA', 'Char', 'NA', 'blank', 'Never, Current, Former, Unknown', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1361, 'CROSSOVR', 'Crossover Nivo to Nivo+Ipi Combo', 'NA', 'Num', 'NA', '.', 'Ipi: ipilimumab. Nivo: nivolumab. 0=Not a crossover subject, 1=Cross over subject', NULL, 0, 'PPK-ISOP-IPI', 0, 1, 0, 0, 0, 1, 1, 1, NULL),
(1362, 'TMB', 'Tumor Mutation Burden', 'mutations/Mb', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 0, 1, 1, 1, NULL),
(1363, 'TMBC', 'Tumor Mutation Burden Category', 'NA', 'Char', 'NA', 'blank', 'High TMB, Low TMB, Not Evaluable. Nivo mono cutoff mutation >=12.61. Nivo + Ipi cutoff mutation >=10.09', 'Derived from TMB and Notes', 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1364, 'BOR', 'Best Overall Response', 'NA', 'Char', 'NA', 'blank', 'CR=Complete response, PR=Partial response, SD=Stable disease, PD=Progressive disease, NE=Unevaluable, NA=Missing or not reported, NN=NON-CR/NON-PD, ND=No Disease.', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1365, 'BORN', 'Best Overall Response (N)', 'NA', 'Num', 'NA', '.', '1=CR, 2=PR, 3=SD, 4=PD, 5=NE, 6=NA, 7=NN, 8=ND', 'Derived from BOR', 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1366, 'BORPER', 'BOR Assessed by', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1367, 'BORCRT', 'BOR Criteria', 'NA', 'Char', 'NA', 'blank', 'mWHO, RECIST v1.0, RECIST v1.1', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1368, 'ETH', 'Ethnicity', 'NA', 'Char', 'NA', 'blank', 'Japanese, Others', 'Derived based on RACE and CNTCODE. ETH=Japanese where RACE=Asian and CNTCODE=Japan', 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1369, 'ETHN', 'Ethnicity (N)', 'NA', 'Num', 'NA', '.', '1=Japanese, 100=Others', 'Derived based on ETH', 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1370, 'ETHJ', 'Japanese Ethnicity', 'NA', 'Char', 'NA', 'blank', 'Japanese, Non-Japanese Asian, Non-Asian', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1371, 'ETHJN', 'Japanese Ethnicity (N)', 'NA', 'Num', 'NA', '.', '1=Japanese, 2=Non-Japanese Asian, 3=Non-Asian', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1372, 'ETHC', 'Chinese Ethnicity', 'NA', 'Char', 'NA', 'blank', 'Chinese, Non-Chinese Asian, Non-Asian', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1373, 'ETHCN', 'Chinese Ethnicity (N)', 'NA', 'Num', 'NA', '.', '1=Chinese, 2=Non-Chinese Asian, 3=Non-Asian', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1374, 'NDOSEDUR', 'Nominal Infusion Duration', 'hr', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1375, 'DOSEP1', 'Planned Ipi Dose at the First Stage', 'NA', 'Num', 'NA', '.', NULL, 'Derived based on TX', 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1376, 'DU1', 'Dose Unit for DOSEP1', 'NA', 'Char', 'NA', 'blank', 'either mg or mg/kg', 'Derived based on TX', 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1377, 'FREQ1', 'Dose Frequency at the First Stage', 'week', 'Num', 'NA', '.', '2=Q2W, 3=Q3W', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1378, 'DOSEPSS', 'Planned Ipi Dose at Maintenance Stage', 'NA', 'Num', 'NA', '.', 'If no maintenance stage, the value of DOSEPSS should be equal to the DOSEP1 (do not leave blank)', 'Derived based on TX', 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1379, 'DUSS', 'Dose Unit for DOSEPSS', 'NA', 'Char', 'NA', 'blank', 'either mg or mg/kg; If no maintenance stage, the value of DUSS should be equal to the DU1 (do not leave blank)', 'Derived based on TX', 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1380, 'FREQSS', 'Dose Frequency at Maintenance Stage', 'week', 'Num', 'NA', '.', 'If no maintenance stage, the value of FREQSS should be equal to the FREQ1 (do not leave blank)', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1381, 'ETIOLOGY', 'Etiology', 'NA', 'Char', 'NA', 'blank', 'HBV, HCV, Uninfected, and Not Reported', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1382, 'ETIOLOGN', 'Etiology (N)', 'NA', 'Num', 'NA', '.', 'For ETIOLOGY=\'UNINFECTED\', ETIOLOGN=1; For ETIOLOGY=\'HCV-INFECTED\', ETIOLOGN=2; For ETIOLOGY=\'HBV - INFECTED\', ETIOLOGN=3; For ETIOLOGY=\'HCV AND HBV COINFECTION\', ETIOLOGN=4', 'Derived from ETIOLOGY', 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1383, 'MSITX', 'MSI Status and Treatment in CA209142', 'NA', 'Char', 'NA', 'blank', 'MSI: Microsatellite Instability. NIVO; NIVO 1 + IPI 1; NIVO 3 + IPI 1; NIVO 1 + IPI 3; NIVO + IPI (MSI-H)', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1384, 'DNCI', 'Dose Normalized Ipi Conc', 'ug/mL/mg', 'Num', 'NA', '.', 'Ipi: Ipilimumab, Conc: Concentration. DV/AMT when AMT is retained from the previous dose record.', NULL, 0, 'PPK-ISOP-IPI', 0, 0, 1, 0, 0, 1, 1, 1, NULL),
(1385, 'BUILDDT', 'Dataset Creation Date', 'NA', 'Char', 'NA', 'blank', NULL, 'Created at run time', 1, 'PPK-ISOP-IPI', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1386, 'STUDYID', 'Study Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1387, 'STUDYIDN', 'Study Identifier (N)', 'NA', 'Num', 'NA', '.', NULL, NULL, 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1388, 'USUBJID', 'Unique Subject Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1389, 'USUBJIDN', 'Unique Subject Identifier (N)', 'NA', 'Num', 'NA', '.', 'Unique numerical representation of USUBJID.', NULL, 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1390, 'ID', 'NONMEM ID', 'NA', 'Num', 'NA', '.', 'Sequential numbering, (1, 2, 3, ...). One ID per subject.', 'Derived based on USUBJID (Exclude \"CA209\", and concatenate numeric values)', 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1391, 'RECSEQ', 'Record Sequence', 'NA', 'Num', 'NA', '.', 'Sequential values should start with 1 on the first non-header row of the data file and incrementing by 1 for each subsequent row.', 'Derived according to notes', 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1392, 'VISIT', 'Visit', 'NA', 'Char', 'NA', 'blank', 'Clinic visit captured in STDM domains EX or PC and variable VISIT', NULL, 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1393, 'AFRELTM', 'Actual Rel Time From First Dose', 'hr', 'Num', '0.01', '.', 'Rel: Relative. Derived from (Analysis date/time of the current event/record of the subject) - (Analysis date/time of the first dosing event/record of the subject)', NULL, 1, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1394, 'NFRELTM', 'Nominal Rel Time From First Dose', 'hr', 'Num', '0.1', '.', 'Rel: Relative. Planned elapsed time (for sample point or start of sampling interval) from first exposure to study treatment.', NULL, 1, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1395, 'NPRELTM', 'Nominal Rel Time From Previous Dose', 'hr', 'Num', '0.1', '.', 'Rel: Relative. For PK it can be derived from NTIME in PC domain.', NULL, 1, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1396, 'APRELTM', 'Actual Rel Time From Previous Dose', 'hr', 'Num', '0.01', '.', 'Rel: Relative. Derived from (Analysis date/time of the current event/record of the subject) - (Analysis date/time of the previous dosing event/record of the subject).', NULL, 1, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1397, 'EVID', 'Event ID', 'NA', 'Num', 'NA', '.', '0=PK event, 1=dose event, 2=not date-matching soluble lag3 record', 'Derived according to notes', 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1398, 'MDV', 'Missing DV', 'NA', 'Num', 'NA', '.', '0=observed value, 1=missing DV or suspicious data or dosing event', 'Derived according to notes', 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1399, 'DOSEA', 'Actual Dose of Relatlimab', 'mg', 'Num', 'NA', '.', 'Populated on all individual records as carry-forward.', NULL, 1, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1400, 'AMT', 'Actual Amount of Relatlimab', 'mg', 'Num', 'NA', '.', 'Only populated on dosing records. Use \".\" for non-dosing record (i.e., observations)', NULL, 1, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1401, 'RATE', 'Infusion Rate', 'mg/hr', 'Num', '0.01', '.', 'AMT/DOSEDUR', NULL, 1, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1402, 'DOSEDUR', 'Duration of Treatment Dose', 'hr', 'Num', '0.01', '.', 'Derived from (End dose date/time) - (Start dose date/time) - (infusion interruption if available).', NULL, 1, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1403, 'DV', 'Serum Concentration of Relatlimab', 'ug/mL', 'Num', 'NA', '.', 'Use \".\" if it\'s a missing values or below LLOQ', NULL, 1, 'PPK-ISOP-RELA', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1404, 'DVL', 'Log Analysis Value', 'NA', 'Num', '4 significant digits', '.', NULL, NULL, 1, 'PPK-ISOP-RELA', 0, 1, 0, 0, 1, 1, 1, 1, NULL),
(1405, 'CONCSTAT', 'Concentration Status', 'NA', 'Num', 'NA', '.', '0=Evaluable Concentration, 1=BLOQ, 2=OUTLIER or Not Reportable, 3=Missing value, 4=Duplicate record for NCA setup. If concstatus in PAMS/eToolbox=missing then always code CONCSTAT=0. Otherwise CONCSTAT=CONCSTATUS. Only populated for pk records.', NULL, 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1406, 'BLQFN', 'Blq Flag', 'NA', 'Num', 'NA', '.', 'BLQ: Below the Limit of Quantification. 0=No, 1=Yes.', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1407, 'DOSEP', 'Planned Dose of Relatlimab', 'mg/kg', 'Num', 'NA', '.', 'DOSEP represents the planned treatment dosage associated with the record. This is the numeric amount of the dose used for the popPK analysis and may differ from the EX.EXDOSE. Populated on all individual records as carry-forward.', NULL, 1, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1408, 'DOSENUM', 'Dose Number', 'NA', 'Num', 'NA', '.', 'Sequential number: 1=first dose, 2=second dose, etc. For PK records retain from dose records', 'Derived according to notes', 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1409, 'OCC', 'Occasion', 'NA', 'Num', 'NA', '.', '1=the first PK-related dose, 2=second PK-related dose, 3=third PK-related dose. After assigning OCC, change pre first PK-related records (pk and dose) from . to 0', 'Derived according to notes', 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1410, 'FREQ', 'Dose Frequency', 'week', 'Num', 'NA', '.', '2=Q2W, 3=Q3W, 4=Q4W', NULL, 1, 'PPK-ISOP-RELA', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1411, 'TRTA', 'Actual Treatment', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1412, 'EXCLF', 'Record Exclusion', 'NA', 'Num', 'NA', '0', NULL, NULL, 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1413, 'EXCLFC', 'Comment for the Record Exclusion', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1414, 'FLAG', 'Flagged Records', 'NA', 'Num', 'NA', '0', NULL, 'FLAG number per Flag table in Programming Algorithms and Imputations section.', 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1415, 'FLAGC', 'Comment for the Flagged Records', 'NA', 'Char', 'NA', 'blank', NULL, 'Description for FLAG per Flag table in Programming Algorithms and Imputations section.', 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL);
INSERT INTO `dsstruct` (`varorder`, `var_name`, `var_label`, `units`, `type`, `round`, `missVal`, `note`, `source`, `requiredFlag`, `SpecType`, `nameChange`, `labelChange`, `unitChange`, `typeChange`, `roundChange`, `missValChange`, `noteChange`, `sourceChange`, `erflag`) VALUES
(1416, 'DTC', 'Date and Time of Event', 'NA', 'Char', 'NA', 'blank', 'Date/time of event. Use ISO 8601 format which is a text representation of date and time e.g., 2013-05-09T08:58 where T is a time designator indicating time follows.', 'Derived according to notes', 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1417, 'SAMPLEID', 'PK Sample ID', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1418, 'NIVOCO', 'Nivo Co-Administered With Rela', 'NA', 'Num', 'NA', '.', 'Nivo: nivolumab. Rela: relatlimab. 1=Yes, 0=No. Time-varying covariate. Get nivo dosing data from ex/adex filtered by EXTRT to ppk dataset by USUBJID and date.  For dose records, if a nivo dose (dose amt > 0) was given on the same date as an rela dose (dose amt > 0) then NIVOCO would be 1.  For pk records please use LOCF from dose records.  Day-1, predose records will have NIVOCO as missing.', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1419, 'NDOSENIV', 'Nominal First Dose for Nivolumab', 'mg/kg or mg', 'Num', 'NA', '.', 'No nivo = 0', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1420, 'NIVFRQ', 'Nominal Frequency for Nivolumab', 'week', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1421, 'COMBO', 'Combination Treatment', 'NA', 'Num', 'NA', '.', '0=relatlimab was administered alone, 1=relatlimab and nivolumab were administered concurrently', 'Derived according to notes', 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1422, 'AGE', 'Age', 'year', 'Num', 'NA', '.', NULL, NULL, 1, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1423, 'SEX', 'Sex', 'NA', 'Char', 'NA', 'blank', 'Male or Female', NULL, 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1424, 'SEXN', 'Sex (N)', 'NA', 'Num', 'NA', '.', '1=Male, 2=Female', NULL, 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1425, 'RACE', 'Race', 'NA', 'Char', 'NA', 'blank', 'White, Black/African American, Asian, American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander, Others, Unknown', NULL, 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1426, 'RACEN', 'Race (N)', 'NA', 'Num', 'NA', '.', '1=White, 2=Black/African American, 3=Asian, 4=Others, 5=Unknown. American Indian/Alaska Native and Native Hawaiian/Other Pacific Islander are coded as 4.', NULL, 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1427, 'COUNTRY', 'Country', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1428, 'WTB', 'Baseline Body Weight', 'kg', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1429, 'HTB', 'Baseline Height', 'cm', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1430, 'BMIB', 'Baseline Body Mass Index', 'kg/m2', 'Num', '0.01', '.', NULL, NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1431, 'BSAB', 'Baseline Body Surface Area', 'm2', 'Num', '0.01', '.', NULL, NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1432, 'ALBB', 'Baseline Serum Albumin', 'g/dL', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1433, 'LDHB', 'Baseline Lactate Dehydrogenase', 'U/L', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1434, 'LDHULN', 'LDH Upper Limit of Normal', 'U/L', 'Num', 'NA', '.', 'LDH: Lactate Dehydrogenase.', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1435, 'LDHULNB', 'Normalized LDHB Upper Limit of Normal', 'NA', 'Num', '0.001', '.', 'LDHB/LDHULN', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1436, 'ALPB', 'Baseline Serum Alkaline Phosphatase', 'U/L', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1437, 'ALTB', 'Baseline Alanine Transaminase', 'U/L', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1438, 'ASTB', 'Baseline Aspartate Transaminase', 'U/L', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1439, 'CRCLB', 'Baseline Creatinine Clearance', 'mL/min', 'Num', '0.01', '.', NULL, 'Derived according to equation in Derivation table.', 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1440, 'CREATB', 'Baseline Creatinine Serum', 'mg/dL', 'Num', 'NA', '.', '*0.011312 convert from umol/L to mg/dL', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1441, 'EGFRB', 'Baseline eGFR', 'mL/min/1.73m2', 'Num', '0.01', '.', 'eGFR: Estimated Glomerular Filtration Rate.', 'Derived according to equation in Derivation table.', 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1442, 'ALCB', 'Baseline Abs Lymphocyte Count', 'x10^3c/uL', 'Num', 'NA', '.', 'Abs: Absolute. x10^9c/L is the same as x10^3c/uL.', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1443, 'TBILB', 'Baseline Total Bilirubin', 'mg/dL', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1444, 'DBILB', 'Baseline Direct Bilirubin', 'mg/dL', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1445, 'CRPB', 'Baseline C-Reactive Protein', 'mg/dL', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1446, 'HEPA', 'Liver Dysfunction Groups', 'NA', 'Char', 'NA', 'blank', 'GROUP A: Normal (total bilirubin<=ULN and AST<=ULN), GROUP B: Mild (total bilirubin > 1.0x-1.5xULN or AST > ULN), GROUP C: Moderate (total bilirubin > 1.5x-3xULN), GROUP D: Severe (total bilirubin > 3xULN). Assign in reverse order to assign most severe group.', NULL, 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1447, 'HEPAN', 'Liver Dysfunction Groups (N)', 'NA', 'Num', 'NA', '.', '1=GROUP A: Normal, 2=GROUP B: Mild, 3=GROUP C: Moderate, 4=GROUP D: Severe', 'Derived from HEPA', 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1448, 'TTYPEF', 'Tumor Type', 'NA', 'Char', 'NA', 'blank', 'Melanoma, SQ Non-Small Cell Lung Cancer, NSQ Non-Small Cell Lung Cancer, Unknown Histology Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Colorectal Cancer, Prostate Cancer, Classical Hodgkin Lymphoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Triple Negative Breast Cancer, Gastric Cancer, Pancreatic Cancer, Small Cell Lung Cancer, Ovarian Cancer, Hepatocellular Carcinoma, Glioblastoma, Adjuvant Melanoma, Cervical Cancer, Multiple Myeloma, Hodgkins Lymphoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Indolent Non-Hodgkins Lymphoma, Other Non-Hodgkins Lymphoma, Breast Cancer, Endometrial Cancer, Thyroid Cancer, Mesothelioma, Nasopharyngeal Carcinoma, Esophageal Cancer, Adjuvant Gastroesophageal Junction Cancer, Juvenile Myelomonocytic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Other', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1449, 'TTYPEN', 'Tumor Type (N)', 'NA', 'Num', 'NA', '.', '1=Melanoma, 2=SQ Non-Small Cell Lung Cancer, 3=NSQ Non-Small Cell Lung Cancer, 4=Unknown Histology Non-Small Cell Lung Cancer, 5=Renal Cell Carcinoma, 6=Colorectal Cancer, 7=Prostate Cancer, 8=Classical Hodgkin Lymphoma, 9=Squamous Cell Carcinoma of the Head and Neck, 10=Bladder Cancer, 11=Triple Negative Breast Cancer, 12=Gastric Cancer, 13=Pancreatic Cancer, 14=Small Cell Lung Cancer, 15=Ovarian Cancer, 16=Hepatocellular Carcinoma, 17=Glioblastoma, 18=Adjuvant Melanoma, 19=Cervical Cancer, 20=Multiple Myeloma, 21=Hodgkins Lymphoma, 22=Diffuse Large B-Cell Lymphoma, 23=Chronic Lymphocytic Leukemia, 24=Indolent Non-Hodgkins Lymphoma, 25=Other Non-Hodgkins Lymphoma, 26=Breast Cancer, 27=Endometrial Cancer, 28=Thyroid Cancer, 29=Mesothelioma, 30=Nasopharyngeal Carcinoma, 31=Esophageal Cancer, 32=Adjuvant Gastroesophageal Junction Cancer, 33=Juvenile Myelomonocytic Leukemia, 34=Acute Myeloid Leukemia, 35=Myelodysplastic Syndromes, 100=Other', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1450, 'TSIZEB', 'Baseline Tumor Burden', 'cm', 'Num', 'NA', '.', 'Sum of longest diameters of all target lesions,  convert tumor burden from mm to cm by dividing by 10', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1451, 'TSIZE2B', 'Baseline Tumor Burden', 'cm2', 'Num', 'NA', '.', 'Sum of products of diameters for all target lesions.', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1452, 'PS', 'Baseline Performance Status', 'NA', 'Num', 'NA', '.', '0 (Normal), 1, 2, 3, 4; If convert from KPS, 0=KPS 100, 1=KPS 90/80, 2=KPS 70/60, 3=KPS 50/40, 4=KPS 30/20/10', 'ECOG or Derived from KPS', 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1453, 'ADA', 'Immunogenicity by Visit Level', 'NA', 'Num', 'NA', '.', '0=negative, 1=positive (any type)', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1454, 'ADALIST', 'Immunogenicity by Subject Level', 'NA', 'Char', 'NA', 'blank', 'Immunogenicity Council Definition - Persistent Positive, Only the Last Sample Positive, Other Positive, Negative, NA', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1455, 'TITER', 'Immunogenicity Titer by Visit Level', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 0, 1, 1, 1, NULL),
(1456, 'LAGC1B', 'Baseline LAG3 Covance Assay (1% cutoff)', 'NA', 'Num', 'NA', '.', '0=Negative, 1=Positive, 2=Unknown', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1457, 'LAGV5B', 'Baseline LAG3 Covance Assay (5% cutoff)', 'NA', 'Num', 'NA', '.', '0=Negative, 1=Positive, 2=Unknown', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1458, 'LAGB', 'Baseline LAG3 Covance Assay Group', 'NA', 'Num', 'NA', '.', '0=Negative, 1=1 to 4%, 2=5% and above, 3=Unknown', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1459, 'LAGCB', 'Baseline LAG3 Exp Covance Assay', '%', 'Num', 'NA', '.', 'Exp: Expression', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1460, 'LAGC', 'LAG3 Exp Covance Assay', '%', 'Num', 'NA', '.', 'Exp: Expression', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1461, 'SLAG', 'Soluble LAG3 by Visit Level', 'pg/mL', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1462, 'SLAGB', 'Baseline Total Soluble LAG3', 'pg/mL', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1463, 'PDL1', 'PDL1 Expression', '%', 'Num', 'NA', '.', 'Continuous variable', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1464, 'PDL11', 'PDL1 Expression (1% cutoff)', 'NA', 'Char', 'NA', 'blank', 'positive, negative status - tumor only (>= 1% cutoff). positive,negative, unknown, missing.', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1465, 'PDL15', 'PDL1 Expression (5% cutoff)', 'NA', 'Char', 'NA', 'blank', 'positive, negative status - tumor only (>= 5% cutoff). positive,negative, unknown, missing.', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1466, 'PDL110', 'PDL1 Expression (10% cutoff)', 'NA', 'Char', 'NA', 'blank', 'positive, negative status - tumor only (>= 10% cutoff). positive,negative, unknown, missing.', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1467, 'LINE', 'Line of Therapy', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1468, 'LINEC', 'Line of Therapy (Categorization)', 'NA', 'Char', 'NA', 'blank', '1, >1', 'LINEC=\'1\' where LINE=1, LINEC=\'>1\' where LINE>1. If LINE is missing then impute LINEC based on protocol', 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1469, 'LINEN', 'Line of Therapy (Categorization, N)', 'NA', 'Num', 'NA', '.', '1, 2', 'LINEN=1 where LINEC=\'1\', LINEN=2 where LINEC=\'>1\'', 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1470, 'PRIO', 'Prior Immunotherapy', 'NA', 'Num', 'NA', '.', '0=IO naïve, 1=Prior IO', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1471, 'PROC', 'Manufacture Process', 'NA', 'Char', 'NA', 'blank', 'Process A, Process B, Process B1, Process B1*', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1472, 'PROCN', 'Manufacture Process (N)', 'NA', 'Num', 'NA', '.', '1=Process A, 2=Process B, 3=Process B1, 4=Process B1*', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1473, 'FORM', 'Formulation', 'NA', 'Char', 'NA', 'blank', 'SAV sequential, SAV coadministration, FDC, Rela Monotherapy', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1474, 'FORMN', 'Formulation (N)', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1475, 'DOSEP1', 'Planned Rela Dose at the First Stage', 'NA', 'Num', 'NA', '.', NULL, 'Derived based on TX', 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1476, 'DU1', 'Dose Unit for DOSEP1', 'NA', 'Char', 'NA', 'blank', 'either mg or mg/kg', 'Derived based on TX', 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1477, 'FREQ1', 'Dose Frequency at the First Stage', 'week', 'Num', 'NA', '.', '2=Q2W, 3=Q3W', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1478, 'DOSEPSS', 'Planned Rela Dose at Maintenance Stage', 'NA', 'Num', 'NA', '.', 'If no maintenance stage, the value of DOSEPSS should be equal to the DOSEP1 (do not leave blank)', 'Derived based on TX', 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1479, 'DUSS', 'Dose Unit for DOSEPSS', 'NA', 'Char', 'NA', 'blank', 'either mg or mg/kg; If no maintenance stage, the value of DUSS should be equal to the DU1 (do not leave blank)', 'Derived based on TX', 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1480, 'FREQSS', 'Dose Frequency at Maintenance Stage', 'week', 'Num', 'NA', '.', 'If no maintenance stage, the value of FREQSS should be equal to the FREQ1 (do not leave blank)', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1481, 'CROSSOVR', 'Crossover Rela to Rela+Nivo Combo', 'NA', 'Num', 'NA', '.', 'Nivo: nivolumab. Rela: relatlimab. 0=Not a crossover subject, 1=Cross over subject', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1482, 'TMB', 'Tumor Mutation Burden', 'mutations/Mb', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-ISOP-RELA', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1483, 'TMBC', 'Tumor Mutation Burden Category', 'NA', 'Char', 'NA', 'blank', 'High TMB, Low TMB, Not Evaluable. Nivo mono cutoff mutation >=12.61. Nivo + Ipi cutoff mutation >=10.09', 'Derived from TMB and Notes', 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1484, 'BOR', 'Best Overall Response', 'NA', 'Char', 'NA', 'blank', 'CR=Complete response, PR=Partial response, SD=Stable disease, PD=Progressive disease, NE=Unevaluable, NA=Missing or not reported, NN=NON-CR/NON-PD, ND=No Disease.', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1485, 'BORN', 'Best Overall Response (N)', 'NA', 'Num', 'NA', '.', '1=CR, 2=PR, 3=SD, 4=PD, 5=NE, 6=NA, 7=NN, 8=ND', 'Derived from BOR', 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1486, 'BORPER', 'BOR Assessed by', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1487, 'BORCRT', 'BOR Criteria', 'NA', 'Char', 'NA', 'blank', 'mWHO, RECIST v1.0, RECIST v1.1', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1488, 'ETH', 'Ethnicity', 'NA', 'Char', 'NA', 'blank', 'Japanese, Others', 'Derived based on RACE and CNTCODE. ETH=Japanese where RACE=Asian and CNTCODE=Japan', 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1489, 'ETHN', 'Ethnicity (N)', 'NA', 'Num', 'NA', '.', '1=Japanese, 100=Others', 'Derived based on ETH', 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1490, 'ETHJ', 'Japanese Ethnicity', 'NA', 'Char', 'NA', 'blank', 'Japanese, Non-Japanese Asian, Non-Asian', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1491, 'ETHJN', 'Japanese Ethnicity (N)', 'NA', 'Num', 'NA', '.', '1=Japanese, 2=Non-Japanese Asian, 3=Non-Asian', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1492, 'ETHC', 'Chinese Ethnicity', 'NA', 'Char', 'NA', 'blank', 'Chinese, Non-Chinese Asian, Non-Asian', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1493, 'ETHCN', 'Chinese Ethnicity (N)', 'NA', 'Num', 'NA', '.', '1=Chinese, 2=Non-Chinese Asian, 3=Non-Asian', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1494, 'TRTSEQFL', 'Treated Sequentially Flag', 'NA', 'Char', 'NA', 'NA', 'Y=Yes, N=No', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1495, 'TRTMIXFL', 'Mixed Treatments Received Flag', 'NA', 'Char', 'NA', 'NA', 'Y=Yes, N=No', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1496, 'TRTINCFL', 'Incorrect Treatment Received Flag', 'NA', 'Char', 'NA', 'NA', 'Y=Yes, N=No', NULL, 0, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1497, 'BUILDDT', 'Dataset Creation Date', 'NA', 'Char', 'NA', 'blank', NULL, 'Created at run time', 1, 'PPK-ISOP-RELA', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1498, 'PROJID', 'Project Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1499, 'PROJIDN', 'Project Identifier (N)', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1500, 'STUDYID', 'Study Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1501, 'STUDYIDN', 'Study Identifier (N)', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1502, 'PART', 'Part of the Study', 'NA', 'Num', 'NA', '.', 'Required when study has more than one part.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1503, 'EXTEN', 'Extension of the Core Study', 'NA', 'Num', 'NA', '.', 'Required if study has an extension.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1504, 'SUBJTYP', 'Subject Type', 'NA', 'Char', 'NA', 'blank', 'For first-in-human studies, the value can be ?Healthy volunteers?.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1505, 'SUBJTYPN', 'Subject Type (N)', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1506, 'USUBJID', 'Unique Subject Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1507, 'USUBJIDN', 'Unique Subject Identifier (N)', 'NA', 'Num', 'NA', '.', 'Unique numerical representation of USUBJID.', NULL, 1, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1508, 'SUBJID', 'Subject Identifier for the Study', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1509, 'SUBJIDN', 'Subject Identifier for the Study (N)', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1510, 'SITEID', 'Study Site Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1511, 'SITEIDN', 'Study Site Identifier (N)', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1512, 'RECSEQS', 'Record Sequence Number Within a Subject', 'NA', 'Num', 'NA', '.', 'Sequential values should start with 1 on the first row for each subject and incrementing by 1 for each subsequent row.', 'Derived according to notes', 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1513, 'RECSEQ', 'Record Sequence', 'NA', 'Num', 'NA', '.', 'Sequential values should start with 1 on the first non-header row of the data file and incrementing by 1 for each subsequent row.', 'Derived according to notes', 1, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1514, 'AVISIT', 'Analysis Visit', 'NA', 'Char', 'NA', 'blank', 'The analysis visit description; required if an analysis is done by nominal, assigned or analysis visit.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1515, 'AVISITN', 'Analysis Visit (N)', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1516, 'VISIT', 'Visit', 'NA', 'Char', 'NA', 'blank', 'Clinic visit captured in STDM domains EX or PC and variable VISIT', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1517, 'VISITNUM', 'Visit (N)', 'NA', 'Num', 'NA', '.', 'Clinic visit captured in STDM domains EX or PC and variable VISITNUM', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1518, 'AFRELTM', 'Actual Rel Time From First Dose', 'hr', 'Num', '0.01', '.', 'Rel: Relative. Derived from (Analysis date/time of the current event/record of the subject) - (Analysis date/time of the first dosing event/record of the subject)', NULL, 1, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1519, 'TPTREF', 'Time Point Reference', 'NA', 'Char', 'NA', 'blank', 'Description of reference dose, e.g. first dose in the period, last dose in the period or anything in between.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1520, 'APRELTM', 'Actual Rel Time From Previous Dose', 'hr', 'Num', '0.01', '.', 'Rel: Relative. Derived from (Analysis date/time of the current event/record of the subject) - (Analysis date/time of the previous dosing event/record of the subject).', NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1521, 'NFRELTM', 'Nominal Rel Time From First Dose', 'hr', 'Num', '0.1', '.', 'Rel: Relative. Planned elapsed time (for sample point or start of sampling interval) from first exposure to study treatment.', NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1522, 'NPRELTM', 'Nominal Rel Time From Previous Dose', 'hr', 'Num', '0.1', '.', 'Rel: Relative. For PK it can be derived from NTIME in PC domain.', NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1523, 'ATPT', 'Planned Time Point Name', 'NA', 'Char', 'NA', 'blank', 'Text description of the planned/protocol time for the specimen collection. Taken from PC.PCTPT.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1524, 'ATPTN', 'Planned Time Point Number', 'NA', 'Num', 'NA', '.', 'PC.PCTPTNUM, numerical representation for PCTPT.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1525, 'ADT', 'Analysis Date', 'NA', 'Num', 'NA', '.', 'YYMMDD10. When AENDT is populated then this will represent the start date of that dose interval.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1526, 'ADY', 'Analysis Relative Day', 'NA', 'Num', 'NA', '.', 'Study day, relative to the start of the study.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1527, 'ATM', 'Analysis Time', 'NA', 'Num', 'NA', '.', 'B8601TM. When AENTM is populated then this will represent the start date of that interval as would be expected in urinalysis.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1528, 'ADTM', 'Analysis Date/Time', 'NA', 'Num', 'NA', '.', 'E8601DT. When AENDTM is populated then this will represent the start date of that dose intervals.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1529, 'AENDT', 'Analysis End Date', 'NA', 'Num', 'NA', '.', 'YYMMDD10.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1530, 'AENTM', 'Analysis End Time', 'NA', 'Num', 'NA', '.', 'B8601TM.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1531, 'AENDTM', 'Analysis End Date/Time', 'NA', 'Num', 'NA', '.', 'E8601DT.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1532, 'OCC', 'Occasion', 'NA', 'Num', 'NA', '.', '1=the first PK-related dose, 2=second PK-related dose, 3=third PK-related dose. After assigning OCC, change pre first PK-related records (pk and dose) from . to 0', 'Derived according to notes', 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1533, 'EXCLFC', 'Comment for the Record Exclusion', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1534, 'EXCLF', 'Record Exclusion', 'NA', 'Num', 'NA', '0', NULL, NULL, 1, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1535, 'FLAG', 'Flagged Records', 'NA', 'Num', 'NA', '0', NULL, 'FLAG number per Flag table in Programming Algorithms and Imputations section.', 1, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1536, 'FLAGC', 'Comment for the Flagged Records', 'NA', 'Char', 'NA', 'blank', NULL, 'Description for FLAG per Flag table in Programming Algorithms and Imputations section.', 1, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1537, 'DVID', 'Dependent Variable Name', 'NA', 'Char', 'NA', 'blank', 'Analyte/drug name.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1538, 'DVIDN', 'Dependent Variable Name (N)', 'NA', 'Num', 'NA', '.', 'Convention is normally 0=dose, 1=for the first observation of interest, etc.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1539, 'CMT', 'Compartment', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1540, 'DV', 'Analysis Value', 'ug/mL', 'Num', 'NA', '.', NULL, NULL, 1, 'PPK-standard', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1541, 'DVC', 'Analysis Value (C)', 'NA', 'Char', 'NA', 'blank', 'Character results/findings in a standard format. PC.PCSTRESC (SDTM) or AVALC (ADaM).', NULL, 0, 'PPK-standard', 0, 1, 0, 0, 0, 1, 1, 1, NULL),
(1542, 'DVL', 'Log Analysis Value', 'NA', 'Num', '4 significant digits', '.', 'Natural log. It\'s \'.\' (CDISC value for null) if value is 0 and log otherwise', NULL, 0, 'PPK-standard', 0, 1, 0, 0, 1, 1, 1, 1, NULL),
(1543, 'EVID', 'Event ID', 'NA', 'Num', 'NA', '.', '0=PK event, 1=dose event.', NULL, 1, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1544, 'MDV', 'Missing DV', 'NA', 'Num', 'NA', '.', '0=observed value, 1=missing DV or suspicious data or dosing event', 'Derived according to notes', 1, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1545, 'PCULOQ', 'Upper Limit of Quantitation', 'ug/mL', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1546, 'PCLLOQ', 'Lower Limit of Quantitation', 'ug/mL', 'Num', 'NA', '.', 'PC.PCLLOQ', NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1547, 'BLQFN', 'Blq Flag', 'NA', 'Num', 'NA', '.', 'BLQ: Below the Limit of Quantification. 0=No, 1=Yes.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1548, 'ALQFN', 'Alq Flag', 'NA', 'Num', 'NA', '.', 'ALQ: Above the Limit of Quantification. 0=No, 1=Yes.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1549, 'DOSEA', 'Actual Treatment Dose', 'mg', 'Num', 'NA', '.', 'Populated on all individual records as carry-forward.', NULL, 1, 'PPK-standard', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1550, 'DOSEP', 'Planned Treatment Dose', 'mg', 'Num', 'NA', '.', 'DOSEP represents the planned treatment dosage associated with the record. This is the numeric amount of the dose used for the popPK analysis and may differ from the EX.EXDOSE. Populated on all individual records as carry-forward.', NULL, 0, 'PPK-standard', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1551, 'AMT', 'Actual Amount of Drug Received', 'mg', 'Num', 'NA', '.', 'Only populated on dosing records', NULL, 1, 'PPK-standard', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1552, 'DOSCUMA', 'Cumulative Amount of Dose Received', 'mg', 'Num', 'NA', '.', 'Calculated by adding the doses up as we go.', NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1553, 'DOSETDD', 'Total Daily Amount of Dose Received', 'mg', 'Num', 'NA', '.', 'Used mostly for b.i.d. dosing schemes.', NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1554, 'DOSEDUR', 'Duration of Treatment Dose', 'hr', 'Num', '0.01', '.', 'Derived from (End dose date/time) - (Start dose date/time) - (infusion interruption if available).', NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1555, 'RATE', 'Infusion Rate', 'mg/hr', 'Num', '0.01', '.', 'AMT/DOSEDUR', NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1556, 'II', 'Dosing Interval', 'hr', 'Num', 'NA', '.', '24 for QD, 12 for BID, etc.', NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1557, 'ADDL', 'Number of Additional Doses', 'NA', 'Num', 'NA', '.', 'Number of additional doses like the current one until the next dose.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1558, 'SS', 'Steady State', 'NA', 'Num', 'NA', '.', 'A steady-state dose is a dose that is imagined to be the last of a series of implied doses, each exactly like the dose in question, given at a regular interval specified by the II data item and leading to steady-state by the time the steady-state dose is given.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1559, 'FORM', 'Formulation', 'NA', 'Char', 'NA', 'blank', 'Type of formulation (e.g., tablet, capsule, aerosole).', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1560, 'FORMN', 'Formulation (N)', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1561, 'ROUTE', 'Route', 'NA', 'Char', 'NA', 'blank', 'Route of treatment delivery.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1562, 'ROUTEN', 'Route (N)', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1563, 'TRTP', 'Planned Treatment', 'NA', 'Char', 'NA', 'blank', 'This variable should contain both the name of the drug and the dose amount and may also include information related to delivery of the drug if it is relevant for the analysis.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1564, 'TRTPN', 'Planned Treatment (N)', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1565, 'TRTA', 'Actual Treatment', 'NA', 'Char', 'NA', 'blank', 'This variable should contain both the name of the drug and the dose amount and may also include information related to delivery of the drug if it is relevant for the analysis.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1566, 'TRTAN', 'Actual Treatment (N)', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1567, 'APHASE', 'Phase', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1568, 'APHASEN', 'Phase (N)', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1569, 'APERIOD', 'Period', 'NA', 'Num', 'NA', '.', 'Record-level timing variable that represents the analysis period within the study associated with the record for analysis purposes.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1570, 'APERIODC', 'Period (C)', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1571, 'ACYCLEC', 'Analysis Cycle', 'NA', 'Char', 'NA', 'blank', 'Record level identifier that reflects cycle and may be of particular importance for studies that examine concentrations in cancer patients.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1572, 'ACYCLEN', 'Analysis Cycle (N)', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1573, 'ARM', 'Description of Planned Arm', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1574, 'ARMN', 'Arm (N)', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1575, 'ACTARM', 'Description of Actual Arm', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1576, 'ACTARMN', 'Actual Arm (N)', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1577, 'COHORT', 'Cohort Subject Enrolled Into', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1578, 'COHORTN', 'Cohort Number Subject Enrolled Into', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1579, 'WT', 'Body Weight', 'kg', 'Num', 'NA', '.', 'Time-varying covariate.', NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1580, 'WTB', 'Baseline Body Weight', 'kg', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1581, 'HTB', 'Baseline Height', 'cm', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1582, 'BMIB', 'Baseline Body Mass Index', 'kg/m2', 'Num', '0.01', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1583, 'BSAB', 'Baseline Body Surface Area', 'm2', 'Num', '0.01', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1584, 'AGE', 'Age', 'year', 'Num', 'NA', '.', NULL, NULL, 1, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1585, 'SEX', 'Sex', 'NA', 'Char', 'NA', 'blank', 'Male or Female', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1586, 'SEXN', 'Sex (N)', 'NA', 'Num', 'NA', '.', '1=Male, 2=Female', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1587, 'RACE', 'Race', 'NA', 'Char', 'NA', 'blank', 'White, Black/African American, Asian, American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander, Others, Unknown', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1588, 'RACEN', 'Race (N)', 'NA', 'Num', 'NA', '.', '1=White, 2=Black/African American, 3=Asian, 4=Others, 5=Unknown. American Indian/Alaska Native and Native Hawaiian/Other Pacific Islander are coded as 4.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1589, 'ETHNIC', 'Ethnicity', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1590, 'ETHNICN', 'Ethnicity (N)', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1591, 'REGION', 'Region', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1592, 'REGIONN', 'Region (N)', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1593, 'COUNTRY', 'Country', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1594, 'COUNTRYN', 'Country (N)', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1595, 'CREATB', 'Baseline Creatinine Serum', 'mg/dL', 'Num', 'NA', '.', '*0.011312 convert from umol/L to mg/dL', NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1596, 'CRCLB', 'Baseline Creatinine Clearance', 'mL/min', 'Num', '0.01', '.', NULL, 'Derived according to equation in Derivation table.', 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1597, 'EGFRB', 'Baseline eGFR', 'mL/min/1.73m2', 'Num', '0.01', '.', 'eGFR: Estimated Glomerular Filtration Rate.', 'Derived according to equation in Derivation table.', 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1598, 'TBILB', 'Baseline Total Bilirubin', 'mg/dL', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1599, 'ASTB', 'Baseline Aspartate Transaminase', 'U/L', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1600, 'ALTB', 'Baseline Alanine Transaminase', 'U/L', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1601, 'ITTFL', 'Intent-to-treat Population Flag', 'NA', 'Char', 'NA', 'blank', NULL, 'ADSL.ITTFL', 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1602, 'ITTFN', 'Intent-to-treat Population Flag (N)', 'NA', 'Num', 'NA', '.', '0=No, 1=Yes', 'ADSL.ITTFL with \"Yes\" or \"Y\"=1 and \"No\" or \"N\"=0', 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1603, 'COMPLFL', 'Completers Population Flag', 'NA', 'Char', 'NA', 'blank', NULL, 'ADSL.COMPLFL', 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1604, 'COMPLFN', 'Completers Population Flag (N)', 'NA', 'Num', 'NA', '.', '0=No, 1=Yes', 'ADSL.COMPLFL with \"Yes\" or \"Y\"=1 and \"No\" or \"N\"=0', 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1605, 'TCOMPLFL', 'Treatment Completers Population Flag', 'NA', 'Char', 'NA', 'blank', NULL, 'ADSL.TCOMPLFL', 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1606, 'TCOMPLFN', 'Treatment Completers Population Flag (N)', 'NA', 'Num', 'NA', '.', '0=No, 1=Yes', 'ADSL.TCOMPLFL with \"Yes\" or \"Y\"=1 and \"No\" or \"N\"=0', 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1607, 'SAFFL', 'Safety Population Flag', 'NA', 'Char', 'NA', 'blank', NULL, 'ADSL.SAFFL', 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1608, 'SAFFN', 'Safety Population Flag (N)', 'NA', 'Num', 'NA', '.', '0=No, 1=Yes', 'ADSL.SAFFL with \"Yes\" or \"Y\"=1 and \"No\" or \"N\"=0', 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1609, 'VOMITFL', 'Flag for Vomit Related to Dose', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1610, 'FOODFL', 'Food Status', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1611, 'ID', 'NONMEM ID', 'NA', 'Num', 'NA', '.', 'Sequential numbering, (1, 2, 3, ...). One ID per subject.', 'Derived according to notes', 1, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1612, 'DOSENUM', 'Dose Number', 'NA', 'Num', 'NA', '.', 'Sequential number: 1=first dose, 2=second dose, etc. For PK records retain from dose records', 'Derived according to notes', 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1613, 'CONCSTAT', 'Concentration Status', 'NA', 'Num', 'NA', '.', '0=Evaluable Concentration, 1=BLOQ, 2=OUTLIER or Not Reportable, 3=Missing value, 4=Duplicate record for NCA setup. If concstatus in PAMS/eToolbox=missing then always code CONCSTAT=0. Otherwise CONCSTAT=CONCSTATUS. Only populated for pk records.', NULL, 1, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1614, 'FREQ', 'Dose Frequency', 'week', 'Num', 'NA', '.', 'eg. 3=Q3W, 6=Q6W, 12=Q12W', NULL, 0, 'PPK-standard', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1615, 'PS', 'Baseline Performance Status', 'NA', 'Num', 'NA', '.', '0 (Normal), 1, 2, 3, 4; If convert from KPS, 0=KPS 100, 1=KPS 90/80, 2=KPS 70/60, 3=KPS 50/40, 4=KPS 30/20/10', 'ECOG or Derived from KPS', 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1616, 'ALBB', 'Baseline Serum Albumin', 'g/dL', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1617, 'LDHB', 'Baseline Lactate Dehydrogenase', 'U/L', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1618, 'LDHULN', 'LDH Upper Limit of Normal', 'U/L', 'Num', 'NA', '.', 'LDH: Lactate Dehydrogenase.', NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1619, 'ALPB', 'Baseline Serum Alkaline Phosphatase', 'U/L', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1620, 'ALCB', 'Baseline Abs Lymphocyte Count', 'x10^3c/uL', 'Num', 'NA', '.', 'Abs: Absolute. x10^9c/L is the same as x10^3c/uL.', NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1621, 'DBILB', 'Baseline Direct Bilirubin', 'mg/dL', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1622, 'HCTB', 'Baseline Hematocrit', '%', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1623, 'HEPA', 'Liver Dysfunction Groups', 'NA', 'Char', 'NA', 'blank', 'GROUP A: Normal (total bilirubin<=ULN and AST<=ULN), GROUP B: Mild (total bilirubin > 1.0x-1.5xULN or AST > ULN), GROUP C: Moderate (total bilirubin > 1.5x-3xULN), GROUP D: Severe (total bilirubin > 3xULN). Assign in reverse order to assign most severe group.', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1624, 'HEPAN', 'Liver Dysfunction Groups (N)', 'NA', 'Num', 'NA', '.', '1=GROUP A: Normal, 2=GROUP B: Mild, 3=GROUP C: Moderate, 4=GROUP D: Severe', 'Derived from HEPA', 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1625, 'TTYPEF', 'Tumor Type', 'NA', 'Char', 'NA', 'blank', 'Melanoma, SQ Non-Small Cell Lung Cancer, NSQ Non-Small Cell Lung Cancer, Unknown Histology Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Colorectal Cancer, Prostate Cancer, Classical Hodgkin Lymphoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Triple Negative Breast Cancer, Gastric Cancer, Pancreatic Cancer, Small Cell Lung Cancer, Ovarian Cancer, Hepatocellular Carcinoma, Glioblastoma, Adjuvant Melanoma, Cervical Cancer, Multiple Myeloma, Hodgkins Lymphoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Indolent Non-Hodgkins Lymphoma, Other Non-Hodgkins Lymphoma, Breast Cancer, Endometrial Cancer, Thyroid Cancer, Mesothelioma, Nasopharyngeal Carcinoma, Esophageal Cancer, Adjuvant Gastroesophageal Junction Cancer, Juvenile Myelomonocytic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Other', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1626, 'TTYPEN', 'Tumor Type (N)', 'NA', 'Num', 'NA', '.', '1=Melanoma, 2=SQ Non-Small Cell Lung Cancer, 3=NSQ Non-Small Cell Lung Cancer, 4=Unknown Histology Non-Small Cell Lung Cancer, 5=Renal Cell Carcinoma, 6=Colorectal Cancer, 7=Prostate Cancer, 8=Classical Hodgkin Lymphoma, 9=Squamous Cell Carcinoma of the Head and Neck, 10=Bladder Cancer, 11=Triple Negative Breast Cancer, 12=Gastric Cancer, 13=Pancreatic Cancer, 14=Small Cell Lung Cancer, 15=Ovarian Cancer, 16=Hepatocellular Carcinoma, 17=Glioblastoma, 18=Adjuvant Melanoma, 19=Cervical Cancer, 20=Multiple Myeloma, 21=Hodgkins Lymphoma, 22=Diffuse Large B-Cell Lymphoma, 23=Chronic Lymphocytic Leukemia, 24=Indolent Non-Hodgkins Lymphoma, 25=Other Non-Hodgkins Lymphoma, 26=Breast Cancer, 27=Endometrial Cancer, 28=Thyroid Cancer, 29=Mesothelioma, 30=Nasopharyngeal Carcinoma, 31=Esophageal Cancer, 32=Adjuvant Gastroesophageal Junction Cancer, 33=Juvenile Myelomonocytic Leukemia, 34=Acute Myeloid Leukemia, 35=Myelodysplastic Syndromes, 100=Other', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1627, 'TSIZEB', 'Baseline Tumor Burden', 'cm', 'Num', 'NA', '.', 'Sum of longest diameters of all target lesions,  convert tumor burden from mm to cm by dividing by 10', NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1628, 'TSIZE2B', 'Baseline Tumor Burden', 'cm2', 'Num', 'NA', '.', 'Sum of products of diameters for all target lesions.', NULL, 0, 'PPK-standard', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1629, 'ADA', 'Immunogenicity by Visit Level', 'NA', 'Num', 'NA', '.', '0=negative, 1=positive (any type)', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1630, 'ADALIST', 'Immunogenicity by Subject Level', 'NA', 'Char', 'NA', 'blank', 'Immunogenicity Council Definition - Persistent Positive, Only the Last Sample Positive, Other Positive, Negative, NA', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1631, 'DTC', 'Date and Time of Event', 'NA', 'Char', 'NA', 'blank', 'Date/time of event. Use ISO 8601 format which is a text representation of date and time e.g., 2013-05-09T08:58 where T is a time designator indicating time follows.', 'Derived according to notes', 1, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1632, 'SAMPLEID', 'PK Sample ID', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1633, 'LINE', 'Line of Therapy', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1634, 'BUILDDT', 'Dataset Creation Date', 'NA', 'Char', 'NA', 'blank', NULL, 'Created at run time', 1, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1635, 'CHEWSNU', 'Chewing Tobacco/Snuff', 'NA', 'Char', 'NA', 'blank', 'Never, Current, Former, Unknown', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1636, 'PIPE', 'Pipe Smoking Status', 'NA', 'Char', 'NA', 'blank', 'Never, Current, Former, Unknown', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1637, 'CIGAR', 'Cigar Smoking Status', 'NA', 'Char', 'NA', 'blank', 'Never, Current, Former, Unknown', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1638, 'CIGARETT', 'Cigarette Smoking Status', 'NA', 'Char', 'NA', 'blank', 'Never, Current, Former, Unknown', NULL, 0, 'PPK-standard', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1639, 'STUDYID', 'Study Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'ER-ISOP-safety', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1640, 'USUBJID', 'Unique Subject Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'ER-ISOP-safety', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1641, 'ID', 'ID', 'NA', 'Num', 'NA', '.', 'Sequential numbering, (1, 2, 3, ...). One ID per subject.', 'Derived according to notes', 1, 'ER-ISOP-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'gr3'),
(1642, 'GR3COD', 'AE Term of Gr3+ AE', 'NA', 'Char', 'NA', 'blank', 'Gr3+: Grade 3 or higher, AE: Adverse Events. Missing if GR3F=0.', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'gr3'),
(1643, 'GR3M', 'Time to Gr3+ AE', 'month', 'Num', 'NA', '.', 'Gr3+: Grade 3 or higher, AE: Adverse Events. GR3D/365.25*12.', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'gr3'),
(1644, 'GR3D', 'Time to Gr3+ AE', 'day', 'Num', 'NA', '.', 'Gr3+: Grade 3 or higher, AE: Adverse Events. Time from 1st treatment to the 1st event/censoring. For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset. Derived according to notes.', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'gr3'),
(1645, 'GR3F', 'Flag of Gr3+ AE', 'NA', 'Num', 'NA', '.', 'Gr3+: Grade 3 or higher, AE: Adverse Events. Gr3+ AE: AETOXGRN>=3, TEAE100=\'Y\', ADSL$SAFFL=\'Y\'. 1-Event, 0-No event (Censored)', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'aedcd'),
(1646, 'AEDCDCOD', 'AE Term of AE-DC/D', 'NA', 'Char', 'NA', 'blank', 'AE: Adverse Events. DC/D: Drug Discontinuation or Death. Missing if AEDCF=0.', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'aedcd'),
(1647, 'AEDCDM', 'Time to AE-DC/D', 'month', 'Num', 'NA', '.', 'AE: Adverse Events. DC/D: Drug Discontinuation or Death. AEDCD/365.25*12.', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'aedcd'),
(1648, 'AEDCDD', 'Time to AE-DC/D', 'day', 'Num', 'NA', '.', 'AE: Adverse Events. DC/D: Drug Discontinuation or Death. Time from 1st treatment to the 1st event/censoring; For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset. Derived according to notes.', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'aedcd'),
(1649, 'AEDCDF', 'Flag of AE-DC/D', 'NA', 'Num', 'NA', '.', 'AE: Adverse Events. DC/D: Drug Discontinuation or Death. AE-DC/D: AEDISCFL^=\"\" or AESDTH=\"Y\"  (also need to review the AEDECOD of the list to exclude disease related terms), TEAE100=\'Y\', ADSL$SAFFL=\'Y\'. 1-Event, 0-No event (Censored).', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'imae'),
(1650, 'IMAECOD', 'AE Term of Immune-Mediated AE', 'NA', 'Char', 'NA', 'blank', 'AE: Adverse Events. Missing if IMAEF=0.', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'imae'),
(1651, 'IMAEM', 'Time to Immune-Mediated AE', 'month', 'Num', 'NA', '.', 'AE: Adverse Events. IMAED/362.25*12.', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'imae'),
(1652, 'IMAED', 'Time to Immune-Mediated AE', 'day', 'Num', 'NA', '.', 'AE: Adverse Events. Time from 1st treatment to the 1st event/censoring. For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset. Derived according to notes.', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'imae'),
(1653, 'IMAEF', 'Flag of Immune-Mediated AE', 'NA', 'Num', 'NA', '.', 'AE: Adverse Events. 1-Event, 0-No event (Censored).', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'imaegr2'),
(1654, 'IMAEGR2C', 'AE Term of Gr2+ IMAE', 'NA', 'Char', 'NA', 'blank', 'AE: Adverse Events, Gr2+: Grade 2 or higher, IMAE: Immune-Mediated Adverse Events. Missing if IMAEGR2F=0.', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'imaegr2'),
(1655, 'IMAEGR2M', 'Time to Gr2+ IMAE', 'month', 'Num', 'NA', '.', 'Gr2+: Grade 2 or higher, IMAE: Immune-Mediated Adverse Events. IMAEGR2D/365.25*12.', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'imaegr2'),
(1656, 'IMAEGR2D', 'Time to Gr2+ IMAE', 'day', 'Num', 'NA', '.', 'Gr2+: Grade 2 or higher, IMAE: Immune-Mediated Adverse Events. Time from 1st treatment to the 1st event/censoring. For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset. Derived according to notes.', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'imaegr2'),
(1657, 'IMAEGR2F', 'Flag of Gr2+ IMAE', 'NA', 'Num', 'NA', '.', 'Gr2+: Grade 2 or higher, IMAE: Immune-Mediated Adverse Events. 1-Event, 0-No event (Censored).', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'draedcd'),
(1658, 'DRAEDCM', 'Time to Drug-Related AE-DC/D', 'month', 'Num', 'NA', '.', 'AE: Adverse Events. DC/D: Drug Discontinuation or Death. DRAEDCD/365.25*12.', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'draedcd'),
(1659, 'DRAEDCD', 'Time to Drug-Related AE-DC/D', 'day', 'Num', 'NA', '.', 'AE: Adverse Events. DC/D: Drug Discontinuation or Death. Time from 1st treatment to the 1st drug-related event/censoring (in month). For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset. Derived according to notes.', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'draedcd'),
(1660, 'DRAEDCDC', 'AE Term of Drug-Related AE-DC/D', 'NA', 'Char', 'NA', 'blank', 'AE: Adverse Events. DC/D: Drug Discontinuation or Death. Missing if DRAEDCF=0.', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'draedcd'),
(1661, 'DRAEDCF', 'Flag of Drug-Related AE-DC/D', 'NA', 'Num', 'NA', '.', 'AE: Adverse Events. DC/D: Drug Discontinuation or Death. Drug-related: AREL=\'RELATED\', AE-DC/D : AEDISCFL^=\"\" or AESDTH=\"Y\" (also need to review the AEDECOD of the list to exclude disease related terms), TEAE100=\'Y\', ADSL$SAFFL=\'Y\'. 1-Event, 0-No event (Censored).', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'drgr2');
INSERT INTO `dsstruct` (`varorder`, `var_name`, `var_label`, `units`, `type`, `round`, `missVal`, `note`, `source`, `requiredFlag`, `SpecType`, `nameChange`, `labelChange`, `unitChange`, `typeChange`, `roundChange`, `missValChange`, `noteChange`, `sourceChange`, `erflag`) VALUES
(1662, 'DRGR2M', 'Time to Drug-Related Gr2+ AE', 'month', 'Num', 'NA', '.', 'Gr2+: Grade 2 or higher, AE: Adverse Events. DRGR2D/365.25*12.', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'drgr2'),
(1663, 'DRGR2D', 'Time to Drug-Related Gr2+ AE', 'day', 'Num', 'NA', '.', 'Gr2+: Grade 2 or higher, AE: Adverse Events. Time from 1st treatment to the 1st drug-related Grade 2+ event/censoring. For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset. Derived according to notes.', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'drgr2'),
(1664, 'DRGR2F', 'Flag of Drug-Related Gr2+ AE', 'NA', 'Num', 'NA', '.', 'Gr2+: Grade 2 or higher, AE: Adverse Events. Drug-related: AREL=\'RELATED\', Gr. 2+ AE: AETOXGRN>=2,  TEAE100=\'Y\', ADSL$SAFFL=\'Y\'. 1-Event, 0-No event (Censored).', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'drgr2'),
(1665, 'DRGR2COD', 'AE Term of Drug-Related Gr2+ AE', 'NA', 'Char', 'NA', 'blank', 'Gr2+: Grade 2 or higher, AE: Adverse Events. Missing if DRGR2F=0.', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'drgr3'),
(1666, 'DRGR3M', 'Time to Drug-Related Gr3+ AE', 'month', 'Num', 'NA', '.', 'Gr3+: Grade 3 or higher, AE: Adverse Events. DRGR3D/365.25*12.', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'drgr3'),
(1667, 'DRGR3D', 'Time to Drug-Related Gr3+ AE', 'day', 'Num', 'NA', '.', 'Gr3+: Grade 3 or higher, AE: Adverse Events. Time from 1st treatment to the 1st drug-related Grade 3+ event/censoring. For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset. Derived according to notes.', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'drgr3'),
(1668, 'DRGR3F', 'Flag of Drug-Related Gr3+ AE', 'NA', 'Num', 'NA', '.', 'Gr3+: Grade 3 or higher, AE: Adverse Events. Drug-related: AREL=\'RELATED\', Gr. 3+ AE: AETOXGRN>=3,  TEAE100=\'Y\', ADSL$SAFFL=\'Y\'. 1-Event, 0-No event (Censored).', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'drgr3'),
(1669, 'DRGR3COD', 'AE Term of Drug-Related Gr3+ AE', 'NA', 'Char', 'NA', 'blank', 'Gr3+: Grade 3 or higher, AE: Adverse Events. Missing if DRGR3F=0.', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'drae'),
(1670, 'DRAEM', 'Time to Drug-Related AE', 'month', 'Num', 'NA', '.', 'AE: Adverse Events. DRAED/365.25*12.', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'drae'),
(1671, 'DRAED', 'Time to Drug-Related AE', 'day', 'Num', 'NA', '.', 'AE: Adverse Events. Time from 1st treatment to the 1st drug-related adverse event/censoring. For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset. Derived according to notes.', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 1, 1, 1, 1, 'drae'),
(1672, 'DRAEF', 'Flag of Drug-Related AE', 'NA', 'Num', 'NA', '.', 'AE: Adverse Events. Drug-related: AREL=\'RELATED\', TEAE100=\'Y\', ADSL$SAFFL=\'Y\'. 1-Event, 0-No event (Censored).', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 0, 1, 1, 1, 'drae'),
(1673, 'DRAECOD', 'AE Term of Drug-Related AE', 'NA', 'Char', 'NA', 'blank', 'AE: Adverse Events. Missing if DRAEF=0.', 'Derived according to notes', 0, 'ER-ISOP-safety', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1674, 'STUDYID', 'Study Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'ER-ISOP-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1675, 'USUBJID', 'Unique Subject Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'ER-ISOP-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1676, 'ID', 'ID', 'NA', 'Num', 'NA', '.', 'Sequential numbering, (1, 2, 3, ...). One ID per subject.', 'Derived according to notes', 1, 'ER-ISOP-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'bor'),
(1677, 'BOR', 'Best Overall Response', 'NA', 'Char', 'NA', 'blank', 'CR=Complete response, PR=Partial response, SD=Stable disease, PD=Progressive disease, NE=Unevaluable, NA=Missing or not reported, NN=NON-CR/NON-PD, ND=No Disease.', NULL, 0, 'ER-ISOP-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'bor'),
(1678, 'BORN', 'Best Overall Response (N)', 'NA', 'Num', 'NA', '.', '1=CR, 2=PR, 3=SD, 4=PD, 5=NE, 6=NA, 7=NN, 8=ND', 'Derived from BOR', 0, 'ER-ISOP-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1679, 'BORPER', 'BOR Assessed by', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'ER-ISOP-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1680, 'BORCRT', 'BOR Criteria', 'NA', 'Char', 'NA', 'blank', 'mWHO, RECIST v1.0, RECIST v1.1', NULL, 0, 'ER-ISOP-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'pfs'),
(1681, 'CNSRPFS', 'Censoring Progression-Free Survival', 'NA', 'Num', 'NA', '.', '0=Censored, 1=Death/Event', NULL, 0, 'ER-ISOP-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'pfs'),
(1682, 'PFSD', 'Time to Progression-Free Survival', 'day', 'Num', 'NA', '.', NULL, NULL, 0, 'ER-ISOP-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'pfs'),
(1683, 'PFSM', 'Time to Progression-Free Survival', 'month', 'Num', 'NA', '.', NULL, NULL, 0, 'ER-ISOP-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'os'),
(1684, 'CNSROS', 'Censoring Overall Survival', 'NA', 'Num', 'NA', '.', '0=Censored, 1=Death/Event', NULL, 0, 'ER-ISOP-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'os'),
(1685, 'OSD', 'Time to Overall Survival', 'day', 'Num', 'NA', '.', NULL, NULL, 0, 'ER-ISOP-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'os'),
(1686, 'OSM', 'Time to Overall Survival', 'month', 'Num', 'NA', '.', NULL, NULL, 0, 'ER-ISOP-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, NULL),
(1687, 'STUDYID', 'Study Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1688, 'USUBJID', 'Unique Subject Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1689, 'ID', 'ID', 'NA', 'Num', 'NA', '.', 'Sequential numbering, (1, 2, 3, ...). One ID per subject.', 'Derived according to notes', 1, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'gr3'),
(1690, 'GR3COD', 'AE Term of Gr3+ AE', 'NA', 'Char', 'NA', 'blank', 'Gr3+: Grade 3 or higher, AE: Adverse Events. Missing if GR3F=0.', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'gr3'),
(1691, 'GR3M', 'Time to Gr3+ AE', 'month', 'Num', 'NA', '.', 'Gr3+: Grade 3 or higher, AE: Adverse Events. GR3D/365.25*12.', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'gr3'),
(1692, 'GR3D', 'Time to Gr3+ AE', 'day', 'Num', 'NA', '.', 'Gr3+: Grade 3 or higher, AE: Adverse Events. Time from 1st treatment to the 1st event/censoring. For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset. Derived according to notes.', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'gr3'),
(1693, 'GR3F', 'Flag of Gr3+ AE', 'NA', 'Num', 'NA', '.', 'Gr3+: Grade 3 or higher, AE: Adverse Events. Gr3+ AE: AETOXGRN>=3, TEAE100=\'Y\', ADSL$SAFFL=\'Y\'. 1-Event, 0-No event (Censored)', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'aedcd'),
(1694, 'AEDCDCOD', 'AE Term of AE-DC/D', 'NA', 'Char', 'NA', 'blank', 'AE: Adverse Events. DC/D: Drug Discontinuation or Death. Missing if AEDCF=0.', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'aedcd'),
(1695, 'AEDCDM', 'Time to AE-DC/D', 'month', 'Num', 'NA', '.', 'AE: Adverse Events. DC/D: Drug Discontinuation or Death. AEDCD/365.25*12.', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'aedcd'),
(1696, 'AEDCDD', 'Time to AE-DC/D', 'day', 'Num', 'NA', '.', 'AE: Adverse Events. DC/D: Drug Discontinuation or Death. Time from 1st treatment to the 1st event/censoring; For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset. Derived according to notes.', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'aedcd'),
(1697, 'AEDCDF', 'Flag of AE-DC/D', 'NA', 'Num', 'NA', '.', 'AE: Adverse Events. DC/D: Drug Discontinuation or Death. AE-DC/D: AEDISCFL^=\"\" or AESDTH=\"Y\"  (also need to review the AEDECOD of the list to exclude disease related terms), TEAE100=\'Y\', ADSL$SAFFL=\'Y\'. 1-Event, 0-No event (Censored).', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'imae'),
(1698, 'IMAECOD', 'AE Term of Immune-Mediated AE', 'NA', 'Char', 'NA', 'blank', 'AE: Adverse Events. Missing if IMAEF=0.', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'imae'),
(1699, 'IMAEM', 'Time to Immune-Mediated AE', 'month', 'Num', 'NA', '.', 'AE: Adverse Events. IMAED/362.25*12.', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'imae'),
(1700, 'IMAED', 'Time to Immune-Mediated AE', 'day', 'Num', 'NA', '.', 'AE: Adverse Events. Time from 1st treatment to the 1st event/censoring. For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset. Derived according to notes.', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'imae'),
(1701, 'IMAEF', 'Flag of Immune-Mediated AE', 'NA', 'Num', 'NA', '.', 'AE: Adverse Events. 1-Event, 0-No event (Censored).', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'imaegr2'),
(1702, 'IMAEGR2C', 'AE Term of Gr2+ IMAE', 'NA', 'Char', 'NA', 'blank', 'AE: Adverse Events, Gr2+: Grade 2 or higher, IMAE: Immune-Mediated Adverse Events. Missing if IMAEGR2F=0.', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'imaegr2'),
(1703, 'IMAEGR2M', 'Time to Gr2+ IMAE', 'month', 'Num', 'NA', '.', 'Gr2+: Grade 2 or higher, IMAE: Immune-Mediated Adverse Events. IMAEGR2D/365.25*12.', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'imaegr2'),
(1704, 'IMAEGR2D', 'Time to Gr2+ IMAE', 'day', 'Num', 'NA', '.', 'Gr2+: Grade 2 or higher, IMAE: Immune-Mediated Adverse Events. Time from 1st treatment to the 1st event/censoring. For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset. Derived according to notes.', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'imaegr2'),
(1705, 'IMAEGR2F', 'Flag of Gr2+ IMAE', 'NA', 'Num', 'NA', '.', 'Gr2+: Grade 2 or higher, IMAE: Immune-Mediated Adverse Events. 1-Event, 0-No event (Censored).', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'draedcd'),
(1706, 'DRAEDCM', 'Time to Drug-Related AE-DC/D', 'month', 'Num', 'NA', '.', 'AE: Adverse Events. DC/D: Drug Discontinuation or Death. DRAEDCD/365.25*12.', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'draedcd'),
(1707, 'DRAEDCD', 'Time to Drug-Related AE-DC/D', 'day', 'Num', 'NA', '.', 'AE: Adverse Events. DC/D: Drug Discontinuation or Death. Time from 1st treatment to the 1st drug-related event/censoring (in month). For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset. Derived according to notes.', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'draedcd'),
(1708, 'DRAEDCDC', 'AE Term of Drug-Related AE-DC/D', 'NA', 'Char', 'NA', 'blank', 'AE: Adverse Events. DC/D: Drug Discontinuation or Death. Missing if DRAEDCF=0.', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'draedcd'),
(1709, 'DRAEDCF', 'Flag of Drug-Related AE-DC/D', 'NA', 'Num', 'NA', '.', 'AE: Adverse Events. DC/D: Drug Discontinuation or Death. Drug-related: AREL=\'RELATED\', AE-DC/D : AEDISCFL^=\"\" or AESDTH=\"Y\" (also need to review the AEDECOD of the list to exclude disease related terms), TEAE100=\'Y\', ADSL$SAFFL=\'Y\'. 1-Event, 0-No event (Censored).', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'drgr2'),
(1710, 'DRGR2M', 'Time to Drug-Related Gr2+ AE', 'month', 'Num', 'NA', '.', 'Gr2+: Grade 2 or higher, AE: Adverse Events. DRGR2D/365.25*12.', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'drgr2'),
(1711, 'DRGR2D', 'Time to Drug-Related Gr2+ AE', 'day', 'Num', 'NA', '.', 'Gr2+: Grade 2 or higher, AE: Adverse Events. Time from 1st treatment to the 1st drug-related Grade 2+ event/censoring. For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset. Derived according to notes.', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'drgr2'),
(1712, 'DRGR2F', 'Flag of Drug-Related Gr2+ AE', 'NA', 'Num', 'NA', '.', 'Gr2+: Grade 2 or higher, AE: Adverse Events. Drug-related: AREL=\'RELATED\', Gr. 2+ AE: AETOXGRN>=2,  TEAE100=\'Y\', ADSL$SAFFL=\'Y\'. 1-Event, 0-No event (Censored).', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'drgr2'),
(1713, 'DRGR2COD', 'AE Term of Drug-Related Gr2+ AE', 'NA', 'Char', 'NA', 'blank', 'Gr2+: Grade 2 or higher, AE: Adverse Events. Missing if DRGR2F=0.', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'drgr3'),
(1714, 'DRGR3M', 'Time to Drug-Related Gr3+ AE', 'month', 'Num', 'NA', '.', 'Gr3+: Grade 3 or higher, AE: Adverse Events. DRGR3D/365.25*12.', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'drgr3'),
(1715, 'DRGR3D', 'Time to Drug-Related Gr3+ AE', 'day', 'Num', 'NA', '.', 'Gr3+: Grade 3 or higher, AE: Adverse Events. Time from 1st treatment to the 1st drug-related Grade 3+ event/censoring. For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset. Derived according to notes.', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'drgr3'),
(1716, 'DRGR3F', 'Flag of Drug-Related Gr3+ AE', 'NA', 'Num', 'NA', '.', 'Gr3+: Grade 3 or higher, AE: Adverse Events. Drug-related: AREL=\'RELATED\', Gr. 3+ AE: AETOXGRN>=3,  TEAE100=\'Y\', ADSL$SAFFL=\'Y\'. 1-Event, 0-No event (Censored).', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'drgr3'),
(1717, 'DRGR3COD', 'AE Term of Drug-Related Gr3+ AE', 'NA', 'Char', 'NA', 'blank', 'Gr3+: Grade 3 or higher, AE: Adverse Events. Missing if DRGR3F=0.', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'drae'),
(1718, 'DRAEM', 'Time to Drug-Related AE', 'month', 'Num', 'NA', '.', 'AE: Adverse Events. DRAED/365.25*12.', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'drae'),
(1719, 'DRAED', 'Time to Drug-Related AE', 'day', 'Num', 'NA', '.', 'AE: Adverse Events. Time from 1st treatment to the 1st drug-related adverse event/censoring. For subjects with AE events, their time to event is calculated by ASTDT-TRTSDT+1; For subjects without the specified AE, their censoring time is calculated by TRTEDT- TRTSDT+101 or ALIVEDT-TRTSDT+1, whichever is earlier.', 'Variables TRTSDT, TRTEDT and ALIVEDT come from ADSL dataset. Derived according to notes.', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'drae'),
(1720, 'DRAEF', 'Flag of Drug-Related AE', 'NA', 'Num', 'NA', '.', 'AE: Adverse Events. Drug-related: AREL=\'RELATED\', TEAE100=\'Y\', ADSL$SAFFL=\'Y\'. 1-Event, 0-No event (Censored).', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'drae'),
(1721, 'DRAECOD', 'AE Term of Drug-Related AE', 'NA', 'Char', 'NA', 'blank', 'AE: Adverse Events. Missing if DRAEF=0.', 'Derived according to notes', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'bor'),
(1722, 'BOR', 'Best Overall Response', 'NA', 'Char', 'NA', 'blank', 'CR=Complete response, PR=Partial response, SD=Stable disease, PD=Progressive disease, NE=Unevaluable, NA=Missing or not reported, NN=NON-CR/NON-PD, ND=No Disease.', NULL, 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'bor'),
(1723, 'BORN', 'Best Overall Response (N)', 'NA', 'Num', 'NA', '.', '1=CR, 2=PR, 3=SD, 4=PD, 5=NE, 6=NA, 7=NN, 8=ND', 'Derived from BOR', 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1724, 'BORPER', 'BOR Assessed by', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1725, 'BORCRT', 'BOR Criteria', 'NA', 'Char', 'NA', 'blank', 'mWHO, RECIST v1.0, RECIST v1.1', NULL, 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'pfs'),
(1726, 'CNSRPFS', 'Censoring Progression-Free Survival', 'NA', 'Num', 'NA', '.', '0=Censored, 1=Death/Event', NULL, 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'pfs'),
(1727, 'PFSD', 'Time to Progression-Free Survival', 'day', 'Num', 'NA', '.', NULL, NULL, 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'pfs'),
(1728, 'PFSM', 'Time to Progression-Free Survival', 'month', 'Num', 'NA', '.', NULL, NULL, 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'os'),
(1729, 'CNSROS', 'Censoring Overall Survival', 'NA', 'Num', 'NA', '.', '0=Censored, 1=Death/Event', NULL, 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 0, 1, 1, 1, 'os'),
(1730, 'OSD', 'Time to Overall Survival', 'day', 'Num', 'NA', '.', NULL, NULL, 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, 'os'),
(1731, 'OSM', 'Time to Overall Survival', 'month', 'Num', 'NA', '.', NULL, NULL, 0, 'ER-ISOP-safety-efficacy', 0, 0, 0, 0, 1, 1, 1, 1, NULL),
(1732, 'STUDYID', 'Study Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'TGD', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1733, 'USUBJID', 'Unique Subject Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'TGD', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1734, 'ID', 'ID', 'NA', 'Num', 'NA', '.', 'Sequential numbering, (1, 2, 3, ...). One ID per subject.', 'Derived according to notes', 1, 'TGD', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1735, 'DAY', 'Time Day', 'Day', 'Num', 'NA', '.', 'Days after initiation of study drug', NULL, 0, 'TGD', 0, 0, 0, 0, 1, 1, 1, 1, NULL),
(1736, 'DAY0', 'Time Day0', 'Day', 'Num', 'NA', '.', 'DAY0=0 if DAY<0, else DAY0=DAY', NULL, 0, 'TGD', 0, 0, 0, 0, 1, 1, 1, 1, NULL),
(1737, 'DAYS', 'Time Days', 'Day', 'Num', 'NA', '.', 'Day from screening. =0 if subjects have first screen tumor assessment', NULL, 0, 'TGD', 0, 0, 0, 0, 1, 1, 1, 1, NULL),
(1738, 'WEEK', 'Time Week', 'week', 'Num', 'NA', '.', 'Weeks after initiation of study drug, DAY/7', NULL, 0, 'TGD', 0, 0, 0, 0, 1, 1, 1, 1, NULL),
(1739, 'SLD', 'Sum of Longest Diam of Index Lesion', 'cm', 'Num', 'NA', '.', 'RECIST, convert tumor burden from mm to cm by dividing by 10.', NULL, 0, 'TGD', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1740, 'LOGSLD', 'log(SLD)', 'NA', 'Num', '4 significant digits', '.', 'ln (SLD) if SLD>0, ln(0.01) if SLD=0', NULL, 0, 'TGD', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1741, 'BSLD', 'Baseline SLD', 'cm', 'Num', 'NA', '.', 'Convert tumor burden from mm to cm by dividing by 10.', NULL, 0, 'TGD', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1742, 'CSLD', 'Change From Baseline SLD', 'cm', 'Num', 'NA', '.', 'RECIST, convert tumor burden from mm to cm by dividing by 10.', NULL, 0, 'TGD', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1743, 'PCSLD', 'Percent Change From Baseline SLD', '%', 'Num', 'NA', '.', NULL, NULL, 0, 'TGD', 0, 0, 0, 0, 1, 1, 1, 1, NULL),
(1744, 'NSLD', 'Normalized SLD', 'NA', 'Num', 'NA', '.', 'SLD/NILSN', NULL, 0, 'TGD', 0, 0, 0, 0, 1, 1, 1, 1, NULL),
(1745, 'NILSN', 'Number of Index Lesion at Baseline', 'NA', 'Num', 'NA', '.', 'Total count baseline index lesion records', NULL, 0, 'TGD', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1746, 'TRTSDT', 'Start of Treatment', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'TGD', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1747, 'TRTEDT', 'End of Treatment', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'TGD', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1748, 'DROPTIME', 'Duration of Treatment', 'day', 'Num', 'NA', '.', NULL, NULL, 0, 'TGD', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1749, 'STUDYID', 'Study Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PKPD-ISOP', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1750, 'USUBJID', 'Unique Subject Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 1, 'PKPD-ISOP', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1751, 'ID', 'ID', 'NA', 'Num', 'NA', '.', 'Sequential numbering, (1, 2, 3, ...). One ID per subject.', 'Derived according to notes', 1, 'PKPD-ISOP', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1752, 'EVID', 'Event ID', 'NA', 'Num', 'NA', '.', '0=PK event, 1=Dose event, 2=PD event', 'Derived according to notes', 0, 'PKPD-ISOP', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1753, 'VISIT', 'Visit', 'NA', 'Char', 'NA', 'blank', 'Clinic visit captured in STDM domains EX or PC and variable VISIT', NULL, 0, 'PKPD-ISOP', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1754, 'AFRELTM', 'Actual Rel Time From First Dose', 'hr', 'Num', '0.01', '.', 'Rel: Relative. Derived from (Analysis date/time of the current event/record of the subject) - (Analysis date/time of the first dosing event/record of the subject)', NULL, 0, 'PKPD-ISOP', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1755, 'APRELTM', 'Actual Rel Time From Previous Dose', 'hr', 'Num', '0.01', '.', 'Rel: Relative. Derived from (Analysis date/time of the current event/record of the subject) - (Analysis date/time of the previous dosing event/record of the subject).', NULL, 0, 'PKPD-ISOP', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1756, 'NFRELTM', 'Nominal Rel Time From First Dose', 'hr', 'Num', '0.1', '.', 'Rel: Relative. Planned elapsed time (for sample point or start of sampling interval) from first exposure to study treatment.', NULL, 0, 'PKPD-ISOP', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1757, 'NPRELTM', 'Nominal Rel Time From Previous Dose', 'hr', 'Num', '0.1', '.', 'Rel: Relative. For PK it can be derived from NTIME in PC domain.', NULL, 0, 'PKPD-ISOP', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1758, 'CONCSTAT', 'Concentration Status', 'NA', 'Num', 'NA', '.', '0=Evaluable Concentration, 1=BLOQ, 2=OUTLIER or Not Reportable, 3=Missing value, 4=Duplicate record for NCA setup. If concstatus in PAMS/eToolbox=missing then always code CONCSTAT=0. Otherwise CONCSTAT=CONCSTATUS. Only populated for pk records.', NULL, 0, 'PKPD-ISOP', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1759, 'DV', 'Analysis Value', 'ug/mL', 'Num', '0.01', '.', NULL, NULL, 0, 'PKPD-ISOP', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1760, 'DVL', 'Log Analysis Value', 'NA', 'Num', '4 significant digits', '.', NULL, NULL, 0, 'PKPD-ISOP', 0, 1, 0, 0, 1, 1, 1, 1, NULL),
(1761, 'MDV', 'Missing DV', 'NA', 'Num', 'NA', '.', '0=observed value, 1=missing DV or suspicious data or dosing event', 'Derived according to notes', 0, 'PKPD-ISOP', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1762, 'AMT', 'Actual Amount of Drug Received', 'mg', 'Num', 'NA', '.', 'Only populated on dosing records. Use \".\" for non-dosing record (i.e., observations)', NULL, 0, 'PKPD-ISOP', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1763, 'DOSEDUR', 'Duration of Treatment Dose', 'hr', 'Num', '0.01', '.', 'Derived from (End dose date/time) - (Start dose date/time) - (infusion interruption if available).', NULL, 0, 'PKPD-ISOP', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1764, 'RATE', 'Infusion Rate', 'mg/hr', 'Num', '0.01', '.', 'AMT/DOSEDUR', NULL, 0, 'PKPD-ISOP', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1765, 'II', 'Dosing Interval', 'hr', 'Num', 'NA', '.', NULL, NULL, 0, 'PKPD-ISOP', 0, 0, 1, 0, 0, 1, 1, 1, NULL),
(1766, 'ADDL', 'Number of Additional Doses', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'PKPD-ISOP', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1767, 'PROJID', 'Project Identifier', 'NA', 'Char', 'NA', 'blank', 'e.g. CA209010, MDX1106-01, ONO-4538-01', 'Derived according to notes', 0, 'ER-optional', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1768, 'STUDYIDN', 'Study Identifier (N)', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'ER-optional', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1769, 'USUBJIDN', 'Unique Subject Identifier (N)', 'NA', 'Num', 'NA', '.', 'Unique numerical representation of USUBJID.', NULL, 0, 'ER-optional', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1770, 'TRTA', 'Actual Treatment', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'ER-optional', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1771, 'REGIMEN', 'Regimen', 'NA', 'Char', 'NA', 'blank', '3 mg/kg Q2W, 240 mg Q2W etc.', NULL, 0, 'ER-optional', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1772, 'DOSEP', 'Planned Treatment Dose', 'mg/kg', 'Num', 'NA', '.', '3=3 mg/kg, etc', NULL, 0, 'ER-optional', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1773, 'FREQ', 'Dose Frequency', 'week', 'Num', 'NA', '.', 'eg. 3=Q3W, 6=Q6W, 12=Q12W', NULL, 0, 'ER-optional', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1774, 'RACE', 'Race', 'NA', 'Char', 'NA', 'blank', 'White, Black/African American, Asian, American Indian/Alaska Native, Native Hawaiian/Other Pacific Islander, Others, Unknown', NULL, 0, 'ER-optional', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1775, 'RACEN', 'Race (N)', 'NA', 'Num', 'NA', '.', '1=White, 2=Black/African American, 3=Asian, 4=Others, 5=Unknown. American Indian/Alaska Native and Native Hawaiian/Other Pacific Islander are coded as 4.', NULL, 0, 'ER-optional', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1776, 'SEX', 'Sex', 'NA', 'Char', 'NA', 'blank', 'Male or Female', NULL, 0, 'ER-optional', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1777, 'SEXN', 'Sex (N)', 'NA', 'Num', 'NA', '.', '1=Male, 2=Female', NULL, 0, 'ER-optional', 0, 0, 0, 0, 1, 1, 1, 1, NULL),
(1778, 'AGE', 'Age', 'year', 'Num', 'NA', '.', NULL, NULL, 0, 'ER-optional', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1779, 'COUNTRY', 'Country', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'ER-optional', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1780, 'TTYPEF', 'Tumor Type', 'NA', 'Char', 'NA', 'blank', 'Melanoma, SQ Non-Small Cell Lung Cancer, NSQ Non-Small Cell Lung Cancer, Unknown Histology Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Colorectal Cancer, Prostate Cancer, Classical Hodgkin Lymphoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Triple Negative Breast Cancer, Gastric Cancer, Pancreatic Cancer, Small Cell Lung Cancer, Ovarian Cancer, Hepatocellular Carcinoma, Glioblastoma, Adjuvant Melanoma, Cervical Cancer, Multiple Myeloma, Hodgkins Lymphoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Indolent Non-Hodgkins Lymphoma, Other Non-Hodgkins Lymphoma, Breast Cancer, Endometrial Cancer, Thyroid Cancer, Mesothelioma, Nasopharyngeal Carcinoma, Esophageal Cancer, Adjuvant Gastroesophageal Junction Cancer, Juvenile Myelomonocytic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Other', NULL, 0, 'ER-optional', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1781, 'TTYPEN', 'Tumor Type (N)', 'NA', 'Num', 'NA', '.', '1=Melanoma, 2=SQ Non-Small Cell Lung Cancer, 3=NSQ Non-Small Cell Lung Cancer, 4=Unknown Histology Non-Small Cell Lung Cancer, 5=Renal Cell Carcinoma, 6=Colorectal Cancer, 7=Prostate Cancer, 8=Classical Hodgkin Lymphoma, 9=Squamous Cell Carcinoma of the Head and Neck, 10=Bladder Cancer, 11=Triple Negative Breast Cancer, 12=Gastric Cancer, 13=Pancreatic Cancer, 14=Small Cell Lung Cancer, 15=Ovarian Cancer, 16=Hepatocellular Carcinoma, 17=Glioblastoma, 18=Adjuvant Melanoma, 19=Cervical Cancer, 20=Multiple Myeloma, 21=Hodgkins Lymphoma, 22=Diffuse Large B-Cell Lymphoma, 23=Chronic Lymphocytic Leukemia, 24=Indolent Non-Hodgkins Lymphoma, 25=Other Non-Hodgkins Lymphoma, 26=Breast Cancer, 27=Endometrial Cancer, 28=Thyroid Cancer, 29=Mesothelioma, 30=Nasopharyngeal Carcinoma, 31=Esophageal Cancer, 32=Adjuvant Gastroesophageal Junction Cancer, 33=Juvenile Myelomonocytic Leukemia, 34=Acute Myeloid Leukemia, 35=Myelodysplastic Syndromes, 100=Other', NULL, 0, 'ER-optional', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1782, 'PS', 'Baseline Performance Status', 'NA', 'Num', 'NA', '.', '0 (Normal), 1, 2, 3, 4; If convert from KPS, 0=KPS 100, 1=KPS 90/80, 2=KPS 70/60, 3=KPS 50/40, 4=KPS 30/20/10', 'ECOG or Derived from KPS', 0, 'ER-optional', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1783, 'WTB', 'Baseline Body Weight', 'kg', 'Num', 'NA', '.', NULL, NULL, 0, 'ER-optional', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1784, 'HTB', 'Baseline Height', 'cm', 'Num', 'NA', '.', NULL, NULL, 0, 'ER-optional', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1785, 'BMIB', 'Baseline Body Mass Index', 'kg/m2', 'Num', '0.01', '.', NULL, NULL, 0, 'ER-optional', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1786, 'BSAB', 'Baseline Body Surface Area', 'm2', 'Num', '0.01', '.', NULL, NULL, 0, 'ER-optional', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1787, 'LDHB', 'Baseline Lactate Dehydrogenase', 'U/L', 'Num', 'NA', '.', NULL, NULL, 0, 'ER-optional', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1788, 'LDHULN', 'LDH Upper Limit of Normal', 'U/L', 'Num', 'NA', '.', 'LDH: Lactate Dehydrogenase.', NULL, 0, 'ER-optional', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1789, 'ALBB', 'Baseline Serum Albumin', 'g/dL', 'Num', 'NA', '.', NULL, NULL, 0, 'ER-optional', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1790, 'ALPB', 'Baseline Serum Alkaline Phosphatase', 'U/L', 'Num', 'NA', '.', NULL, NULL, 0, 'ER-optional', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1791, 'ALTB', 'Baseline Alanine Transaminase', 'U/L', 'Num', 'NA', '.', NULL, NULL, 0, 'ER-optional', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1792, 'ASTB', 'Baseline Aspartate Aminotransferase', 'U/L', 'Num', 'NA', '.', NULL, NULL, 0, 'ER-optional', 0, 0, 1, 0, 0, 1, 1, 1, NULL),
(1793, 'CRCLB', 'Baseline Creatinine Clearance', 'mL/min', 'Num', '0.01', '.', NULL, 'Derived according to equation in Derivations table.', 0, 'ER-optional', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1794, 'CREATB', 'Baseline Creatinine Serum', 'mg/dL', 'Num', 'NA', '.', '*0.011312 convert from umol/L to mg/dL', NULL, 0, 'ER-optional', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1795, 'EGFRB', 'Baseline eGFR', 'mL/min/1.73m2', 'Num', '0.01', '.', 'eGFR: Estimated Glomerular Filtration Rate.', 'Derived according to equation in Derivations table.', 0, 'ER-optional', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1796, 'ALCB', 'Baseline Abs Lymphocyte Count', 'X10^3c/uL', 'Num', 'NA', '.', 'Abs: Absolute. x10^9c/L is the same as x10^3c/uL.', NULL, 0, 'ER-optional', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1797, 'TBILB', 'Baseline Total Bilirubin', 'mg/dL', 'Num', 'NA', '.', NULL, NULL, 0, 'ER-optional', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1798, 'DBILB', 'Baseline Direct Bilirubin', 'mg/dL', 'Num', 'NA', '.', NULL, NULL, 0, 'ER-optional', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1799, 'PLATB', 'Baseline Platelet Count', 'X10^3c/uL', 'Num', 'NA', '.', 'x10^9c/L is the same as x10^3c/uL', NULL, 0, 'ER-optional', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1800, 'WBCB', 'Baseline White Blood Count', 'X10^3c/uL', 'Num', 'NA', '.', 'x10^9c/L is the same as x10^3c/uL', NULL, 0, 'ER-optional', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1801, 'NEUTB', 'Baseline Neutrophil Count', 'X10^3c/uL', 'Num', 'NA', '.', 'x10^9c/L is the same as x10^3c/uL', NULL, 0, 'ER-optional', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1802, 'MONOB', 'Baseline Monocyte Count', 'X10^3c/uL', 'Num', 'NA', '.', 'x10^9c/L is the same as x10^3c/uL', NULL, 0, 'ER-optional', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1803, 'HEPA', 'Liver Dysfunction Groups', 'NA', 'Char', 'NA', 'blank', 'GROUP A: Normal (total bilirubin<=ULN and AST<=ULN), GROUP B: Mild (total bilirubin > 1.0x-1.5xULN or AST > ULN), GROUP C: Moderate (total bilirubin > 1.5x-3xULN), GROUP D: Severe (total bilirubin > 3xULN). Assign in reverse order to assign most severe group.', NULL, 0, 'ER-optional', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1804, 'HEPAN', 'Liver Dysfunction Groups (N)', 'NA', 'Num', 'NA', '.', '1=GROUP A: Normal, 2=GROUP B: Mild, 3=GROUP C: Moderate, 4=GROUP D: Severe', 'Derived from HEPA', 0, 'ER-optional', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1805, 'LINE', 'Line of Therapy', 'NA', 'Num', 'NA', '.', NULL, NULL, 0, 'ER-optional', 0, 0, 0, 0, 1, 1, 1, 1, NULL),
(1806, 'PDL11', 'PDL1 Expression (1% cutoff)', 'NA', 'Char', 'NA', 'blank', 'positive, negative status - tumor only (>= 1% cutoff). positive,negative, unknown, missing.', NULL, 0, 'ER-optional', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1807, 'PDL15', 'PDL1 Expression (5% cutoff)', 'NA', 'Char', 'NA', 'blank', 'positive, negative status - tumor only (>= 5% cutoff). positive,negative, unknown, missing.', NULL, 0, 'ER-optional', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1808, 'PDL110', 'PDL1 Expression (10% cutoff)', 'NA', 'Char', 'NA', 'blank', 'positive, negative status - tumor only (>= 10% cutoff). positive,negative, unknown, missing.', NULL, 0, 'ER-optional', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1809, 'TSIZEB', 'Baseline Tumor Burden', 'cm', 'Num', 'NA', '.', 'Sum of longest diameters of all target lesions,  convert tumor burden from mm to cm by dividing by 10', NULL, 0, 'ER-optional', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1810, 'TSIZE2B', 'Baseline Tumor Burden', 'cm2', 'Num', 'NA', '.', 'Sum of products of diameters for all target lesions.', NULL, 0, 'ER-optional', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1811, 'FLAG', 'Flagged Records', 'NA', 'Num', 'NA', '0', NULL, 'FLAG number per Flag table in Programming Algorithms and Imputations section.', 0, 'ER-optional', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1812, 'FLAGC', 'Comment for the Flagged Records', 'NA', 'Char', 'NA', 'blank', NULL, 'Description for FLAG per Flag table in Programming Algorithms and Imputations section.', 0, 'ER-optional', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1813, 'DTC', 'Date and Time of Event', 'NA', 'Char', 'NA', 'blank', 'Date/time of event. Use ISO 8601 format which is a text representation of date and time e.g., 2013-05-09T08:58 where T is a time designator indicating time follows.', 'Derived according to notes', 0, 'ER-optional', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1814, 'BUILDDT', 'Dataset Creation Date', 'NA', 'Char', 'NA', 'blank', NULL, 'Created at run time', 0, 'ER-optional', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1815, 'RECSEQ', 'Record Sequence', 'NA', 'Num', 'NA', '.', 'Sequential values should start with 1 on the first non-header row of the data file and incrementing by 1 for each subsequent row.', 'Derived according to notes', 0, 'ER-optional', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1816, 'CMIN1', 'Simulated Min Conc Cycle 1', 'ug/mL', 'Num', 'NA', '.', 'Min: minimum, Conc: concentration.', NULL, 0, 'ER-optional', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1817, 'CMAX1', 'Simulated Max Conc Cycle 1', 'ug/mL', 'Num', 'NA', '.', 'Max: maximum, Conc: concentration.', NULL, 0, 'ER-optional', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1818, 'CAVG1', 'Simulated Avg Conc Cycle 1', 'ug/mL', 'Num', 'NA', '.', 'Avg: average, Conc: concentration.', NULL, 0, 'ER-optional', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1819, 'CMINSS', 'Simulated Min Conc Steady State', 'ug/mL', 'Num', 'NA', '.', 'Min: minimum, Conc: concentration.', NULL, 0, 'ER-optional', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1820, 'CMAXSS', 'Simulated Max Conc Steady State', 'ug/mL', 'Num', 'NA', '.', 'Max: maximum, Conc: concentration.', NULL, 0, 'ER-optional', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1821, 'CAVGSS', 'Simulated Avg Conc Steady State', 'ug/mL', 'Num', 'NA', '.', 'Avg: average, Conc: concentration.', NULL, 0, 'ER-optional', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1822, 'CL', 'Baseline Clearance', 'mL/h', 'Num', 'NA', '.', NULL, NULL, 0, 'ER-optional', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1823, 'STUDYID', 'Study Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'Blank Template', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1824, 'USUBJID', 'Unique Subject Identifier', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'Blank Template', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1825, 'ID', 'ID', 'NA', 'Num', 'NA', '.', 'Sequential numbering, (1, 2, 3, ...). One ID per subject.', 'Derived according to notes', 0, 'Blank Template', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1826, 'EVID', 'Event ID', 'NA', 'Num', 'NA', '.', '0=PK event, 1=Dose event, 2=Other event.', 'Derived according to notes', 0, 'Blank Template', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1827, 'VISIT', 'Visit', 'NA', 'Char', 'NA', 'blank', 'Clinic visit captured in STDM domains EX or PC and variable VISIT', NULL, 0, 'Blank Template', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1828, 'AFRELTM', 'Actual Rel Time From First Dose', 'hr', 'Num', '0.01', '.', 'Rel: Relative. Derived from (Analysis date/time of the current event/record of the subject) - (Analysis date/time of the first dosing event/record of the subject)', NULL, 0, 'Blank Template', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1829, 'APRELTM', 'Actual Rel Time From Previous Dose', 'hr', 'Num', '0.01', '.', 'Rel: Relative. Derived from (Analysis date/time of the current event/record of the subject) - (Analysis date/time of the previous dosing event/record of the subject).', NULL, 0, 'Blank Template', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1830, 'NFRELTM', 'Nominal Rel Time From First Dose', 'hr', 'Num', '0.1', '.', 'Rel: Relative. Planned elapsed time (for sample point or start of sampling interval) from first exposure to study treatment.', NULL, 0, 'Blank Template', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1831, 'NPRELTM', 'Nominal Rel Time From Previous Dose', 'hr', 'Num', '0.1', '.', 'Rel: Relative. For PK it can be derived from NTIME in PC domain.', NULL, 0, 'Blank Template', 0, 0, 1, 0, 1, 1, 1, 1, NULL),
(1832, 'CONCSTAT', 'Concentration Status', 'NA', 'Num', 'NA', '.', '0=Evaluable Concentration, 1=BLOQ, 2=OUTLIER or Not Reportable, 3=Missing value, 4=Duplicate record for NCA setup. If concstatus in PAMS/eToolbox=missing then always code CONCSTAT=0. Otherwise CONCSTAT=CONCSTATUS. Only populated for pk records.', NULL, 0, 'Blank Template', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1833, 'DV', 'Analysis Value', 'ug/mL', 'Num', '0.01', '.', NULL, NULL, 0, 'Blank Template', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1834, 'DVL', 'Log Analysis Value', 'NA', 'Num', '4 significant digits', '.', NULL, NULL, 0, 'Blank Template', 0, 1, 0, 0, 1, 1, 1, 1, NULL),
(1835, 'MDV', 'Missing DV', 'NA', 'Num', 'NA', '.', '0=observed value, 1=missing DV or suspicious data or dosing event', 'Derived according to notes', 0, 'Blank Template', 0, 0, 0, 0, 0, 1, 1, 1, NULL),
(1836, 'AMT', 'Actual Amount of Drug Received', 'mg', 'Num', 'NA', '.', 'Only populated on dosing records. Use \".\" for non-dosing record (i.e., observations)', NULL, 0, 'Blank Template', 0, 1, 1, 0, 1, 1, 1, 1, NULL),
(1837, 'SAMPLEID', 'PK Sample ID', 'NA', 'Char', 'NA', 'blank', NULL, NULL, 0, 'Blank Template', 0, 0, 0, 0, 0, 1, 1, 1, NULL);

-- --------------------------------------------------------

--
-- Stand-in structure for view `new_view`
-- (See below for the actual view)
--
CREATE TABLE `new_view` (
`user_id` varchar(20)
,`role_name` varchar(50)
,`screen_name` varchar(50)
,`first_name` varchar(50)
,`last_name` varchar(50)
);

-- --------------------------------------------------------

--
-- Table structure for table `roles`
--

CREATE TABLE `roles` (
  `role_name` varchar(50) NOT NULL COMMENT 'Name of the role',
  `role_description` varchar(200) DEFAULT NULL COMMENT 'Role description',
  `created_by` varchar(20) NOT NULL COMMENT 'User id of user that created the record',
  `created_date` datetime NOT NULL COMMENT 'Date when record was created',
  `last_modified_by` varchar(20) NOT NULL COMMENT 'User id of user that modified the record',
  `last_modified_date` datetime NOT NULL COMMENT 'Date when record was last modified'
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

--
-- Dumping data for table `roles`
--

INSERT INTO `roles` (`role_name`, `role_description`, `created_by`, `created_date`, `last_modified_by`, `last_modified_date`) VALUES
('Admin', 'Administrator Role to add users', 'pmwebspecadmin@140.1', '2018-09-05 14:28:05', '', '2021-10-26 01:48:40'),
('CreateSpecOnly', 'To allow users only to create spec', 'pmwebspecadmin@140.1', '2018-09-05 14:28:05', 'chenl125', '2019-10-30 13:29:09'),
('Directory Setup', 'Test', 'chenl125', '2021-10-14 10:47:02', 'chenl125', '2021-10-14 10:47:02'),
('SuperUser', 'to create and export spec', 'pmwebspecadmin@140.1', '2018-09-05 14:28:06', '', '2021-10-22 01:43:02'),
('test_role', 'just for testing ', 'dhokn', '2020-08-05 05:29:05', 'dhokn', '2020-08-05 05:29:05');

-- --------------------------------------------------------

--
-- Table structure for table `role_screen_mapping`
--

CREATE TABLE `role_screen_mapping` (
  `role_name` varchar(50) NOT NULL COMMENT 'Name of the role',
  `screen_name` varchar(50) NOT NULL COMMENT 'Name of the screen',
  `created_by` varchar(20) NOT NULL COMMENT 'User id of the user that created the record',
  `created_date` datetime NOT NULL COMMENT 'Date when record was created',
  `last_modified_by` varchar(20) NOT NULL COMMENT 'User Id of the user who modified this record',
  `last_modified_date` datetime NOT NULL COMMENT 'Date when record was last modified'
) ENGINE=InnoDB DEFAULT CHARSET=latin1 COMMENT='roles vs screen mapping';


-- --------------------------------------------------------

--
-- Table structure for table `screens`
--

CREATE TABLE `screens` (
  `screen_name` varchar(50) NOT NULL COMMENT 'Name of the screen',
  `screen_description` varchar(200) DEFAULT NULL COMMENT 'Short description of the screen',
  `created_by` varchar(20) NOT NULL COMMENT 'User id of user that created the record',
  `created_date` datetime NOT NULL COMMENT 'Date when record was created',
  `last_modified_by` varchar(20) NOT NULL COMMENT 'User id of user that last modified the record',
  `last_modified_date` datetime NOT NULL COMMENT 'Date when record was last modified'
) ENGINE=InnoDB DEFAULT CHARSET=latin1 COMMENT='screen records';

-- --------------------------------------------------------

--
-- Table structure for table `users`
--

CREATE TABLE `users` (
  `user_id` varchar(20) NOT NULL COMMENT 'BMS Id of the user',
  `first_name` varchar(50) DEFAULT NULL COMMENT 'First Name of the user',
  `last_name` varchar(50) DEFAULT NULL COMMENT 'Last Name of the user',
  `email_address` varchar(50) DEFAULT NULL COMMENT 'Email Address of the user',
  `created_by` varchar(20) NOT NULL COMMENT 'User Id of the user who created this record',
  `created_date` datetime NOT NULL COMMENT 'Date when record was created',
  `last_updated_by` varchar(20) NOT NULL COMMENT 'User Id of the user who last modified this record',
  `last_updated_date` datetime NOT NULL COMMENT 'Date when record was modified',
  `isactive` int(11) NOT NULL DEFAULT 1
) ENGINE=InnoDB DEFAULT CHARSET=latin1 COMMENT='User records';

-- --------------------------------------------------------

--
-- Table structure for table `user_role_mapping`
--

CREATE TABLE `user_role_mapping` (
  `user_id` varchar(20) NOT NULL COMMENT 'BMS Id of the user',
  `role_name` varchar(50) NOT NULL COMMENT 'Name of the role',
  `end_date` date DEFAULT NULL COMMENT 'User lost access',
  `created_by` varchar(20) NOT NULL COMMENT 'User id of the user that created the record',
  `created_date` datetime NOT NULL COMMENT 'Date when record was created',
  `last_modified_by` varchar(20) NOT NULL COMMENT 'User Id of the user who last modified this record',
  `last_modified_date` datetime NOT NULL COMMENT 'Date when record was last modified'
) ENGINE=InnoDB DEFAULT CHARSET=latin1;

-- --------------------------------------------------------

--
-- Stand-in structure for view `vw_user_access`
-- (See below for the actual view)
--
CREATE TABLE `vw_user_access` (
`user_id` varchar(20)
,`role_name` varchar(50)
,`screen_name` varchar(50)
,`first_name` varchar(50)
,`last_name` varchar(50)
);

-- --------------------------------------------------------

--
-- Structure for view `new_view`
--
DROP TABLE IF EXISTS `new_view`;

CREATE ALGORITHM=UNDEFINED DEFINER=`pmwebspecadmin`@`%` SQL SECURITY DEFINER VIEW `new_view`  AS SELECT `u`.`user_id` AS `user_id`, `urm`.`role_name` AS `role_name`, `rsm`.`screen_name` AS `screen_name`, `u`.`first_name` AS `first_name`, `u`.`last_name` AS `last_name` FROM ((`users` `u` join `user_role_mapping` `urm` on(`u`.`user_id` = `urm`.`user_id`)) join `role_screen_mapping` `rsm` on(`rsm`.`role_name` = `urm`.`role_name`)) ;

-- --------------------------------------------------------

--
-- Structure for view `vw_user_access`
--
DROP TABLE IF EXISTS `vw_user_access`;

CREATE ALGORITHM=UNDEFINED DEFINER=`pmwebspecadmin`@`%` SQL SECURITY DEFINER VIEW `vw_user_access`  AS SELECT `a`.`user_id` AS `user_id`, `a`.`role_name` AS `role_name`, `b`.`screen_name` AS `screen_name`, `c`.`first_name` AS `first_name`, `c`.`last_name` AS `last_name` FROM ((`user_role_mapping` `a` join `role_screen_mapping` `b`) join `users` `c`) WHERE `a`.`role_name` = `b`.`role_name` AND `a`.`user_id` = `c`.`user_id` AND `a`.`end_date` is null ;

--
-- Indexes for dumped tables
--

--
-- Indexes for table `dsstruct`
--
ALTER TABLE `dsstruct`
  ADD PRIMARY KEY (`varorder`);

--
-- Indexes for table `roles`
--
ALTER TABLE `roles`
  ADD PRIMARY KEY (`role_name`) USING BTREE,
  ADD KEY `role_name` (`role_name`);

--
-- Indexes for table `role_screen_mapping`
--
ALTER TABLE `role_screen_mapping`
  ADD KEY `Role constraint` (`role_name`),
  ADD KEY `Screen Constraint` (`screen_name`);

--
-- Indexes for table `screens`
--
ALTER TABLE `screens`
  ADD PRIMARY KEY (`screen_name`) USING BTREE,
  ADD KEY `screen_name` (`screen_name`);

--
-- Indexes for table `users`
--
ALTER TABLE `users`
  ADD UNIQUE KEY `user_id` (`user_id`),
  ADD KEY `user_id_2` (`user_id`);

--
-- Indexes for table `user_role_mapping`
--
ALTER TABLE `user_role_mapping`
  ADD KEY `User Id constraint` (`user_id`),
  ADD KEY `Role Constraint1` (`role_name`);

--
-- AUTO_INCREMENT for dumped tables
--

--
-- AUTO_INCREMENT for table `dsstruct`
--
ALTER TABLE `dsstruct`
  MODIFY `varorder` int(11) NOT NULL AUTO_INCREMENT, AUTO_INCREMENT=1838;

--
-- Constraints for dumped tables
--

--
-- Constraints for table `role_screen_mapping`
--
ALTER TABLE `role_screen_mapping`
  ADD CONSTRAINT `Role constraint` FOREIGN KEY (`role_name`) REFERENCES `roles` (`role_name`),
  ADD CONSTRAINT `Screen Constraint` FOREIGN KEY (`screen_name`) REFERENCES `screens` (`screen_name`);

--
-- Constraints for table `user_role_mapping`
--
ALTER TABLE `user_role_mapping`
  ADD CONSTRAINT `Role Constraint1` FOREIGN KEY (`role_name`) REFERENCES `roles` (`role_name`),
  ADD CONSTRAINT `User Id constraint` FOREIGN KEY (`user_id`) REFERENCES `users` (`user_id`);
COMMIT;

/*!40101 SET CHARACTER_SET_CLIENT=@OLD_CHARACTER_SET_CLIENT */;
/*!40101 SET CHARACTER_SET_RESULTS=@OLD_CHARACTER_SET_RESULTS */;
/*!40101 SET COLLATION_CONNECTION=@OLD_COLLATION_CONNECTION */;
